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Abstract 
 
Anti-cancer immunotherapies aim to mediate a specific response targeting 
malignant cells without accompanying damage to normal tissue associated 
with conventional therapies, but induction of T cell differentiation and 
exhaustion enables successful tumour progression. In this thesis I will explore 
different means of enhancing the accumulation and function of therapeutic 
CD8 T cells, as a means of achieving functional cure through persisting 
immunological memory. I will show that the key features of T cell memory can 
be imprinted upon CD8+ T cells by enhancing homing to specific organs, 
enabling privileged access to cell-mediated factors.  
 
The interaction between the chemokine receptor CXCR4 and the ligand 
CXCL12/SDF-1 is required for successful homing of haematopoietic stem 
cells (HSCs) to stromal niches within the bone marrow (BM). The bone 
marrow is known to be a unique organ for immunological memory, including 
memory T cells. I hypothesised that replicating this bone marrow homing 
interaction in CD8+ T cells would preferentially generate memory T cells. I 
demonstrate through in vivo imaging and flow cytometric analyses that T cells 
over-expressing CXCR4 accumulate preferentially in the BM near vascular-
associated CXCL12+ cells, retain a less differentiated central memory 
phenotype despite repeated antigenic stimulation, and produce enhanced 
effector cytokines on restimulation. Compared to control T cells, these cells 
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demonstrate lower expression of exhaustion and senescence markers, 
suggesting the capacity for long-term persistence after activation.  
 
I go on to show that numerical accumulation and many of these functional 
attributes are dependent upon cell-extrinsic expression of IL-15Rα. TCXCR4 
demonstrate heightened graft-versus-tumour effects in allogeneic bone 
marrow transplant models of B-cell lymphoma in comparison to control T cells.  
I provide evidence that this anti-tumour effect is mediated by enhanced 
functional capacity rather than numerical accumulation or out-competing 
immunosuppressive populations. In summary, this strategy offers a tractable 
means of enhancing T cell engraftment, persistence and function, with 
potential for cross-platform therapeutic applications including anti-cancer 
immunotherapy.  
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Impact Statement 
 
Immunotherapy is currently upending conventional ideas regarding optimal 
treatment of malignancies, which have largely exhausted the possibilities of 
chemotherapy and radiotherapy. A large number of trials have been initiated 
to explore the potential of various agents, yet thus far results have not fulfilled 
high expectations.  
The two most promising and advanced approaches currently involve the use 
of genetically modified chimeric-antigen receptor T cells (CAR-T cells) and 
checkpoint inhibiting antibodies (CPI). These approaches display dramatic 
responses in subsets of patients, but are yet to be widely applicable to the 
majority of patients who still receive conventional therapy. For these 
approaches to become more widely applicable, three key issues need to be 
tackled. Firstly, current approaches to generate sufficient numbers of modified 
T cells are expensive, require substantial preparation time and fail to generate 
sufficient cells in a substantial proportion of patients. Secondly, tumours 
generate intrinsic mechanisms of resistance to the immune system, 
preventing T cells from homing to the tumour niche or prematurely exhausting 
them to limit potency. Thirdly, current adoptive cell therapy often uses 
terminally differentiated T cells with limited potential for long-term 
immunosurveillance: the median time to relapse for adults with acute 
leukaemia receiving CAR-T cells is just six months (1). 
The approach detailed in this thesis aims to combat these three problems 
through a unified strategy. The formation of immunological memory is known 
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to be critical for long-term immune surveillance including our most effective 
vaccines (2). The bone marrow is important for the generation of long-lived 
memory T cells with enhanced protection against tumours (3, 4). These highly 
potent central memory T cells are able to reconstitute the entire T cell immune 
response while renewing themselves akin to stem cells in other organs. The 
magnitude of these cells within a CAR-T cell product correlates with the anti-
tumour response. The ability to reliably generate early memory T cells is the 
focus of intensive research efforts, but proven methods to maintain their 
phenotype in vivo are lacking (5, 6).  
In this project we demonstrate the ability to generate large numbers of these 
early memory cells and maintain them over extended periods in living animals 
despite repeated exposure to antigen. We do this by means of enhanced 
homing to the bone marrow niche, which enables privileged exposure to a 
potent memory-generating cytokine, IL-15. In other words, these T cells are 
able to access a molecular pharmacy to create large numbers of powerful 
immune cells. These cells are capable of generating long-lasting anti-tumour 
immunity addressing all three of the challenges described above: namely 
engraftment, persistence and self-renewal. This strategy is applicable not just 
to CAR-T cells, but to the range of adoptive T cell therapies, including the 
potentially game-changing ability of T cell receptor-gene modified cells to 
target mutations in any tumour. This tractable method could also potentially 
be harnessed for treatment of a variety of autoimmune diseases such as 
diabetes and rheumatoid arthritis, which cause enormous morbidity, mortality 
and financial burdens, through regulatory T cell expansion. This work has 
been disseminated through presentations at national and international 
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conferences, and publication in a high-impact peer reviewed open-access 
journal, and is the subject of a patent application for translational work. 
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1 Introduction 
 
1.1 Chemokines and chemokine receptors 
 
The chemokines are a group of small, secreted proteins united by their ability 
to induce cell migration. They are distinguished from other cytokines by their 
ability to bind to G-protein coupled chemokine receptors (GPCRs) but can be 
more readily conceptualised into inflammatory (inducible) and homeostatic 
(developmentally regulated) subgroups, although this useful division can be 
fluid and several receptors fit into both categories (Table 1). Members of the 
homeostatic group are produced constitutively and have numerous roles in 
lymphoid organogenesis, limb development, stem cell maintenance, 
angiogenesis and even metastasis (7, 8).  
Despite considerable sequence variability, almost all chemokines share a 
characteristic tetracysteine motif with two disulphide bridges. This motif forms 
a fold comprising three β strands, a carboxy (C) terminal α-helix and an amino 
(N) terminal region. The four chemokine subtypes are named according to the 
location of the first two-cysteine groups: the CXC-chemokines (α subclass), 
the CC-chemokines (β subclass), C-chemokines and CX3C-chemokines, 
where X denotes an amino acid (9). 
Chemokine receptors also share a characteristic structure. They are almost all 
composed of seven-transmembrane polypeptide chains containing three 
extracellular and three intracellular loops, an extracellular N terminal domain  
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Chemokine Chemokine  
Partners 
 Group Function Disease 
Association 
CXCR1 CXCL8 (IL-8), 
CXCL6 (GCP-2) 
 I Neutrophil 
trafficking 
Sepsis 
Atherosclerosis 
CXCR2 CXCL7, CXCL5, 
CXCL1, CXCL2, 
CXCL3, CXCL8 
 I Neutrophil 
trafficking 
Sepsis 
Atherosclerosis 
CXCR3 CXCL9, 
CXCL10, 
CXCL11 
 I TH1 
response, NK 
and CD8+ T 
cell trafficking 
MS, RA, 
transplant 
rejection, 
GVHD 
CXCR4 CXCL12  
(SDF-1)  
 Dual Bone marrow 
homing, 
cardiac, 
immune and 
neurological 
development 
Cancer 
metastasis, 
angiogenesis, 
HIV, IBD, RA, 
nephritis 
CXCR5 CXCL13  H B cell and TFH 
localisation in 
mature lymph 
nodes 
 
CXCR6 CXCL16  H NK, NKT, ILC 
and TRM 
migration 
 
CCR1 CCL5 
(RANTES) 
CCL3 (MIP-1α), 
CCL7 (MCP-3) 
 I Macrophage 
and NK, T 
cell migration, 
T-DC 
interaction 
MS, transplant 
rejection, RA, 
asthma, 
nephritis 
CCR2 CCL2 (MCP-1), 
CCL8 (MCP-2), 
CCL7, CCL13 
(MCP-4) 
 I Monocyte 
and T cell 
trafficking 
MS, RA, 
transplant 
rejection, 
asthma, 
atherosclerosis 
CCR3 CCL11, CCL28, 
CCL5 
 I Eosinophil 
and basophil 
migration 
Asthma 
CCR4 CCL17, CCL22  I TH2 response 
and 
migration, 
Treg migration 
Asthma 
CCR5 CCL4 (MIP-1β), 
CCL5, CCL3 
 I Macrophage 
and NK 
migration, T-
DC 
interaction 
MS, RA, 
asthma, 
nephritis, IBD, 
HIV, transplant 
rejection, 
GVHD 
CCR6 CCL20 (MIP-3α)  Dual TH17 
responses, B 
and DC gut 
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homing 
CCR7 CCL19, CCL21  Dual T and DC LN 
homing 
 
CCR8 CCL1  Dual TH2 and Treg 
trafficking 
Possibly 
asthma 
CCR9 CCL25  H T cell gut 
homing, 
thymocyte 
migration 
 
CCR10 CCL28, CCL27  H T cell and IgA 
plasma cell 
mucosal/skin 
homing 
 
CCR11 CCL25  I T cell gut 
homing, 
thymocyte 
migration 
 
CX3CR1 CX3CL1 
(Fractalkine), 
CCL26 
 D NK, 
monocyte 
and T 
migration 
Immune 
evasion 
XCR1 XCL1 
(Lymphotactin) 
 D CD8+ DC 
cross-
presentation 
 
 
Table 1 Chemokine receptors and their ligands 
Major homeostatic and inflammatory chemokine receptors and their 
partners, grouped via subclass: α (CXC, blue), β (CC, red), CX3C 
(green) and C (black). I denotes Inducible, H Homeostatic, D Dual, TH1 
T-helper 1 cell, NK natural killer cell, NKT natural killer T cell, ILC 
innate lymphoid cell, TH2 T-helper 2 cell, TH17 T-helper 17 cell, Treg 
regulatory T cell, TRM tissue-resident memory T cell, DC dendritic cell, 
MS multiple sclerosis, RA rheumatoid arthritis, IBD inflammatory bowel 
disease. 
 
and a serine/threonine-rich intracellular C-terminal domain. The external 
structure allows for specificity of ligand recognition while conserved 
transmembrane sequences, cytoplasmic loops and the C-terminal are 
relevant to signaling and receptor internalization. Chemokine monomers are 
thought to bind to GPCRs in a two-site model of receptor activation. The 
negatively charged receptor N-terminus and extracellular loops interact with 
the chemokine core domain (chemokine recognition site 1, CRS1) while the 
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chemokine N-terminus (triggering domain) interacts with the ligand-binding 
pocket of the receptor (chemokine receptor site 2, CRS2) (10), resulting in 
receptor activation. This model is supported by evidence that truncation 
mutations in chemokine N-termini lead to loss of signaling activity despite 
ongoing receptor binding (11). Further evidence for this paradigm is 
demonstrated by the ability of the small molecule antagonist AMD3100 to 
dislodge the CXCL12 N-terminus from its binding pocket in the CXCR4 
transmembrane region (CSR2) without displacing the binding of the 
chemokine core domain to the CXCR4 extracellular region (12); this activity 
has been exploited for mobilization of haematopoietic stem cells (see below). 
The chemokine-receptor system displays substantial flexibility as evidenced 
by the existence of several ‘silent’ non-signaling receptors historically thought 
to regulate immune reactions by acting as decoy or scavenger receptors to 
restrict migration. These molecules do not initiate classical chemokine 
receptor signaling responses to ligand and are now referred to as atypical 
chemokine receptors (ACKR) in the new nomenclature, eg. Duffy antigen 
receptor for chemokines (DARC) is now known as ACKR1 and CXCR7 as 
ACKR3 (13). Upon binding to ACKRs, chemokines can be internalized and 
destroyed in lysosomes to deplete extracellular chemokines, transported 
intact across polarized cells, or taken up and released. For example, ACKR1 
may act as a chemokine sink or buffer in times of abundance. The beta-
arrestins are polyfunctional cytosolic adapter proteins initially known for 
desensitisation of GPCRs (14). CXCL12 binding to ACKR3 induces beta-
arrestin relocalisation and hence signal transduction of CXCR4, modulating 
chemokine responses without activating G-protein signalling (15). In addition, 
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ACKRs can homodimerize or heterodimerize with conventional chemokine 
receptors, such as CXCR4, to alter signaling outputs (16, 17).  
Soluble chemokines can interact with carbohydrate structures called 
glycosaminoglycans (GAGs) to promote cellular directionality. GAGs are 
attached to cell proteoglycans or shed into the extracellular matrix, and 
prevent chemokines being washed away by the bloodstream, enabling 
formation of chemokine gradients and facilitating local rather than paracrine 
action.  
Many chemokines bind to multiple receptors and vice versa, potentially 
leading to high levels of redundancy. This redundancy is thought to provide 
evolutionary robustness in the face of pathogen evasion strategies and 
natural genetic polymorphisms within populations (18). However, this 
interpretation has been challenged by evidence of differential effects based 
upon cellular localisation within the body, and formation of chemokine 
receptor heteromers that allow for fine tuning of receptor signaling (9). Many 
chemokine receptors form oligomers during protein biosynthesis to facilitate 
protein folding (19). In contrast, only chemokine monomers are required for 
activation of receptors and oligomers must dissociate to bind GPCRs (20).  
Chemokines can adopt a wide variety of oligomerization structures to bind to 
GAGs, from dimers to polymers.  Oligomerization can dramatically alter 
binding affinity; for example the binding affinity of CXCL4 and CCL5 
monomers to chondroitin sulfate is lost in dimerization, while XCL1 
interconverts between the canonical structure binding to XCR1 receptors and 
the GAG-binding dimer (21). Furthermore, activation of the same receptor by 
different ligands has differential effects, e.g. CCL19 and CCL21 both promote 
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calcium signaling via CCR7, but only CCL19 induces efficient phosphorylation 
and receptor internalization. This functional selectivity allows for modulation of 
important roles in cellular signaling and movement (9). 
 
1.2 Physiological roles of chemokines  
 
Chemokines are critical for the movement of all immune cells. This movement 
encompasses a range of roles from developmental migration and 
homeostasis to primary and recall responses of both the cellular and humoral 
branches of the immune system. In addition to the cardinal feature of 
chemotaxis, chemokines and their receptors can be subdivided by their ability 
to orchestrate cell migration under conditions of inflammation or establish 
homeostatic microenvironments conducive to immune cell growth and 
maintenance.  
Pro-inflammatory chemokines are produced by a range of cells to recruit 
inflammatory cells to sites of injury, for example interleukin-8 (IL-8) produced 
by macrophages and endothelial cells primarily recruits neutrophils via 
CXCR1 and CXCR2, to induce phagocytosis and activation (22). The 
development of immune progenitor cells is exquisitely dependent upon 
expression of chemokine receptors. In the bone marrow, retention of 
haematopoietic progenitors and the development of the majority of their 
immune descendants including B cells, monocytes, macrophages and 
neutrophils is almost entirely dependent upon CXCL12/ CXCR4 interactions 
(23). As these cells develop, they downregulate CXCR4 to allow migration out 
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of the BM, in conjunction with upregulation of other signals such as CCR2 in 
monocytes and sphingosine-1-phosphate in B cells, to counteract the CXCR4 
retention signal.  
The vertebrate immune response requires that naïve T cells undergo thymic 
selection to eliminate or induce anergy of autoreactive cells. Following thymic 
selection, naïve T cells undergo activation and differentiation in response to 
cognate antigen in controlled molecular contexts. To enable successful 
recognition of the vast array of potential antigens, professional antigen-
presenting cells and lymphocytes are preferentially guided to specific 
microenvironments within secondary lymphoid organs such as lymph nodes 
by chemokines (24). Chemokines therefore play a central role in the migration 
and hence development of lymphocytes, from progenitor stage to antigen 
exposure and differentiation, as detailed below. 
Following haematopoietic development, T cell progenitors migrate from the 
BM to the thymus in response to CCL21, CCL25 and CXCL12 secreted by 
thymic stroma, and subsequently progress through intra-thymic development 
via expression of CCR7, CXCR4 and CCR9. Upon release into the circulation, 
they enter the high endothelial venules (HEVs), where in the absence of 
inflammation, stromal cells secrete CCL21 onto the luminal surface of the high 
endothelial venules (HEVs).  Initial binding of lymphocytes to the endothelium 
is mediated by selectins, particularly L-selectin, expressed on most leucocytes. 
This initial tethering stage is converted to rolling adhesions due to the high 
shear forces involved. During this process naïve T cells expressing CCR7 
engage with CCL19 and CCL21, triggering integrin activation and firm arrest 
(24, 25). A minor role is also played by CXCL12 produced by fibroblastic 
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reticular cells (FRCs), which interacts with CXCR4 on naïve T cells to further 
activate LFA-1 (lymphocyte function-associated antigen-1) and increase LN 
entry, a process upregulated in the context of an inflammatory stimulus (23, 
26). Following arrest, T cells migrate through the endothelial and stromal 
layers, presumably following chemokine gradients, and migrate along paths 
parallel to the course of the FRC network, allowing optimal scanning of 
multiple dendritic cells (DCs).  Lymphatic endothelium secretes CCL21 to 
guide DC migration and in turn, DCs secrete CCL3, CCL4, CCL5 and CCL17 
to attract naïve T cells and promote T cell priming (23). 
When considering cell migration, a distinction is drawn between migration 
along a gradient of immobilised chemoattractant (haptotaxis), migration driven 
by soluble chemokines without a directional gradient (chemokinesis) and 
migration driven by a gradient of soluble chemokines (chemotaxis) (27). Basal 
motility for naïve T cells within lymph nodes is maintained by chemokines 
such as CCL19 and CCL21, fitting the pattern of chemokinesis. In the 
inflammatory setting, activated and memory T cells express a range of 
chemokine receptors and ligands such as CXCR3 and XCL1 in response to 
microenvironmental cues, shaping multicellular encounters in a model more 
consistent with the concept of chemotaxis and amplifying the memory 
response (27).   
T cell movement was initially thought to resemble a random walk, ie. 
stochastic movements of seemingly chaotic steps interspersed with pauses 
(28). This concept is known as a Brownian walk, analogous to the random 
motion of particles suspended in a fluid colliding with other molecules. 
Inflammatory T cell motion within the brain has also been described as 
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resembling a Lévy walk, named for the French mathematician who described 
a pattern of many small moves associated with a few longer movements. This 
pattern, widely found in the biological world from hunter-gatherers to 
honeybees (29, 30), is more efficient when seeking rare targets. In the same 
setting CXCL10 enhanced speed in response to pathogens, shortening the 
time to antigen recognition (31). This finding has not been replicated within 
the steady-state lymph node, where heterogeneous migration modes have 
been observed, and debate continues over the role of the microenvironment, 
possible interference of long Levy walk movements with optimal DC scanning, 
and variation in statistical approaches used (32). Similarly, movement within 
the tumour microenvironment may be altered by immune evasion strategies to 
prevent optimal antigen presentation and T cell motility, as discussed below. 
The extent of CXCL12’s role in T cell motility within the BM parenchyma itself 
is still unclear. 
In the setting of inflammation, lymph node egress is reduced and mediators 
including hyperthermia, IL-6 and ICAM-1, enhance T cell homing to the lymph 
node. Tumor necrosis factor-dependent production of CXCL9 and CXCL10 on 
HEV surfaces allows recruitment of CXCR3+ effector T cells and NK cells, 
whilst CCL3 and CCL4 production in the paracortex mediates enhanced 
trafficking and multicellular encounters of CCR5+ naïve and memory CD8+ T 
cells with CD4+ T cells and DCs (24). 
T cell positioning in relation to antigen and inflammatory cues in secondary 
lymphoid organs is key in determining T cell phenotype. Expression of 
CXCR3 by central memory CD8+ T cells is essential for efficient antiviral recall 
responses, due to re-localisation towards antigen (33). In CD4+ T cells, 
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CXCR3 upregulation is associated with differentiation to a TH1 phenotype, 
and amplification of interferon-γ (IFN-γ) dependent recruitment to peripheral 
sites of infection (34). As a transcriptional target of T-bet, CXCR3 expression 
has also been suggested to predispose both CD4+| and CD8+ T cells towards 
an effector phenotype (35).  
Another chemokine receptor, CCR5, is also known to play an important role in 
lymphocyte trafficking. In conjunction with ligands CCL3, CCL4 and CCL5 it 
has been implicated in GVHD and solid organ transplant rejection. CCR5 is 
known to be important for lymphocyte recruitment to GVHD target organs 
such as liver, lung and spleen. CCR5 blockade has been explored as a 
therapeutic option to prevent visceral acute GVHD with promising results. The 
finding that CXCR3 signaling may be an important resistance mechanism in 
this case highlights the overlap in chemokine function (36, 37).  
Chemokines also play in central role in humoral immunity. Follicular dendritic 
cell networks direct B cell localisation in mature lymph nodes via CXCR5 and 
CXCL13, and in the spleen marginal zone B cells use CXCR7. Chemokine 
control over immune localisation is reinforced in tertiary lymphoid organs at 
sites of chronic inflammation. Inflammatory cytokines induce expression of 
lymphocyte-attractants CXCL13 and CCL19, and hence extend chemokine 
control over the range of immune cells in the periphery (26). 
Inflammatory chemokines also direct migration of the innate immune system, 
via expression of CXCR2, CCR1 and CXCR1 on neutrophils, CXCR2 on 
monocytes, CCR1 and CCR3 on eosinophils and CXCR3 and CXCR6 on NK 
cells, amplifying subsequent binding to selectins and integrins and hence 
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promoting endothelial transmigration to the source of inflammation. 
Chemokines also have an important role in angiogenesis, primarily defined by 
presence of the ELR motif. Angiogenic, ELR-positive chemokines, such as 
CXCL1 and CXCL8/IL-8, act through CXCR2 whilst non-ELR chemokines, 
such as CXCL4, are angiostatic and act through CXCR3B. The exception is 
CXCL12, a non-ELR containing angiogenic chemokine, with relevance in 
physiological (38) and malignant settings (39).  
CXCR4 plays an important role in orchestrating tissue regeneration following 
injury and inflammation. High mobility group box 1 (HMGB1) functions as a 
damage-associated molecular pattern, released on injury to trigger 
inflammation. HMGB1 has been shown to form a complex with CXCL12, 
inducing migration of muscle stem cells and regeneration via CXCR4 
interactions (40). Furthermore, the transcription factor hypoxia-inducible factor 
1a (HIF-1α) binds to the hypoxia-responsive element (HRE) on the CXCL12 
promoter under conditions of low oxygen levels, promoting CXCL12 increase 
at the site of tissue injury. This homeostatic process is essential to damaged 
tissue repair and migration of progenitor cells, for example following bony 
fracture. This interaction can become corrupted because like many 
haematopoietic and non-haematopoietic tissue-committed stem/progenitor 
cells (TCSCs) expressing CXCR4 (41), cancer stem cells can use the same 
axis to egress from their tissue of origin. In much the same way as 
lymphocytes egress into lymph nodes, these cells can then adhere to 
metastatic niches using reciprocal CXCR4 interactions with integrins and 
selectins such as LFA-1, VLA-4 (very late activation antigen-4) and L-selectin 
(42, 43). 
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1.3 The CXCL12-CXCR4 axis: structure and signaling 
 
A Japanese group, studying the relationship between the bone marrow 
microenvironment and the haematopoietic system first discovered the 
importance of CXCL12 (44).  Interleukin 7 (IL-7) had been identified as a 
cytokine produced by bone marrow stromal cell lines which enhanced pre-B 
cell proliferation but although several lines of evidence pointed to the 
requirement for an as yet unidentified factor produced by the PA6-stromal line, 
none of the tested cytokines could induce proliferation (45). To address this 
issue, Takashi Nagasawa and co-workers first cultured stromal cells in the 
presence of haematopoietic cells separated by a membrane filter, proving the 
importance of a soluble factor in proliferation of B cell precursors. They 
subsequently isolated a complementary DNA (cDNA) clone encoding this 
growth-stimulating factor and initially named the molecule PBSF (pre-B-cell 
growth-stimulating factor). The amino acid sequence was soon found to be 
identical to the recently cloned stromal cell-derived factor 1α (SDF-1α, 
otherwise known as CXCL12). Direct contact between stromal and 
haematopoietic cells was important for cell survival, suggesting avenues for 
later work which unveiled the importance of CXCL12 in the context of the 
niche (44).  
Further studies from the same group identified the CXCL12 receptor partner, 
CXCR4, by synthesizing conserved transmembrane proteins known to be 
present in previously identified chemokine receptor chains and using them as 
primers in reverse transcription PCR experiments from a CXCL12 responsive 
pre-B-cell clone. To their surprise, the identified seven-transmembrane 
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receptor corresponded almost exactly to a human HIV-1 entry coreceptor 
known as fusin (46). They went on to show that Cxcl12 knockout was 
embryonic lethal in mice, inducing severe defects in B-cell progenitors, bone 
marrow myelopoiesis, cerebellar and cardiac defects (47). Other groups 
showed that CXCL12 could prevent HIV-1 infection of T cells (48). 
The CXCL12-CXCR4 axis has since been implicated in many homeostatic 
processes including haematopoietic stem cell (HSC) homing and 
maintenance, B cell and plasma cell maintenance, embryogenesis, vascular, 
cardiac and neurological development, in addition to T cell trafficking (49-51). 
The same Japanese group confirmed that deletion of CXCR4 in adult mice 
severely impaired the numbers of HSCs, altered cell-cycle status and 
increased sensitivity to DNA damage, but had less effect upon mature 
progenitors. Importantly, most HSCs were in contact with a small population 
of reticular cells with long processes which are prominently associated with 
vascular niches and express large amounts of CXCL12 (52).  
Defects induced in mice lacking CXCR4 are identical to those in CXCL12-
deficient mice, confirming the importance of this pairing (50). Mice 
reconstituted with CXCR4-deficient fetal liver cells have reduced granulocytic 
cells in the bone marrow and elevated peripheral blood progenitors, 
suggesting therapeutic potential later exploited to mobilise stem cells for 
transplantation (53). These twin roles as growth promoter and 
chemoattractant highlight the unexplored therapeutic potential of this signaling 
axis, which will be discussed further in this thesis.  
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Recent studies have also highlighted unsuspected roles for CXCL12, such as 
a critical role in linking innate and adaptive immunity. Neutrophils have been 
shown to leave long-lasting trails of packaged CXCL12 to guide virus-specific 
CD8+ T cell recruitment to infected organs (54). Tissue insults such as 
hypoxia, toxins or irradiation also act to increase local CXCL12 expression, 
improving recruitment of CXCR4-expressing stem cells to the 
microenvironment. These studies highlight pleiotropic roles in inflammation 
and immune surveillance, straddling the boundary between homeostatic and 
inflammatory chemokines (55-57). 
CXCL12 therefore stands apart from its fellow CXC chemokines in a number 
of ways, not least its chromosomal location. Whilst most CXC chemokine 
genes are located on 4q21, CXCL12 is situated on the long arm of 
chromosome 10. Expression is tightly regulated, presumably due to its 
numerous critical roles; it is the only CXC chemokine to exhibit differential 
splicing with six different variants in humans and three variants in mice (58). 
The classical α and β variants bind CXCR4 with comparable affinity but the 
importance of the different tissue distribution and function of the alternative 
isoforms is unknown. The high degree of sequence and amino acid homology 
between humans and evolutionarily distinct species such as frogs and 
zebrafish confirms its primordial biological importance (59).  
CXCL12 initiates signal transduction by binding to the membrane-spanning G 
protein-coupled receptor and activating intracellular heterotrimeric G protein 
subunits (α, β, and γ). GPCRs are the largest family of membrane proteins, 
mediating most hormonal and neurological signals. CXCR4 is a member of 
the rhodopsin family, characterised by significant sequence homology and 
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implying shared activation mechanisms. Recent crystal structures of CXCR4 
in complex with antagonists have however suggested it has a different shape 
and binding site location to other GPCRs such as rhodopsin, the β2-
adrenergic receptor and the A2A adenosine receptor (60).  
Intracellular signalling 
Activation of the G protein heterotrimer triggers release of bound guanine 
diphosphate (GDP), replacement by guanine triphosphate (GTP) and 
dissociation into α and βγ subunits. Gα itself consists of 4 families: Gαi, Gαs, 
Gαq and Gα12.  Gαi inhibits adenyl cyclase, while Gαs stimulates this pathway, 
resulting in conversion of ATP to the second messenger cyclic adenosine 
monophosphate (cAMP). Gαq acts on phospholipase C (PLC) to hydrolyse 
phosphatidylinositol 4,5-biphosphate (PIP2) to generate inositol triphosphate 
(IP3) and diacyl glycerol (DAG), which increase intracellular calcium 
concentrations and activate multiple protein kinases including the mitogen-
activated protein kinase (MAPK) pathway inducing chemotaxis. Gα12 also 
regulates chemotaxis via the Rho and Ras families of small GTPases (61). 
The majority of G-protein coupled pathways involved in CXCR4 are thought to 
be Gαi dependent as they are inhibited by pertussis toxin through ADP-
ribosylation in the cytoplasm (62) while the Gβγ subunit can also trigger PLC 
activation and calcium flux. Both Gαi and Gβγ activate the phosphatidylinositol 
3-kinase (PI3K) pathway to trigger chemotaxis independently, or mediate 
transcription of cell survival genes through the serine-threonine kinase Akt 
(61) (Figure 1-1).  
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CXCL12 also triggers receptor desensitisation, via G-protein uncoupling, 
phosphorylation of the CXCR4 cytoplasmic tail by protein kinase C and 
GPCR-kinases and subsequent β-arrestin interactions. These β-arrestins then 
target CXCR4 for endocytosis in clathrin-coated pits, and some arrestin 
pathways are also linked to further p38 and ERK kinase signaling and 
chemotaxis (62). Further G protein-independent signalling is mediated by 
activation of the JAK/STAT family of transcription factors (63). In summary, 
CXCR4 activation triggers multiple downstream intracellular signaling 
pathways variously resulting in chemotaxis, cell survival, proliferation, gene 
transcription and increased intracellular calcium (64) (Figure 1-1).  
CXCR4 is expressed on an enormous variety of cell types, ranging from 
haematopoietic progenitors to peripheral blood B and naïve/activated T cells, 
plasma cells, monocytes, NK and dendritic cells, mast cells, vascular smooth 
muscle cells, endothelial cells, microglia, neurons, astrocytes and some 
epithelial cells, as well as stromal cells in organs such as lung, bone marrow 
and small bowel (50, 65-73). The complexity of the CXCR4 system is 
highlighted by the variety and nature of alternative ligands and antagonists. 
Other CXCR4 ligands include the HIV envelope glycoprotein gp120, 
extracellular ubiquitin and macrophage inhibitory factor (MIF), which also 
mediate T cell chemotaxis and arrest, and trefoil factor 2 (74) and human beta 
defensin protein 3 (75), which do not. The extent and importance of these 
alternative pathways is still unknown, as is the role of ACKR3 in CXCL12 
signaling. ACKR3 has over 10-fold higher affinity for CXCL12 compared to 
CXCR4, and is thought to mediate G protein-independent signaling, although 
this is controversial (73). Furthermore, heterodimerization of ACKR3 with 
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CXCR4 has been shown to cause β-arrestin-mediated downregulation of Gαi 
signaling, inducing activation of MAP kinases ERK1/2, p38 and SAPK in T 
cells (17, 76). Further evidence demonstrating that ACKR3 function is not 
redundant includes its ability to stimulate neural progenitor cell proliferation in 
response to CXCL12, in contrast to CXCR4 (77). ACKR3 also has an 
essential role in homing and migration of normal progenitors and acute 
myeloid leukaemia (AML) cells to cellular niches (78). CXCL12 signaling is 
therefore cell-type and context-specific.  In some tissues, heterodimerization 
is required, or CXCR7 substitutes for CXCR4 to mediate crucial signaling, 
further highlighting the unique characteristics of this pathway (79). 
 
 
Figure 1-1 CXCR4-CXCL12 Signalling Pathways 
CXCL12 binding to CXCR4 activates a variety of intracellular pathways 
resulting in diverse outcomes including cell migration, integrin 
activation and transcriptional activation of survival and proliferation 
pathways. β-arrestin pathways can result in receptor ubiquitination and 
degradation or recycling, but may have other downstream effects 
(dotted line). 
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1.4 Regulation of CXCR4 and CXCL12 
 
Understanding the tight regulation of both gene and protein expression is 
important to decipher the role of CXCR4 in health and disease. The major 
transcription factor positively regulating CXCR4 expression is Nuclear 
Respiratory Factor-1 (NRF-1), acting on the promoter, with additional effects 
from the SP-1 transcription factor. The opposing negative regulatory factor is 
thought to be Yin-Yang 1 (62, 80). CXCR4 expression and signaling activation 
is upregulated by a host of molecules including calcium, cyclic AMP, IL-2, IL-4, 
IL-7, IL-10, IL-15, transforming growth factor beta 1 (TGFβ-1), CD3 and CD28 
costimulation, vascular endothelial growth factor (VEGF) and epidermal 
growth factor (EGF). In contrast, TCR activation, CXCL12 signalling, tumour 
necrosis factor-α (TNF-α), IFN-γ and IL-1β all reduce CXCR4 expression (81-
85).  
The CXCR4 protein is further modified by post-translational glycosylation and 
tyrosine sulphation, both of which alter CXCL12 binding. Differential hetero- or 
homodimerisation and even tetramer formation of CXCR4 with other receptors 
such as CCR2, CD4 and CD8, has been proposed as a further level of 
regulation to alter signaling (86-88). Various extracellular molecules also 
modify CXCL12 binding. For example, during inflammatory degranulation, 
cathepsin G and neutrophil elastase cleave five N-terminal residues on 
CXCL12, yielding inactive forms of the chemokine (6-67) (89). Disruption of 
CXCL12 signaling appears to have a dominant role in mobilization of HSCs 
following administration of granulocyte colony stimulating factor (GCSF), a 
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drug that is used in haematopoietic stem cell transplantation (HSCT) for a 
variety of diseases. The precise mechanism underpinning its biological effect 
is still unclear, but G-CSF treatment leads to reduction in BM CXCL12 mRNA 
and protein levels, and reduced CXCR4 expression on mobilised HSCs, and 
is likely to relate to the effect of neutrophil-derived proteases suppressing 
interactions between stroma and HSCs (90).  
Numerous other pathways modulate CXCL12/CXCR4 signaling, notably 
CD26 (dipeptidylpeptidase 4, DPPIV). This membrane-bound peptidase 
cleaves dipeptides from N-termini of certain molecules, including CXCL12. 
CD26 is expressed on the surface of a large variety of haematopoietic cells, 
including HSCs, progenitors, activated T cells, stimulated B and NK cells, and 
also fibroblasts, endothelial and epithelial cells. CD26 is also present in a 
soluble active form in plasma. Truncated inactive CXCL12 acts as an 
antagonist, blocking chemotaxis of full-length CXCL12. CD26 inhibitors, such 
as diprotin A, are able to enhance chemotaxis of bone marrow progenitors in 
response to CXCL12. Interestingly CD26 inhibition interferes with GCSF-
induced progenitor mobilization, suggesting that CD26 is involved in the 
mechanism of action (91, 92).  
Exploitation of the DDP4 axis has been suggested as a potentially tractable 
route to improve the efficiency of HSC mobilization and transplantation. 
Several selective DPPIV inhibitors are safe and approved in medicine for 
other indications such as type 2 diabetes. Sitagliptin has been trialed with 
some success in an attempt to maintain higher levels of active CXCL12 and 
enhance engraftment in cord blood transplants (93, 94).  Encouraging yet 
inconclusive results suggest that the ability of DPPIV to modify colony 
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stimulating factors and other chemokines such as CXCL10 may have additive 
effects upon HSCs and lymphocyte trafficking, in the tumour and bone 
marrow environment (95, 96).  
To add to the variety of factors interacting with CXCL12, GAGs such as 
heparin sulfate interact with CXCL12 polymers to aid chemokine 
immobilization of the chemokine, forming gradients for leukocyte migration (97, 
98). Alternative strategies can also prime the CXCR4 response in HSCs to 
lower levels of CXCL12, for example via platelet-derived micro-particles or 
leucopheresis products containing adhesion and coagulation-related 
molecules, possibly through incorporation of membrane CXCR4 into lipid rafts 
(99, 100).  
 
1.5 Chemokines and receptors in disease 
 
With the notable exception of CXCR4, the majority of homeostatic chemokine 
receptors do not play a major role in disease. Inflammatory chemokines are 
by contrast heavily implicated in a wide variety of pathological processes. For 
example, CCR5 is implicated in the development of multiple sclerosis (101), 
rheumatoid arthritis (102), inflammatory bowel disease (103) and Acquired 
Immuno Deficient Syndrome (AIDS) (104), while neutrophil receptors such as 
CXCR1 and CXCR2 are implicated in sepsis and atherosclerosis amongst 
others (105-107) .  The profound effect of mutations in each of these 
chemokines highlights the importance of correctly functioning signaling 
pathways.   
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In the example of CXCR4, a heterozygous truncation mutation in the 
cytoplasmic tail results in enhanced leukocyte chemotaxis to CXCL12 and the 
clinical WHIM syndrome (warts, hypogammaglobulinemia, infections and 
myelokathexis). This causes neutropenia with excessive retention of mature 
neutrophils in the BM and impaired receptor desensitization (108). WHIM 
patients have responded to low dose treatment with the CXCR4 antagonist 
AMD3100 (Plerixafor), highlighting the potential susceptibility to 
pharmacological modification of this axis. CXCR4 has also been implicated in 
various inflammatory and autoimmune disorders including inflammatory bowel 
disease, rheumatoid arthritis and lupus (109, 110), where the degree of renal 
CXCL12 expression correlates with severity of lupus nephritis, further 
highlighting the double-edged nature of chemokine signaling. 
 
1.6 Chemokines in the cancer microenvironment 
 
Of relevance to this thesis, CXCR4 is the most common chemokine receptor 
expressed on cancer cells, having been identified in at least 23 different 
cancers of diverse origin (111).  Cancer cell populations have co-opted the 
CXCR4-CXCL12 axis to enhance adhesion, angiogenesis and metastasis to 
distant organs. CXCR4 is the key signaling axis mediating metastasis in 
breast cancer to organ sites such as lung, brain, liver and bone marrow; these 
organs express the highest levels of CXCL12 in the body, and expression is 
upregulated under hypoxic conditions, acting to promote survival and invasion. 
The CXCR4/CXCL12 axis promotes an invasive metastatic phenotype in 
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ovarian and medullary thyroid cancer (112-114), and high CXCL12 levels are 
associated with worse survival in ovarian cancer amongst many others (115). 
The nuclear factor-κB (NF-κB) transcription factor binds the CXCR4 promoter 
to promote dysregulation and chemotherapy resistance in a host of cancers 
(116, 117) and CXCR4 expression has been suggested as a marker of 
‘stemness’ in solid tumours (118, 119). 
In the haematological setting, CXCR4 occupies a similarly central position. 
Somatic, WHIM-like CXCR4 mutations are present in over 25% of patients 
with the B-cell malignancy, Waldenstrom’s macroglobulinemia. These 
mutations activate the AKT and ERK/MAPK signaling pathways, are 
associated with higher BM involvement and resistance to novel B-cell receptor 
targeted agents such as ibrutinib (120, 121). Nearly half of all myelomas over-
express CXCR4, which is implicated in cell adhesion-mediated drug 
resistance (122).  B-cell chronic lymphocytic leukaemia (CLL) cells express 
higher levels of CXCR4 than normal B cells, in association with increased 
chemotactic responses to CXCL12 secreted by stroma or protective nurse-like 
cells (123, 124). CXCR4 expression in acute myeloid leukaemia (AML) is an 
independent predictor of disease relapse and has a dismal effect upon overall 
survival of similar magnitude to that of unfavourable cytogenetics (125). High 
CXCR4 expression in B-cell acute lymphoblastic leukaemia (ALL) predicts 
extramedullary organ infiltration and worse survival (126, 127) and has 
recently been found to be essential for leukaemia-initiating cell activity in T-
ALL (128). As in the context of normal T cells, CXCR4 triggering in T-ALL 
leads to integrin receptor activation, allowing migration across vascular beds. 
Interestingly, ACKR3 is also overexpressed by both ALL and AML cells; it 
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contributes to CXCL12-induced T-ALL migration, possibly by preventing 
CXCR4 downregulation, suggesting a potential leukaemic resistance 
mechanism (78, 129).  In the context of standard therapy approaches, 
chemotherapy has been shown to induce CXCR4 upregulation in AML cell 
lines and subsequent stromal protection from apoptosis (130). Stromal 
CXCL12 promotes an enhanced energy supply (glycolytic shift) via the 
mammalian target of rapamycin (mTOR) signaling axis in AML cells (131, 
132). Further effects follow from CXCR4-mediated downregulation of the 
micro RNA, let-7a, which drives chemoresistance.  Similarly, studies in 
chronic myeloid leukaemia (CML) have shown that an unexpected effect of 
BCR-ABL kinase inhibition by imatinib is to trigger CXCR4-dependent 
migration to BM stroma, leading to cell cycle arrest and drug resistance (133). 
 
1.7 Antagonizing the CXCR4/CXCL12 signaling pathway 
 
Given the profound importance of CXCR4 in a host of disease processes, 
attempts at antagonising this pathway are of great research interest. 
AMD3100 (Plerixafor), a bicyclam compound, was initially developed as an 
inhibitor of human immunodeficiency virus (HIV) replication in 1994 (134, 135). 
The surprising lack of activity against simian immunodeficiency virus (SIV) 
was explained three years later when it became clear that the mode of action 
was through direct inhibition of T-cell tropic strains of HIV (not present in SIV) 
interacting with CXCR4 after binding to the CD4 receptor on T cells (136, 137). 
Plerixafor is able to selectively and reversible antagonise chemotaxis to 
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CXCL12, resulting in complete blockade of the normal calcium flux response 
to CXCR4 signaling. Subsequent clinical trials in HIV patients noted a rapid 
dose-dependent increase in peripheral blood white blood cell counts, in 
particular those carrying the stem cell marker CD34+ (138).  
In combination with the established stem cell mobilizing agent, GCSF, 
Plerixafor induces a tripling of selective stem cell mobilization and has 
become a standard of care for people failing standard autologous mobilization 
regimes prior to transplantation for lymphoma or myeloma. Interestingly, 
Plerixafor-related stem cell mobilization may occur without more tumour cell 
contamination than occurs with GCSF alone, as long-term survival outcomes 
after autologous transplantation are equivalent (139). Direct comparison is 
difficult because the stem cell product mobilised by Plerixafor is qualitatively 
different compared with GCSF. Plerixafor has been suggested to mobilise 
more of a primitive CD34+/CD38- stem cell subpopulation, as well as 
increased number of CD4+ and CD8+ T cells, NK cells and plasmacytoid DCs, 
independent of stem cell yield (140). Other studies have suggested GCSF 
alone mobilises more of the most primitive multipotent progenitors 
(CD34+CD38lowCD133+CD45RA-) whilst combination treatment with GCSF 
and Plerixafor yields more mature CD34+ progenitors and differentiated cells 
such as late granulocyte-monocyte progenitors (GMPs) and CD8+ T, B and 
NK cells (141); this latter study is difficult to interpret because only poor 
mobilisers received combination therapy.  Another recent study has shown 
that intravenous Plerixafor preferentially mobilises more pre-plasmacytoid 
DCs with a putatively favourable immuno-regulatory phenotype, correlating 
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with low CMV viraemia and GVHD rates post allogeneic stem cell transplant 
(142). 
Recent studies have suggested that the gene expression profile of Plerixafor-
mobilised T cells differs from that characteristic of T cells mobilised by GCSF. 
Plerixafor-mobilised human T cells had similar phenotype and gene 
expression levels to non-mobilised T cells, whereas GCSF-mobilised cells 
had significant reduction in CD62L+ CD4+ and CD8+ T cells, and lower 
proportions of CD27+ CD8+ T cells (143). CD27 is a costimulatory molecule 
involved in augmented T cell activation and required for the development and 
maintenance of long-term memory (144). Whilst CD62L shedding post GCSF-
administration may be a temporary phenomenon (143), the association of 
Plerixafor-mobilised grafts with increased GVHD relative to GCSF-mobilised 
grafts in murine transplant models (145) suggests that CXCR4 antagonism 
may mobilise a more potent memory T cell subset from putative BM niches. 
The picture is complicated by GCSF-mobilisation inducing a skewed T helper 
2 and regulatory CD4+ T cell phenotype (146, 147), which may affect GVHD 
rates. 
Several groups have tested the biological activity of CXCR4 inhibitors in 
synergy with chemotherapy or targeted kinase inhibition in acute and chronic 
leukaemias (148, 149). Theoretically, inducing mobilization of leukaemic stem 
cells could sensitize them to chemotherapy outside a protective BM niche; 
however clinical responses have thus far failed to yield dramatic benefits (150, 
151). More potent agents including an apoptosis-inducing humanised anti-
CXCR4 antibody (ulocuplumab) are in clinical development (152). In murine 
models, Plerixafor has also been shown to inhibit collagen-induced arthritis 
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(153), medulloblastoma and glioblastoma (154), promote blood flow 
restoration in diabetic ischaemia (155) and enhance survival post West Nile 
virus via enhanced central nervous system (CNS) CD8+ T cell homing (156). 
Intriguingly, CXCR4 blockade has also been reported to reduce the proportion 
of exhausted CD4+ T cells and improve survival in murine polymicrobial 
sepsis (157). The authors speculate that this may be due to replenishment of 
exhausted peripheral T cells from bone marrow populations of PD-1low T cells. 
These results would be consistent with mobilisation from the BM of a more 
potent T cell subset. 
 
1.8 Malignancy and immune evasion 
 
Although initiating events in development of malignancy often involve 
sustaining proliferative signaling and resisting cell death, further mutations 
and epigenetic modifications are usually necessary to create successful 
malignant phenotypes, comprising alteration of metabolic pathways, evasion 
of immune destruction and metastasis (158). This process takes place over a 
prolonged period of time associated with multiple interactions with the tumour 
microenvironment and the immune system. The idea that the immune system 
could control the growth of pre-malignant cells was first given voice in 1909 by 
Ehrlich (159), and later developed by Burnet and Thomas (160, 161). 
Immunosurveillance remained a hypothesis, despite evidence of increased 
tumour rates in immuno-suppressed transplant patients, until the development 
of knockout mice deficient in immune effector cells in recent decades. 
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Numerous studies have now demonstrated that T cells can recognize 
neoantigens, successfully infiltrate and induce long-term responses in diverse 
tumours such as melanoma, colon and ovarian carcinoma (154, 162, 163). 
The genomic instability present in most cancers dictates that as cancer cells 
acquire mutations in protein-coding genes or epigenetic alterations, they 
express tumour-specific (TSAs) or tumour-associated antigens (TAAs). Some 
of these antigens, either neoantigens or embryonic, are expected to be 
immunogenic due to recognition of the non-self (or ‘non-adult self’) peptides in 
association with major histocompatibility complexes (MHC) on the cancer cell 
surface by cytotoxic T lymphocytes. 
This is evidenced by variation in the degree of immunogenicity in tumours 
based upon mutation frequency. For example, melanomas as the prototypical 
immune-sensitive tumour are highly mutated due to the effects of UV light, 
and have been shown to spontaneously regress in association with clonal 
expansion of T cells (164). Similarly microsatellite instability (MSI) in 
colorectal cancer, which involves DNA mismatch repair defects and hence 
high levels of genomic instability, is strongly predictive of activated cytotoxic T 
cell infiltration, reduced metastases and better survival than MSI negative 
cases (165). Renal and bladder cancers, despite a relative paucity of somatic 
mutations, are also responsive to immunotherapy, suggesting the existence of 
multiple factors dictating the quality of the antigenic stimulus and 
corresponding immune response (166). 
In response to the apparent failure of the immune system to control cancerous 
growth in individuals first presenting with cancer, the immunosurveillance 
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hypothesis has been refined by acknowledging a complementary role in 
selecting for tumours with decreased immunogenicity. This process of 
immunoediting is conceived as three sequential phases: elimination, 
equilibrium and escape (167). In the first phase, malignant growth induces 
inflammatory signals recruiting first the innate immune system (macrophages, 
NKT and NK cells, γδ T cells and dendritic cells) and subsequently an 
adaptive response by means of IFN-γ, CXCL9, CXCL10, CXCL11 and IL-12 
to destroy antigen-bearing tumour cells. In the equilibrium phase, the inherent 
genetic instability of tumours that have not been destroyed induces multiple 
escape variants, some of which are able to persist and hamper immune 
detection, although the majority of tumour cells are still undergoing detection 
and a degree of destruction. As this phase evolves, the selection pressure of 
the immune system increasingly enables genetic and epigenetic alterations in 
the tumour and microenvironment to downregulate the immune response, 
leading to malignant growth. 
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Figure 1-2 Cancer immunoediting. 
The three phases by which the immune system sculpts malignancy to 
evade cytotoxic attack. Elimination involves chemokines and cytokine 
(red circles) recruitment of immune effectors such as CD4+ and CD8+ T 
cells, NK and NKT cells to engage in cytotoxic destruction (yellow 
lightning bolt) of tumour (beige). As this Darwinian process proceeds to 
dynamic equilibrium, the immune response promotes the increasing 
prevalence of mutated tumour variants (brown and grey) more capable 
of withstanding an immune response, until these variants become the 
predominant cell type in the Escape phase, suppressive cell types such 
as regulatory T cells (Treg) and tumour-associated macrophages (M2) 
suppress the cytotoxic response, and the tumour is able to expand 
unchecked. 
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Evolutionary theory predicts that different tumours will employ a large array of 
different strategies to induce a suppressive TME (168).  This may occur 
through blockade of physical T cell recruitment to the tumour, for example 
cancer-associated fibroblasts (CAFs) coat pancreatic carcinoma cells with 
CXCL12 to exclude T cells (169) or nitration of the chemokine CCL2 by 
myeloid-derived suppressor cells (MDSCs) in prostate and colon cancer (170). 
Tumour-associated endothelial cells can be induced to express Fas ligand 
(FasL) signals to preferentially recruit Foxp3+ regulatory T cells (Treg cells) and 
myeloid cells rather than T effectors (171). Treg cells suppress anti-cancer 
immunity through several distinct mechanisms including CTLA4-mediated 
inhibition of antigen-presenting cells (APCs), consumption of IL-2 and 
secretion of inhibitory molecules including IL-10 and TGF-β.  
A recent study has elegantly highlighted the intimate connection between 
homeostatic immunoregulatory processes and their corruption in the tumour 
microenvironment. The enhanced sensitivity of Treg cells to oxidative stress 
suggests their utility in limiting excessive reactive oxygen species generated 
by neutrophils in the setting of infectious and inflammatory stimuli. Apoptotic 
Treg cells therefore release ATP, which is converted to immunosuppressive 
adenosine to dampen down harmful immune-related destruction of normal or 
malignant tissue once the initial stimulus has been cleared. This pathway is 
co-opted by ovarian cancer when free oxygen species in the tumour 
microenvironment induce Treg cell apoptosis, triggering a suppressive cascade 
to nullify effective T and APC responses (172).  
Other mechanisms of immune suppression include hypoxia-triggered 
upregulation of programmed cell death protein ligand 1 (PD-L1) on 
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myelomonocytic cells (173), tumour and myeloid cell production of 
immunomodulatory enzymes such as indoleamine 2,3 dioxygenase (IDO) 
(174, 175) and B cells reprogramming macrophages to a tumour-associated 
phenotype (176). Myeloid-derived suppressor cells can themselves induce 
Treg cell production, produce TGF-β and deplete arginine and cysteine or 
nitrosylate the T cell receptor (TCR) to inhibit T cell function (177). Finally, 
breast and lung cancer cells can directly trigger activation of the nucleotide-
binding oligomerization domain-, leucine-rich repeat- and pyrin domain-
containing 3 (NLRP3) inflammasome and IL-1β to induce CD4+ memory T 
cells to secrete the cancer-promoting cytokine IL-22. 
 
1.9 T cell memory 
 
‘The same man was never attacked twice’ 
Thucydides recounting the plague of Athens, 430BC (178) 
 
Immune memory as first observed by Thucydides is defined as the ability of 
the immune system to respond more effectively to a secondary encounter with 
non-self antigen (179). The persistence of long term memory for many years 
following initial exposure, for example in yellow fever vaccination, suggests 
the facility for a long-lived population of antigen-specific lymphocytes that re-
expand upon secondary encounter to drive a more effective response (180). 
An anti-tumour memory T cell response thus represents a potent long-term 
solution to the thorny issue of preventing both disease relapse and 
chemotherapy-resistant clonal evolution (181).  
 45 
Memory T cells demonstrate great functional and phenotypic heterogeneity, 
resulting from the quality of the initial antigenic stimulus and antigen 
persistence, coupled to environmental signals including the balance of co-
stimulatory and co-inhibitory molecules, homeostatic cytokines and stromal 
inputs (182-184). The ontogeny and lineage relationship between different 
subsets is still a matter of ongoing debate and at least three models of 
memory formation have been put forward, each supported by differing strands 
of experimental evidence (185).  
 
Linear differentiation model 
This model proposes that naïve T cells differentiate directly into effector T 
cells (TEFF) after priming. The majority of TEFF (KLRG1HIGHCD127LOW short-
lived effector cells, SLECs) die after pathogen clearance but a subset of 
effectors (memory precursors, MPECs) develop further into CCR7- CD62L- 
effector memory T cells (TEM) and then central memory T cells (TCM). TEM 
cannot home to lymphoid tissues or recapitulate earlier T cell subsets, while 
TCM can self-renew in the absence of antigen through homeostatic 
proliferation. This model is based upon studies showing that TCM become the 
predominant subset after transfer of a predominantly TEM subset (186). New 
light has been shed upon these findings by recent data from epigenetic 
analyses. Recent reports suggest that MPECs can acquire then erase 
repressive methylation programs, allowing them to re-express critical naïve-
associated genes such as Sell (coding for CD62L), Ccr7 and Bcl2 (187). 
Intriguingly, long-lived memory cells appear to retain an ‘epigenetic memory’ 
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of transitioning through an activated stage, delineated by persisting 
demethylated CpG sites near loci for granzyme B and perforin. This effector-
like epigenetic landscape is very different from the methylation pattern seen in 
naïve T cells. Unlike effector cells, long-lived memory cells do not express 
either granzyme B or perforin, and have a naïve-like transcriptome, but the 
transcriptional permissiveness of their open chromatin suggests they are 
poised to rapidly acquire effector functions if needed (187, 188). 
 
Bifurcative model 
The bifurcative model proposes a single naïve T cell can give rise to 
differentially fated daughter cells by means of an important evolutionarily 
conserved mechanism known as asymmetric cell division. The positioning of 
daughter T cells proximal or distal to the APC at first cell division results in 
unequal distribution of key molecules mediating cell fate, including CD8, 
CD25, the transcription factor T-bet and the master regulator of cell growth 
mammalian target of rapamycin complex 1 (mTORC1) (189-191). 
 
Progressive differentiation model 
Also known as the signal-strength model, this delineates a clear pathway from 
naïve to stem cell memory (TSCM), central memory, then effector memory and 
effector cells (192). The greater the magnitude of the input signal, the further 
down the pathway the cells progress, losing self-renewal capacity and anti-
tumour efficacy as they differentiate. Increasing evidence supports this model, 
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including telomere length measurements (193), mass cytometric analysis of 
phenotypic markers such as co-stimulatory molecules CD27 and CD28  (194, 
195), gene-expression profiling (196-198) and in vitro analyses of self-renewal 
and differentiation (198, 199).  
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Figure 1-3 Models of T cell memory formation. 
The linear differentiation model proposes that naïve cells (TN) 
differentiate directly into effector cells (TEFF) after interaction with 
antigen-presenting cells (APC). Effector cells either become terminally 
differentiated short-lived T cells, or survive to differentiate into effector 
memory (TEM) and then TCM. The bifurcative model proposes that 
asymmetric division of amino acids and other key determinants at time 
of priming determines cell fate, such that one T cell can give rise to two 
daughter cells: the distal daughter cell gives rise to TCM, while the 
proximal cell develops into TEM or TEFF. The linear differentiation or 
signal-strength model proposes that T cell fate is determined by the 
strength of interaction with the APC and exposure to IL-7 and IL-15, 
such that weak interactions given rise to memory stem cells (TSCM) and 
TCM, which possess superior antitumour efficacy due to ‘stemness’ 
properties of self-renewal and multi-potency. Stronger TN-APC 
interactions and IL-2 give rise to more differentiated TEM and TEFF. 
 
 
These models represent a simplification and elements of these models 
overlap.  In particular, the bifurcative model could be consistent with findings 
from the other two models. Other data using mice with Cre-mediated 
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expression of yellow fluorescent protein (EYFP) upon transcription of the gene 
for granzyme B (Gzmb) note that CD8+ CD62Lhigh cells remain present 
throughout the primary response to influenza infection and express GzmB 
(200) These data argue for a modification of the linear differentiation model 
and to some extent the bifurcative model in that TCM do not develop from 
effector T cells, but as discussed above elaborate effector functions 
themselves through epigenetic modifications. 
As well as great phenotypic diversity, and variation depending upon the 
antigen itself, there may well be diversity in mechanisms of memory formation 
encompassing phenotypically diverse memory populations evolutionarily 
adapted for cooperative roles in host defence. For example, tissue-resident 
memory T cells (TRM) undergo no recirculation but function as important 
organ-specific sentinels at mucosal borders (201). A recent study showed that 
induced deletion of a transcriptional repressor gene Id2 was able to transform 
KLRG1HIGH terminal effector/effector-memory CD8+ T cells into a KLRG1LOW 
memory-like population, suggesting that the dogma of terminal programming 
may need to be revised to incorporate some flexibility of memory status, 
dependent upon sustained transcription factor regulation of target genes (202). 
Further elucidation of the complexities of memory fate specification awaits 
studies combining large-scale single-cell analysis with comprehensive in vivo 
fate mapping technologies. Much of the debate over ontology may be a 
semantic issue relating to experimental models and limited tools with which to 
delineate cell status. A more holistic definition of memory subsets examining 
self-renewal, homing and the epigenetic landscape in toto may resolve these 
issues. 
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The role of chemokines in T cell memory 
In facilitating the interplay between innate and adaptive arms of the immune 
system chemokines play an important role in the development of 
immunological memory. CCR4 and CCR5 are important for naïve CD8+ T cell 
interactions with DCs and CD4+ T cells, and in turn for enhancing the quality 
and persistence of the memory CD8+ T cell response. Inflammatory 
chemokine receptors such as CXCR3 and CCR5 also have important effects 
upon memory fate.  CCR5 accelerates effector memory T cell recruitment to 
the airways early following viral challenge-induced inflammation (203) while 
the absence of CXCR3 enhances generation of memory cells at the expense 
of effector cells (35, 204). CXCR3 positions T cells in the marginal zone, 
exposed to high levels of antigen on APCs and promoting effector 
differentiation for control of acute infection such as influenza, while CCR10 
and CXCR6 have been suggested to promote tissue-resident memory CD8+ T 
cells formation (TRM) (205). The role of CXCR4 in memory T cells is discussed 
separately in 1.11 below. 
 
Memory subsets 
TCM and TEM possess contrasting homing properties in viral infection models 
and can be differentiated by surface phenotype, being respectively 
CD62LhighCCR7+CD27high and CD62LlowCCR7-CD27low/int. TCM have a gene 
expression profile closer to naïve T cells, patrol lymph nodes, are more 
responsive to CCL19 and CCL21, but are present in equal quantities to TEM in 
spleen and BM. In contrast TEM express receptors for inflammatory 
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chemokines, preferentially patrol inflamed nonlymphoid organs and have a 
more senescent replicative history with impaired expansion potential (198, 
206). All of the models of memory described above conclude that TCM display 
greater capacity for accumulation at the location of antigen-exposure, self-
renewal and anti-tumour efficacy compared to effector memory T cells (4). 
Consistent with preclinical models, the proportion of TCM in the infused 
product corresponds very strongly with long-term persistence of CAR-T cells 
and improved outcomes in trials of patients with solid malignancies (207). 
The key properties of immunological memory are thought to rest upon the 
capacity of long-lived lymphocytes to self-renew and generate effector 
lymphocytes in response to antigenic challenge (208). A population 
designated T stem cell memory (TSCM), displaying a naïve-like CD45RO- 
CD62L+ CD45RA+ phenotype but superior antitumour responses to TCM has 
now been described in humans, mice and non-human primates (198). Stem 
and central memory CD8+ T cells share a transcriptional program and key 
properties of self-renewal and multi-potency with long-term haematopoietic 
stem cells (209). They express a common set of markers including CD62L, 
CCR7, IL-2/15Rβ, Sca-1 (in mice) and BCL2 and require IL-15 (210, 211). 
The limitations of stem memory CD8+ T cells relate to difficulties identifying 
them in several models and isolating them for clinical use (5). Autologous 
TSCM are preferentially depleted by commonly used conditioning 
chemotherapy such as cyclophosphamide and cytarabine, in contrast to 
preserved TCM (212). This issue is particularly important given the limited 
availability of early memory T cells for autologous adoptive cell therapy (ACT) 
in older patients with lymphoma and solid tumours (212). Pre-transplant 
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depletion of CD44lowCD8+ T cells has been shown to abrogate GVHD (213) 
suggesting an association with persistent GVHD that is not seen with TCM 
(210). In addition, serial single cell transfer fate mapping experiments have 
shown adult tissue stem cells within the TCM compartment, such that the tiny 
numbers of tertiary TCM progeny from a single primary TCM are able to 
reconstitute full antigen-specific immunocompetence in immunocompromised 
hosts (5). 
A large number of factors are involved in promoting T cell memory. Initial 
formation of the immune synapse involves adhesion molecules stabilizing the 
initial structure then the mature immunological synapse forms as a tight 
cluster of T cell receptors surrounded by a ring of adhesion molecules. This 
allows transport of ligands into the central cluster to form stable long-lasting 
interactions (214, 215). Naïve T cells are then thought to require further 
signals to be primed efficiently, including a costimulatory signal 2 from T cell 
CD28 binding to CD80/CD86 on APCs become fully activated. This crucial 
link between innate and adaptive immunity is enabled by inflammatory 
cytokine and toll-like receptor (TLR) signaling upregulating CD80 and CD86 
on DCs.  
CD28 costimulation increases production of the transcription factors AP-1 and 
NF-κB, increases transcription of IL-2 and stabilizes IL-2 mRNA, resulting in T 
cell proliferation (216, 217). In the absence of CD28, little IL-2 is produced 
and hence activated cells die or become anergic (218). Activated CD8+ T cells 
primarily use aerobic glycolysis for their bioenergetic requirements, while the 
dominant process in naïve and memory T cells is oxidative phosphorylation of 
pyruvate and fatty acids (219). CD28 has also been shown to promote 
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expression of carnitine palmitoyltransferase 1a (Cpt1a), facilitating 
mitochondrial fatty acid oxidation in memory cells (220). 
The fate of activated T cells varies according to the strength of the activating 
signal and other local environmental signals, known as signal 3. These 
comprise a number of different cytokine and chemokine combinations often 
initially secreted by antigen-presenting cells, for example IFN-γ and IL-12 
shape CD4 differentiation towards a T-helper 1 (TH1) phenotype. The 
environment in which activation occurs hence plays a crucial role in shaping T 
cell fate. APCs upregulate costimulatory molecules in an inflammatory 
context; for example conditioning chemotherapy-related tissue damage during 
HSCT results in release of damage-associated molecular patterns (DAMPs) 
such as ATP and uric acid. Signaling through TLRs and nucleotide-binding 
oligomerization domain–like receptors (NLRs) leads to inappropriate antigen 
presentation by a host of innate and adaptive cells. In the context of thymic 
injury, expression of tissue-restricted antigens and impaired negative 
selection, aberrant priming of autoreactive CD4+ T cells and B cells can lead 
to chronic GVHD (221).  
In addition to TCR signaling strength, surface molecules, and asymmetric 
division of metabolic regulators, tissue microenvironments are key to 
determining cytokine signaling and nutrient bioavailability. In particular mTOR 
integrates multiple environmental cues and cytokine inputs to promote protein 
synthesis and glycolysis via HIF-1α while the 5’ adenosine monophosphate-
activated protein kinase (AMPK) complex inhibits mTOR and induces fatty 
acid oxidation. Other regulators of memory formation include the ratio of 
transcription factor pairs such as T-bet and Eomes or Blimp-1 and Bcl-6. 
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Large meta-analyses of gene expression profiles have not identified lineage-
defining genes but instead have identified key networks of multiple regulators 
working in concert to promote particular memory or effector states (222, 223).   
Finally, the relevance of chromatin accessibility is becoming increasingly 
considered in how we think about T cell memory. The remarkable variety of 
memory and effector phenotypes generated from clones with identical DNA 
sequences hints at the potential for therapeutic modification of ‘stemness’ and 
effector-associated genes via epigenomic alterations mediated by chromatin 
regulators such as histone methyltransferases (224). In place of the traditional 
terminology of ‘fate’, integration of multiple signal inputs of differing strengths 
is now thought to guide cells along a gradient towards or away from particular 
states (219). A key question in the field is how exactly these signals are 
integrated and the degree of influence that extrinsic tissue 
microenvironmental signals have over cell-intrinsic factors such as the 
epigenetic landscape.  
 
1.10 CXCL12-CXCR4 in T cell biology 
 
The role of CXCR4 and CXCL12 in T cell biology has been under-explored 
compared to what is known about its central role in haematopoietic stem cell 
and even B cell biology. CXCR4 is expressed constitutively at low levels on 
the majority of human CD8+ T cells. CD27+CD28+ CCR7+CCR5- naïve and 
central memory subsets express higher levels than effector cells (225). The 
greater protective immunity mediated by central memory CD8+ T cells has 
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been suggested to be due in part to their greater migratory flexibility. Central 
memory CD8+ T cells roll and adhere firmly to high endothelial venules in 
order to access lymph nodes, and this behaviour is dependent upon CXCL12, 
persisting even when CCR7 signaling is not present. In contrast naïve CD8+ T 
cell lymph node migration is almost completely abolished by lack of CCR7 
ligands (226), whilst both naïve and memory CD4+ T cells arrest and adhere 
to integrin receptors following CXCL12 triggering (227).  
The WNT family of secreted glycoproteins is known to be critical to the 
generation and long-term maintenance of memory CD8+ T cells (228, 229). 
The WNT downstream effector transcription factor TCF7 (transcription factor 7 
or T-cell factor 1, TCF-1) is highly expressed in naïve and early memory T 
cells and progressively lost with differentiation (230). Activation of the 
canonical WNT-β-catenin pathway promotes generation of TSCM and TCM 
(211) while Tcf-1-deficient CD8+ T cells exhibit deficient TCM formation, 
reduced CD122 and Bcl-2 expression, diminished responsiveness to IL-15 
and impaired pathogen responses (231, 232). CXCL12-treated human T cells 
upregulate non-canonical Wnt pathway members such as Wnt5A, while down-
regulating canonical family members such as Wnt3A. Wnt5A expression is 
required for CXCL12-induced migration in vivo and enhances CXCL12-
CXCR4 signalling through protein kinase C activation (233), raising the 
prospect that altered CXCR4 expression may have multiple differing effects 
upon memory formation. 
CXCR4 is also expressed upon naïve and memory CD4+ cells and expression 
is upregulated by IL-4 in addition to the common gamma-chain cytokines. 
CXCL12 promotes CD4+ T cell survival through the PI3K and MAPK pathways, 
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inactivated pro-apoptotic mediators and promoted responsiveness to TCR-
mediated signals (234).  Activated dendritic cells induce strong expression of 
CXCR4 on central memory CD4+ T cells in a CD40/CD154 and 
CD134/CD134L dependent interaction (83). These interactions are exploited 
by HIV, allowing T cell tropic strains (X4) to interact with both CD4 and 
CXCR4 and adhere to the cell, inducing conformational changes in 
gp120/gp41 complex and membrane fusion (235). Indeed, mutations in SDF-1 
confer much stronger protective effects against the onset of acquired 
immunodeficiency syndrome (AIDS) than CCR5 and CCR2 variants (236). 
CXCR4 expression is downregulated upon activation of T cells, in the 
opposing direction to expression of CD25.  
The function of CXCR4 in T cells beyond migration is still unclear. CCR5 and 
CXCR4 are co-recruited into the immunological synapse and receptor 
cooperation is required for chemokine-mediated costimulation. This 
recruitment reduces T cell responsiveness to other chemoattractant sources 
and may serve the function of increasing the duration and stability of T cell-
APC interactions and enhancing activation (237). Notably, CXCL12 and CCL3 
(a CCR5 ligand) chemokine gradients are unable to dislodge effector T cells 
bound to ICAM-1 and MHC-peptide complexes, in contrast to ligands for 
chemokine receptors such as CCR7 and CXCR3 (238). Indeed, 
CXCL12/CXCR4 signaling has been shown to be necessary for immune 
synapse formation (239), phosphorylation of TCR-associated adaptor proteins 
(240) and thymic TCRβ-selection (241, 242). 
CXCL12-CXCR4 signaling has been shown to activate multiple downstream 
pathways in T cells, including the extracellular signal-regulated kinases (ERK-
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1 and ERK-2) (64, 243). The mechanism of pertussis toxin inhibition of Gαi-
protein-mediated chemotaxis involves activation of the TCR signalling network, 
which may reflect an evolutionary mechanism to prevent newly activated T 
cells from migrating away from antigen (244). This interaction is bidirectional, 
as close physical association of CXCR4 and the TCR results in 
phosphorylation of the intracellular TCR signaling apparatus and resultant AP-
1 transcription and cytokine secretion (245). Recently, ligation of the TCR has 
been shown to trigger this association, trans-activating a CXCR4 signaling 
pathway resulting in stabilization of IL-2, IL-4 and IL-10 mRNA in naïve and 
memory CD4+ T cells (246). It is therefore possible that altered T cell 
expression of CXCR4 will also modulate T-APC interactions with further 
effects upon differentiation and function.  
 
1.11 T cell homing and the BM microenvironment 
 
A wealth of evidence has suggested the importance of the BM in generating 
and maintaining memory T cells, as it does for other important components of 
the immune system (49, 68, 247, 248). Although T cell precursors migrate to 
the thymus for development of naïve T cells, the BM is a major reservoir for 
protective memory CD8+ T cells, including central memory CCR7+ CD62L+ T 
cells (249, 250). These cells are preferentially recruited to the BM ahead of 
naïve and effector cells due to more efficient selectin and integrin activation 
and adherence to BM microvessels, and increased responsiveness to 
CXCL12 which is required for arrest prior to migration into the BM (3).  
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Naïve and memory T cells differ in their cytokine requirements. Naïve CD8+ T 
cells require IL-7Rα signaling whilst memory T cells require IL-15 for basal 
proliferation although IL-7 is thought to have a role in mediating cell survival 
(251). In contrast, homeostatic proliferation of memory CD4+ T cells demands 
a larger role for IL-7 in addition to TCR signaling and/or MHC class II 
molecules (252-254).  
After antigen clearance, memory CD4+ and CD8+ T cells are maintained by 
slow turnover. The BM has been found by several groups to be the 
preferential site for homeostatic proliferation of memory CD8+ T cells. These 
cells express lower levels of the IL-7Rα (CD127) (255), suggesting that 
proliferation is IL-15 dependent as this cytokine is known to downregulate IL-
7Rα expression in the BM (256) (257).  
IL-15 also promotes the survival of naïve and memory phenotype CD8+ T 
cells at much lower concentrations than those required for proliferation, via 
upregulation of survival signals such as B cell lymphoma 2 (BCL-2) and BCL-
XL (258), and inhibiting activation-induced cell death mediated by IL-2. Both 
IL-7 and IL-15 are known to increase the survival and frequency of early 
memory phenotype native T cells and autologous CAR-T cells, subsequently 
enhancing antitumour immunity via resistance to cell death (212, 259).  
The precise nature of the signals received by T cells in the BM, and the 
phenotype of differing populations of memory T cells is controversial, with 
some groups demonstrating the existence of predominantly resting human 
memory T cells in G0 phase of cell cycle (260), whilst other groups have found 
highly proliferative and activated populations (261). Analogous to 
 59 
haematopoietic stem cells, the possiblity that separate niches exist to support 
both memory T cell proliferation and quiescence has been suggested (262). 
Shortly after acute infection, quiescent cells with lower CD25 and Ki-67 
expression localise to the bone marrow (263). Quiescent human CD8+ 
memory T cells can be mobilised from the BM using the CXCR4 antagonist 
Plerixafor (264). 
This memory niche is thought to be organized by access to mesenchymal 
stromal cells producing IL-7 and IL-15 (265). In support of this concept, 
expression of IL-15 mRNA is much higher in CXCL12-abundant reticular cells 
than other BM cells and NK cells, which require IL-15 for development and 
maintenance, are mostly in contact with these reticular cells (68). High affinity 
IL-15 signalling is mediated by trans-presentation. This is the concept that IL-
15 and the high affinity IL-15 receptor α subunit (IL-15Rα, CD215) are 
expressed by the same cellular source, and bind to memory T or NK cells 
expressing low affinity β and γ receptor subunits to form a high-affinity trimeric 
receptor (266-268). This mechanism is rarely found amongst cytokines and 
has the advantage of controlled cytokine delivery to appropriate cellular 
targets. CXCL12-abundant reticular cells therefore represent a putative niche 
that can trans-present IL-15 to memory T and NK cells (266, 269).   
The BM is therefore a rich source of polyfunctional human memory T cells, 
important for defence against pathogens, and possibly also cancer, as 
suggested by studies highlighting the accumulation of memory CD8+ T cells 
specific for tumour antigens such as WT-1 amongst others within the BM (270, 
271). BM memory T cells display faster antigen responses compared to 
splenic counterparts (272). This is likely to be due to the fact that BM is an 
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important site for antigen-dependent priming of both CD8+ and CD4+ T cells, 
acting as a secondary lymphoid organ to mediate cognate interactions 
observed between clusters of dendritic cells and naïve T cells (273). Further 
studies have found that large clusters of CD4+ memory cells (non-follicular 
helper type) engage in prolonged contact with B cells and antigen laden 
dendritic cells for multiple days post antigen boosting, resulting in pronounced 
numerical amplification. Peritumoural mature DCs in tertiary lymphoid 
structures are associated with extranodal activation, strong CD8+ memory T 
cell infiltration and improved survival in human cancers (274, 275). In a similar 
way, the BM microenvironment could allow for the formation and maintenance 
of ‘immune niches’ as well as memory niches (276, 277).  
The shared transcriptional program between long-term haematopoietic stem 
cells and memory T cells also raises the possibility of overlap between HSC 
and T cell niches within the BM (209). A great deal of attention has been paid 
to the constituents of the HSC niche, and as comparatively little known about 
the localisation and cells that comprise a CD8+ T cell memory niche, a key 
question is whether similar cells can be identified in association with T cells in 
the BM. In order to ask relevant questions regarding the nature of a putative 
memory T cell BM niche, it is therefore important to review the key 
components of the HSC BM niche, with particular reference to CXCL12 
production and signalling (Figure 1-4). 
The precise nature of HSC stromal niches in the BM is a matter of complex 
ongoing investigation with multiple heterogeneous cell types expressing 
overlapping combinations of markers (278-282). The key stromal elements 
are perivascular cells, endothelial cells and osteoblasts, whilst sympathetic 
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nerves, non-myelinating Schwann cells, macrophages and osteoclasts also 
contribute to niche regulation. Sean Morrison’s lab amongst others has shown 
that most HSCs reside close to vascular sinusoids within the bone marrow. 
The highest levels of CXCL12 are expressed by perivascular stromal cells 
(15,000-fold the level of unfractionated BM), then sequentially endothelial 
cells (120-fold), osteoblasts (13-fold) and some cells of haematopoietic origin 
(3-fold) (281). 90% of CD45-PDGFRα+ TER119- mesenchymal cells express 
CXCL12, as compared to 70% of VE-cadherin+ endothelial cells (281, 283) 
(Figure 1-4B).    
Conditional deletion experiments have shown that HSCs are dependent upon 
a perivascular niche, composed of leptin receptor (LepR) or paired related 
homeobox 1 (Prx1)-expressing perivascular stromal cells, in addition to 
endothelial cells (284). The close spatial association of perivascular 
mesenchymal and endothelial cells may be therefore be important for 
cytokine-mediated cellular development and full niche functioning (285). Niche 
positioning also regulates cell cycle status. Quiescent HSCs associate with 
sparse NG2+ Nestin-GFPbright arterioles, as opposed to Nestin-GFPdim 
sinusoids (286). Depletion of these periarteriolar cells induces HSCs into cell 
cycle and reduces long-term repopulation ability.  
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In contrast, early lymphoid progenitors (common lymphoid progenitors (CLP) 
and IL7Rα+ lymphoid-primed multipotent progenitors (LMPP) occupy a 
spatially distinct niche dependent upon endosteal cells expressing the 
osteoblast-lineage type I collagen a1 promoter (Col2.3) (281, 282). 
Interestingly, committed B lineage progenitors have been shown to return not 
to this endosteal niche but a perivascular Prx-1+ stromal niche. These Prx-1+ 
cells overlap strongly with the above-mentioned CD45+PDGFRα+ TER119- 
mesenchymal cells and CXCL12-abundant reticular cells (52, 287, 288).  
A niche for mature T cells, quiescent or otherwise, has not yet been identified. 
In vivo imaging has identified Treg cells co-localising with HSCs on the 
endosteal surface of the BM post allogeneic transplant to provide immune 
sanctuary (289). Treg cell trafficking to the BM is dependent upon 
CXCL12/CXCR4 (290), suggesting that the CXCR4/CXCL12 axis is one of the 
critical factors dictating the balance between tolerance and immunity in the 
BM as in other stromal and malignant niches (169, 291, 292). Given the 
frequency of bone marrow metastases in solid tumours, the bone marrow has 
been suggested as an immuno-suppressive microenvironment (293) and 
further detailed study of the interaction between inflammatory and regulatory 
populations within the niche is required. Murine bone marrow transplant 
(BMT) models have demonstrated that BM-derived CD8+ T cells possess 
strong anti-tumour activity but induce lower rates of GVHD. The mechanism 
underlying this is still unclear but may relate to lower proportions of naïve or 
effector memory T cells (294, 295). 
The prevailing view in the field is thus that tissue niches play a major role in 
determining cell fate in health and disease. Specifically, the bone marrow 
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niche is thought to be vital for the maintenance of normal haematopoietic 
stem cells. Leukaemic cells have been suggested to remodel this 
microenvironment to their own advantage, disrupting normal HSC niches and 
sequestering normal stem cells (296-298). Human acute myeloid leukaemia 
stem cells (LSCs) engraft in osteoblast-rich endosteal regions of murine BM, 
which may mediate apoptosis resistance via quiescence (299). In contrast, 
chronic myeloid leukaemia cells induce a reduction in BM CXCL12 expression, 
abnormal LSC localisation and suppression of normal HSC growth (300), 
suggesting that variations in disease-specific niches may require differing 
therapeutic approaches.  
Recently, in vivo imaging of human T-cell acute lymphoblastic leukaemia (T-
ALL) in a murine model from Cristina Lo Celso’s lab has upended dogma by 
suggesting that T-ALL migrate dynamically across multiple BM regions rather 
than using a specific BM niche (301). Furthermore, chemotherapy resistant 
cells were highly migratory, suggesting that survival in this model may be 
stochastic rather than niche-dependent. Importantly, disease progression 
induces endosteal remodelling, resulting in depletion of mature osteoblasts 
while preserving perivascular mesenchymal stroma. This accords with other 
studies demonstrating osteoblast loss in acute myeloid leukaemia (AML) (302, 
303) and dysfunctional osteoblast expansion in myeloproliferative neoplasia 
(304). 
The Lo Celso study suggests the possibility that cellular therapies with similar 
migratory capacities to leukaemic T cells may be more effective than specific 
pharmacological interventions targeting the niche. Furthermore, disease-
induced remodelling of the BM niche, in particular CXCL12-producing cells, 
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may alter the trafficking abilities of engineered therapeutic T cells in 
unexpected ways. For example, T-ALL express CXCR4 at higher levels than 
normal CD4+ and CD8+ T cells, hence over-expression of CXCR4 in 
therapeutic T cells may mimic and disrupt the ability of T-ALL to interact with 
multiple stromal components. Alternatively, loss of a physiological memory T 
cell niche may similarly affect the survival and function of therapeutic T cells. 
Defining the existence and nature of a cellular niche for therapeutic T cells is 
therefore of great importance in the era of adoptive immunotherapy. 
Despite the important contributions of the studies above, no studies have yet 
shown that directly modulating T cell trafficking to the bone marrow alters 
phenotype. Higher CXCR4 expression on pathogenic T cells in immune-
mediated aplastic anaemia facilitates BM entry, suggesting a viable 
mechanism for improving T cell homing to immune niches within the BM (291). 
Of relevance to this concept, genetic deletion of CXCR4 in mature CD8+ T 
cells does not alter antigen-dependent expansion but markedly reduces 
homeostatic self-renewal and memory T cell frequency, particularly in the BM 
(305). 
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Figure 1-4 The stromal BM microenvironment.  
(A) The bone marrow niche comprises many different cell types 
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residing within the marrow cavity. The interface between bone and 
bone marrow, known as the endosteum, contains bone-forming 
osteoblasts. Many haematopoietic cells reside close to blood vessels, 
particularly sinusoids, which allow cell migration from the circulation, 
and oxygenated arterioles. Vascular structures are covered on the 
lumenal side by endothelial cells, and ensheathed by perivascular 
stromal cells, including CXCL12-abundant reticular (CAR) cells. (B) 
Schematic indicating the degree of CXCL12 production in various 
stromal populations. Perivascular stromal cells targeted by Cre-
mediated recombination of identifying transcription factors (Prx1 and 
LepR) overlap with Nestin-Gfp+ cells in producing the largest amounts 
of CXCL12, and progressively lower amounts are produced by osteo-
progenitors (marked by Osterix-cre), endothelial cells (Tie2-cre) and 
osteoblasts (Col2.3-cre). 
 
 
1.12 Immunotherapy and its challenges 
 
1.12.1 The range of immunotherapeutic agents 
The possibility of redirecting the immune system to treat cancer has been well 
described for some time now. In 1891 William’s Coley’s pioneering 
streptococcal injections into sarcomas to stimulate an immune cycle were 
published as case series’ and not taken up widely by the field. The dangerous 
side effects, including systemic fever, were cited as a major disadvantage. 
Over one hundred years later, bone marrow transplantation is well established 
as a powerful treatment for haematological malignancies but there is now 
increasing interest in manipulating the immune system to evoke specific 
immunogenicity against neoplastic cells. Active agents currently being 
explored include T and DC growth factors and agonists, antagonists of 
immunosuppressive cytokines, immune checkpoint inhibitors (CPI), vaccines 
and cellular therapies (including CAR-T cells, TCR-modified T cells, tumour-
infiltrating lymphocytes (TILs), NK and gamma delta T cells). 
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Immune growth factors and agonists 
The original ‘T-cell growth factor’, IL-2, was discovered in 1976 and greatly 
facilitated experimental exploration of the T cell properties. Although approved 
for use in metastatic renal cell carcinoma and melanoma, high expression of 
IL-2Rα (CD25) on Treg cells potentiates a dual immune effector and regulatory 
function, raising concerns over excessive differentiation and limited anti-
tumour utility (306). Memory T cells generated without IL-2 predominantly 
express a central memory phenotype and retain CD62L expression and IL-2 
secretory capacity. In contrast to the usual paradigm of CD4+ ‘helper’ T cells 
providing the majority of IL-2, autocrine CD8+ T cell IL-2 secretion is thought to 
permit memory expansion (307, 308). This concept suggests complementary 
and opposing roles in immunity for the other common gamma chain cytokines, 
particularly IL-15.  
Human IL-15 is encoded close by IL-2 on the short arm of chromosome 4, 
and binds to the same β (CD122) and γ receptor subunits (CD132), yet 
shares little homology with IL-2 at the protein level and initiates a distinct gene 
expression program culminating in maintenance of memory CD8+ T and NK 
cell homeostasis with limited differentiation (309). The mechanism of this 
distinctive effect is not fully understood but may be mediated by the in vivo 
requirement for trans-presentation (310). This model suggests that IL-15 
acquires some of the property of a cell surface molecule, requiring close 
physical proximity for activity and potentially mediating more potent signaling 
in a niche environment. This makes immuno-regulatory sense, preventing 
formation of an intrinsic amplification loop through memory CD8+ T expression 
of IL-15Rα. Trans-presented IL-15 was initially suggested to be primarily 
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dendritic cell and monocyte-derived; however recent reporter mice 
experiments have demonstrated non-haematopoietic stromal niches to be the 
major sources, particularly CXCL12-abundant reticular cells in the BM (311).  
IL-15 enhances antitumour activity of CD8+ T cells in poorly immunogenic 
tumours (312) and reduced levels of IL-15 are associated with malignancy 
relapse post allogeneic bone marrow transplant (313). IL-15 is the number 
one target in a list of twelve immunotherapy drugs formulated by the US 
National Cancer Institute (NCI) as having the greatest potential to cure cancer 
in novel combination therapies (314). In inflammatory settings, IL-15 permits 
more rapid division of memory cells after antigen encounter and enhances 
protective capacity (315). Studies in IL-15 deficient mice show similar deficits 
in CD8+ memory T cells to mice lacking CXCR4 (316).  
IL-15 also induces expression of several costimulatory TNF receptor family 
proteins such as glucocorticoid induced TNFR-related protein (GITR) and 4-
1BB (CD137) on BM memory CD8+ T cells in contrast to other secondary 
lymphoid tissues such as spleen and LN (317, 318). 4-1BB is required on T 
cells for maximal recall responses and more accurately identifies tumour-
reactive TILs than PD-1 (319). 4-1BB is more highly expressed on tumour-
reactive and BM memory CD8+ T cells compared to spleen and LN, in an 
antigen-independent mechanism dependent upon IL-15 (318, 319), while 4-
1BBL expression on VCAM-1+ BM stromal cells provides survival signals 
downregulating pro-apoptotic Bim signaling in BM CD8+ T memory cells (320).  
Engineering of costimulatory domains is an active area of study for 
researchers aiming to shape the effector/memory balance and functional 
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capacity of therapeutic T cells. Inclusion of a 4-1BB intracellular domain in 
chimeric antigen receptor T cells (CAR-T cells) enhances in vitro persistence 
by increased fatty acid oxidation, forms superior quality immune synapses 
and enhances anti-tumour efficacy (321-323) while CAR-T cells incorporating 
CD28 domains demonstrated enhanced aerobic glycolysis characteristic of 
effector T cells (324). Intratumoral CD8+ T cell apoptosis has been shown to 
be a major component underlying T cell dysfunction and preventing effective 
antitumour immunity in mouse models (325), while a concern regarding tonic 
CAR-T cell CD3-ζ phosphorylation is the early induction of exhaustion, limiting 
anti-leukaemia efficacy (326). Mechanisms for enhancing T cell persistence in 
these settings are hence much sought after. A 4-1BB agonist antibody 
combined with checkpoint inhibition increases accumulation of TILs through 
enhanced survival rather than proliferation, resulting in synergistic tumour 
control in murine models, and suggesting the potential for further exploration 
of this idea (325).   
A cautionary note is provided by the observation that IL-15-dependent NK 
cells can develop ageing-related dysfunction and impaired cytotoxicity due to 
defective maturational cues from BM stromal niches (327). Research targeting 
BM stromal niches as a source of cells for immune therapy must consider the 
effects of an ageing niche and proinflammatory cytokines. IL-6 and IL-15 are 
known to be increased in the ageing human BM, as are TEM and a putative 
highly activated CD28-CD57- CD8+ T cell population, and this may have 
relevance for the use of adoptive immunotherapies in older people and 
damaged stromal niches (328). 
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IL-7 is similarly known to promote CD8+ T cell survival in both the naïve and 
memory setting. It signals through a heterodimeric receptor composed of IL-
7Rα (CD127) and CD132 but is thought to be more important for CD4+ T cell 
development and homeostasis. CD127 expression has been suggested as a 
marker of CD8+ T cells fated for long-term memory development (329). 
Limiting secretion from non-haematopoietic stromal niches in the thymus and 
bone marrow is enhanced during periods of lymphopenia and induces 
expression of BCL-2 family members (330). Recombinant IL-7 has shown pre-
clinical promise in amplifying polyfunctional CD4+ antitumour effects and 
immune reconstitution, but may also potentiate B-cell malignancies, and 
aggravate GVHD in the post-allogeneic transplantation setting, limiting its 
utility (331-334).  
IL-21 is another common gamma chain cytokine of clinical interest in 
promoting a less differentiated CD27highCD28high CD45RO+ CD8+ T cell 
phenotype. Produced by activated CD4+ T cells, it is non-essential for 
lymphoid development but synergises with IL-7 and IL-15 to promote naïve 
and memory CD8+ T cell proliferation and IFN-γ expression (335-337). Finally, 
IL-12 has been suggested as a potent anti-tumour cytokine, primarily secreted 
by activated APCs, shaping a TH1-biased innate and adaptive immune 
response. Despite this mooted potency, clinical trials have been limited by 
toxicities, development of adaptive negative feedback to IFN-γ generation and 
a myeloid-coordinated immunosuppressive milieu (338, 339). Combination 
approaches are under investigation, such as T cells redirected for universal 
cytokine-mediated killing (TRUCKs), which aim to deposit IL-12 in the tumour 
and unleash an immuno-stimulatory cycle (340). 
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Checkpoint inhibition 
As more became known regarding the role of immune evasion in cancer, a 
handful of researchers identified proteins on T cells that appeared to inhibit 
their action. CTL activation gene number 4 (CTLA-4) was initially identified in 
activated T cells but despite sequence homology with the pivotal costimulator 
CD28, it was found to have an inhibitory role, binding with significantly greater 
binding affinity to the B7 ligands than CD28 (341, 342). Researchers 
interested in apoptosis first identified programmed cell death protein 1 (PD-1) 
and further collaborations identified its ligands as homologous to the B7 
ligands (343, 344). The finding that deletion of either of these molecules 
results in autoimmunity led to the key conceptual breakthrough - the immune 
system as a finely tuned network of opposing forces, ripe for exploitation. This 
equilibrium, termed the ‘cancer-immune set point’, is defined as the balance 
between factors acting to enhance and subdue antitumour immunity (345). 
The fact that T cell stimulation in the absence of a vaccine can induce disease 
regression further suggests a requirement for therapies able to potentiate 
latent tumour-specific potential within many patients. The discovery that the 
newly discovered PD-1 ligand (B7-H1) is not expressed in normal tissues but 
upon a range of human cancers, and that expression is upregulated upon 
exposure to IFN-γ, led to the conclusion that cancer cells have hijacked the 
utility of co-inhibitory molecules to evade immune attack (346). Previous 
attempts to harness immune potency by vaccination had elicited weak and 
ineffective responses, but the fatal lymphoproliferative disease seen in Ctla4 
knockout mice, suggested the potency of CTLA-4 compared to CD28 as a 
means of dramatically enhancing these weak responses. James Allison and 
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others were subsequently able to prove that this approach could enable 
checkpoint inhibition as an entirely novel method of cancer treatment (347).  
The differences between patterns of checkpoint molecule expression on 
immune subsets have allowed for experimental dissection of their 
mechanisms, and potential utility in different scenarios. CTLA4 is expressed 
only upon activation, predominantly by Treg cells. Inhibition is associated with 
a high degree of autoimmune side effects, suggesting that blockade or 
depletion of Treg cells may be the major mode of action (348). In contrast, PD-
1 is expressed on activated T and B cells but is sustained in a subset of 
antigen-specific T cells rendering them inactive in chronic viral infection and 
cancer (349, 350).  IFN-γ produced by cytotoxic T lymphocytes is a key 
pathway targeted for immune evasion by upregulation of the key checkpoint 
ligands PD-L1 and PD-L2 on malignant and accessory cells (351). The 
hallmarks of exhausted PD-1HI cells are co-expression of a host of inhibitory 
receptors such as Tim-3 (T cell immunoglobulin and mucin domain-containing 
protein 3), Lag-3 (lymphocyte activation gene 3) and TIGIT (T cell 
immunoglobulin and ITIM domain) amongst others.  They are poorly 
responsive to common gamma-chain cytokines such as IL-2, IL-7 and IL-15, 
have impaired homeostatic proliferation and a reduced capacity to produce 
IFN-γ, IL-2 and TNF-α upon re-stimulation (352). 
Melanomas as the prototypical immune-sensitive tumour are highly mutated 
(0.5 to >100 mutations per megabase) and have been shown to be highly 
sensitive to immune checkpoint blockade by antibodies to CTLA-4 and PD-1 
(353). Patients with a higher mutational burden were more likely to experience 
durable clinical responses, hinting that the genetic diversity of cancer may be 
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an Achilles heel in the context of immunotherapy. Responses to PD-1 
blockade in melanoma patients have been shown to correlate with increases 
in the number of CD4+ central memory T cells (354). Importantly, patients 
responding to CPI show a survival plot plateau at 2 years, suggesting that 
long-term immunosurveillance can produce functional cures (355). 
In efforts to analyse the mechanisms underlying some of the extraordinary 
responses to PD-1 blockade in advanced cancer, some groups have defined 
a CXCR5+CD8+ T cell subset that preferentially proliferates after antibody 
treatment in chronic viral infection and express higher levels of co-stimulatory 
receptors such as OX40 and 4-1BB. They are enriched for genes associated 
with mitochondrial fatty acid oxidation and exhibit a transcriptional profile 
similar to memory precursor cells, including markedly enhanced expression of 
CXCR4 (356, 357). In contrast to the primarily metabolic effects of PD-1 
blockade, profiling of TILs post CTLA-4 blockade show changes in cell cycle 
and effector memory pathways (358). Further studies in viral infection have 
highlighted heterogeneous subsets of PD-1+ T cells with differing roles. 
‘Progenitor-like’ T-betHI PD-1INT CD8+ T cells are more susceptible to the 
proliferative effects of CPI, but can develop into the terminally differentiated 
EomesHI PD-1HI subset, which localise to peripheral tissues and lack the 
capacity for restoration of T cell functions, possibly due to lack of CD28 (359, 
360). The ratio of the magnitude of T cell response to tumour size has been 
directly correlated with anti-PD-1 response in metastatic melanoma, 
highlighting the importance of the size of the PD-1+CXCR5+ population (361). 
Although PD-1/PD-L1 inhibitors have mediated powerful responses in 
tumours such as melanomas and non small cell lung cancer, these tumours 
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bear a median of 200 nonsynonymous mutations per tumour (362). The 
response to CPI correlates with the tumour mutation burden and PD-L1 
expression (363, 364). Other cancers such as acute myeloid leukaemia 
express lower numbers of mutations.  These cancers are expected to be less 
intrinsically immunogenic, and may also deploy additional immune evasion 
strategies. Furthermore, recognition of mutant antigens is inefficient; only a 
fraction of peptides derived from potential neoantigens are in fact 
immunogenic. Rational strategies are also required to overcome the key 
issues of (a) defective homing to the tumour site and (b) an 
immunosuppressive microenvironment. Durable complete responses (CRs) to 
CPI are limited to a small subgroup (<20%) in most studies, whilst off-target 
treatment-related adverse events are extraordinarily common, and frequently 
severe (365). As with the notable examples of curative chemotherapeutic 
regimes, combination therapy is likely to be required to increase cure rates, in 
addition to strategies targeting multiple tumour-associated antigens. Recent 
novel work has hinted at the importance of enhancing T cell homing; 
alterations of microbiome can enhance efficacy of PD-1 blockade in an IL-12 
dependent manner by inducing recruitment of CCR9+CXCR3+CD4+ T cells 
into the tumour (366, 367). 
 
Cellular therapies and vaccines 
Preliminary studies have suggested the effectiveness of combination PD-1 
pathway blockade and adoptive T cell therapies in increasing T cell 
persistence, activation and chemokine homing capacities (368, 369). 
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Generation of T cells specific for mutation-associated peptides and 
personalized vaccines has also been shown to be feasible. Use of vaccination 
to enhance engineered T cell homing to solid tumour sites is therefore an 
attractive approach to overcome defective localisation (370). Further 
combinatorial approaches using novel nanomaterial-based delivery 
mechanisms, dendritic-cell based vaccines, oncolytic viruses or adoptive 
therapy with novel combinatorial CAR-T cells or TCR-transduced T cells are 
likely to be incrementally more successful (371, 372). Current CAR-T 
protocols have yielded historically high responses rates in the 
relapsed/refractory setting of CD19+ haematological malignancies but toxicity 
is an issue and relapses are frequent in the adult setting, only some of which 
relate to antigen-loss variants (373, 374). There is therefore an important 
therapeutic need for cellular therapies suitable for older patients and 
mediating long-term disease control. 
A recent example used established granulocyte-macrophage colony-
stimulating factor (GM-CSF)-producing cellular cancer vaccines formulated 
with cyclic dinucleotides to induce type 1 interferon responses and hence DC 
and CD8+ T cell activation. This approach uses pathogen-associated 
molecular patterns (PAMPs) to elicit activation of the innate immune system 
via the stimulator of interferon gene (STING) signaling pathway. This can in 
turn be harnessed to effective adaptive antitumour immunity by combination 
with PD-1 blockade (375). Other novel tactics include using anti-tumour TCR-
engineered cells with a second TCR recognizing a bacterial antigen to 
enhance tumour homing and reverse microenvironment immunosuppression, 
consistent with the known effects of pathogen-based immunotherapies in 
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altering the phenotype of MDSCs and inducing IL-12 production (376-378). 
Steve Rosenberg at the National Cancer Institute, a pioneer in the field of 
genetically modified lymphocytes to treat human cancer, has achieved 
durable remission in hard-to-treat large breast and liver tumours using dual-
specific CAR-T cells and tumour antigen vaccination incorporating vaccinia 
virus. In this setting considerable T cell infiltration was achieved in a CXCR3-
dependent pattern (379). 
 
Combination regimes and synthetic niches 
It may be also possible to combine therapies enhancing a particular cell fate 
with synergistic molecular agents. Demethylating agents (DNMTis) such as 
azacitidine and decitabine are active agents in treatment of myeloid 
leukaemias and are known to increase expression of multiple endogenous 
retroviruses (ERVs) and upregulate tumour-associated antigens and co-
stimulatory ligands. This leads to induction of a double-stranded RNA 
(dsRNA) sensing pathway and enhanced T cell infiltration (380-383). There is 
potential for synergistic use of DNMTis in combination with memory T cells 
specific for leukaemia-associated antigens such as WT-1, MAGE-A and 
PRAME. This allows for targeting of resistant or quiescent tumour stem cell 
populations responsible for relapse. Encouraging historically high complete 
responses to azacitidine and PD-1 blockade combination therapy in relapsed 
AML are associated with progressive increases in BM CD8+ T cell infiltration, 
suggesting the importance of enhanced lymphocyte homing (384).  
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The use of radiation or poly ADP ribose polymerase (PARP) inhibitors to 
prevent repair of single-strand DNA breaks, can synergize with CPI, linking 
chronic DNA damage with formation of a proinflammatory immune 
environment involving enhanced chemokine production (385, 386). 
Other strategies to mobilise patient T cells in site-specific approaches are 
promising. A direct pre-clinical approach involves injecting a TLR9 ligand 
directly into tumour to induce expression of the TNFR superfamily 
costimulator OX40 on intratumoral CD4 T cells. Combination therapy with an 
anti-OX40 antibody resulted in cure of the majority of mice in a variety of 
tumour models, in contrast to combination with anti-PD1 antibodies. 
Interestingly, the mechanism here seems to involve OX40 stimulation directly 
impairing Treg immune suppression, resulting in myeloid cell infiltration, and 
CD8+ T and NK cell activation (387). Further approaches in this vein to break 
tumour-specific tolerance are likely to be highly effective because they target 
the microenvironment without inducing systemic toxicity. 
Synthetic immune niches represent another promising concept to reprogram 
an antitumour response. Reminiscent of tertiary lymphoid structures, they 
consist of biomaterial-based scaffolds designed to mimic lymph nodes. The 
porous structure acts as a finely tuned delivery vehicle for T memory and 
other immune effector cells, loaded with antigen-presenting cells and 
immunostimulatory ligands. This provides the advantage of retaining cells in a 
tumour-specific location while providing them with activation cues such as IL-
15 superagonists, cytokines and CpG oligonucleotides, and has been shown 
to be more effective than directly injected ex vivo stimulated T cells in the 
presence of an immunosuppressive microenvironment (388-390). The 
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scaffolds can be tailored to the precise type of tumour targeted, in terms of 
pore structure and biomolecule integration. For example, chemokine receptor-
expressing T cells could be induced to localise towards a scaffold expressing 
the reciprocal chemokine for optimal in vivo activation at the tumour location 
(391). Experimental models have demonstrated important roles for CD8+ DCs 
and plasmacytoid DCs (pDCs) in association with heightened local 
concentrations of IL-12 and GCSF in successful melanoma vaccines (392, 
393). These therapies can be combined with agents that directly counter 
immuno-suppressive microenvironments such as immune checkpoint and 
TGF-β inhibitors (394-396). Considerable hurdles need to be overcome in 
terms of understanding these complex molecular and physical interactions, 
selecting rational combinations from a bewildering choice, limiting chronic 
inflammation and toxic degradation, and ensuring the safety of complex cell 
and biomolecule-based systems. 
 
Haematopoietic stem cell transplantation 
Whilst awaiting the development of precision immunotherapies effective 
against molecularly targeted populations, the optimal treatment for many 
poor-risk haematological malignancies remains the original immunotherapy – 
allogeneic haematopoietic stem cell transplant. This is still the most powerful 
and durable anti-leukaemic treatment yet developed, predicated as it is upon 
adaptive immune recognition of minor histocompatibility antigens expressed 
by host leukaemic cells. In this regard, strategies to enhance the survival and 
persistence of anti-viral T cells in the setting of delayed immune reconstitution 
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and life-threatening infection, or to enhance the graft versus leukaemia (GVL) 
effect mediated by donor lymphocyte infusions without triggering GVHD are 
much needed. Precise mechanistic separation of GVHD from GVL has not yet 
been achieved in the clinic. Use of adoptive cellular therapy in conjunction 
with inducible suicide genes could mitigate this risk, reducing the element of 
risk accompanying every transplant currently performed. One concern 
regarding use of potent CD62L+ early memory phenotypes is the possibility of 
increased incidence and severity of GVHD, hence experimental 
demonstration of utility will also need to provide of safety (397). Interestingly, 
the use of CD19 CAR-T cells of defined CD8+ TCM and CD4+ T cell 
composition post-allograft was associated with very low levels of GVHD in 
clinical studies (398, 399). This is in stark contrast to the rates of severe 
treatment-refractory GVHD post allograft and immune-related adverse events 
generally seen with CPI such as the PD-1 antibody nivolumab, and suggests 
an advantage for cell-specific therapy in an immune-inflamed environment 
(400). 
 
Targeting somatic neoantigens 
A number of lines of evidence support the proposition that targeting somatic 
neoantigens (the products of unique patient-specific tumour mutations) will 
eventually become a definitive and potent form of cancer immunotherapy 
(401). Tumours with high somatic mutation burdens are particularly 
responsive to immunotherapy. Driver mutations are by definition required to 
enable tumour growth hence targeting is expected to cause tumour death or 
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loss of fitness. Secondly, the exclusivity of neoantigens renders toxicity to 
normal tissues highly unlikely. Thirdly, T cells expressing TCRs specific for 
new tumour neoantigens are unlikely to have been deleted by central 
tolerance during thymic education and may well be present in patient’s blood. 
TILs extracted from patients with melanomas induce durable CRs with 
minimal autoimmune toxicities, in contrast to CPI and TCR gene-engineered T 
cells targeting pigment antigens (162, 402). CD19 is in many respects an 
exception in that elimination of expression in normal tissues by B cell 
depletion can be safely managed. Targeting differentiation, cancer germline 
and over-expressed antigens expressed on normal tissue such as 
carcinoembryonic antigen (CEA) can mediate severe toxicity and are likely to 
be ineffective, in part due to high-avidity TCR-bearing cells undergoing thymic 
deletion (403, 404).  
Somatic patient-specific neoantigens can now be readily identified. The rapid 
availability of whole exome and transcriptome sequencing can be used to 
analyse circulating tumour cells (CTCs) or biopsy specimens for founder 
mutations likely to be expressed in all tumour cells (405-407). Mutation-
encoding minigenes can then be introduced into autologous antigen-
presenting cells and cultured with PD-1+ patient T cells to identify tumour-
reactive T cells. These TCRs can then be sequenced and used to modify 
expanded patient T cells for re-infusion. This method has been used to 
identify tumour-reactive T cells even in patients with low mutation burden 
cancers (406, 408). Furthermore T cells from one patient were found to target 
the KRASG12D hotspot common to many human cancers, suggesting potential 
widespread utility of this technique in targeting clinically important ‘trunk’ 
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mutations (409). As yet, these T cells cannot mediate high remission rates, 
again highlighting the need for improved methods to enhance potency and 
persistence of the transferred cells. Key determinants of immunogenicity 
include the binding affinity between mutated peptides and MHC (410) and 
downregulation of antigen processing and presenting machinery (411, 412). 
Overcoming these challenges may require use of combination therapies 
targeting intratumoural heterogeneity and the genetic instability that is the 
hallmark of cancer. 
 
1.12.2 The cancer immune set point  
A successful anti-tumour cellular therapy must surmount several hurdles. 
Immune cells must be able to traffic to the tumour site, overcome local 
immune evasion strategies to infiltrate and recognise tumour antigens as 
foreign, expand and successfully destroy large tumour burdens, all whilst 
minimising off-target systemic tissue damage. As a means of understanding 
how to rise to these challenges, histological data investigating the low 
frequency of responses to anti-PD-1 pathway antibodies has been 
interrogated to yield three conceptual types of immune profile (413, 414).  
The immune-inflamed profile comprises frequent T cells within the tumour 
parenchyma, associated with checkpoint ligand expression on tumour cells 
and suppressive populations. Responses to CPI are most often associated 
with this profile, suggesting a pre-existing immune response requiring 
potentiation. The rate-limiting step in this profile is therefore the differentiation 
and exhaustion phenotype of the T cell (415). 
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In contrast, the immune-excluded phenotype constitutes abundant T cells in 
the tumour stroma, suggesting the evasive strategy has limited their 
penetrative ability. The rate-limiting step here constitutes T cell homing to the 
tumour parenchyma. Finally, the immune desert phenotype contains few T 
cells, presumably due to non-immunogenic tumours carrying few neoantigens, 
and subsequent lack of a native anti-tumour T cell response as the rate-
limiting step (345). These phenotypes represent a useful simplification of the 
vast diversity of immune evasion strategies, to aid in design of differing 
therapeutic strategies.  
In the first profile, exhausted T cells acquire transcriptional and epigenetic 
modifications distinct from memory cells, rendering the majority insensitive to 
anti-PD-1 blockade alone.  Successful antitumour cells may therefore require 
a persistent early memory phenotype despite repeated antigenic stimulation. 
The response to homeostatic cytokines (IL-7) is augmented by PD-1 blockade, 
suggesting a rationale for combination therapies focusing on these pathways. 
This could be performed in conjunction with genetic modifications aiming to 
limit exhaustion and re-activate important transcription factors, perhaps 
through modification of PDCD1 gene enhancer regions (416, 417). The role of 
the microbiome in enhancing systemic immunity will also be highly relevant 
(366, 367). 
In contrast, the non-inflamed microenvironments of immune-excluded and 
immune desert profiles require the generation of a functional anti-tumour 
response able to successfully expand and target the tumour.  TCXCR4 have 
demonstrated enhanced and functional capacities fitting these specifications. 
In addition, their homing capacities have been engineered to be particularly 
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relevant to the requirements of haematological malignancies. One could 
envision the infusion of early memory T cells equipped with TCRs recognizing 
disease and pathogen-specific antigens and chemokine receptors specialized 
for particular tumour profiles, in conjunction with intratumoral pathogen-based 
vaccination to enhance inflammatory signalling (376). Increased leucocyte 
chemokine levels have been noted in association with complete responses to 
CTLA-4 blockade for relapsed extramedullary acute myeloid leukaemia post 
allogeneic stem cell transplant (418). This suggests a further pathway for 
exploiting low mutational burden tumours, and also hints at the importance of 
exploiting lymphocyte trafficking in specific high-risk situations.  
Further useful combination strategies to promote antitumour responses could 
involve targeting angiogenesis and epigenetic repression of chemokine 
expression. Expression of vascular endothelial growth factor-C (VEGF-C) in 
melanoma potentiates cancer immunotherapy via enhanced CCL21 and T cell 
tumour infiltration, hence strategies enhancing angiogenesis may be effective 
in inducing tumour-associated inflammation (419). Tumour-intrinsic β-catenin 
signalling and epigenetic silencing of genes encoding TH1-type chemokines 
such as CXCL9 and CXCL10 represses T cell infiltration and impairs patient 
survival (420-422). Pharmacological epigenetic modulation such as β-catenin 
suppression and enhancer of zeste homologue 2 (EZH2) and DNMT inhibitors 
(421, 423-425) could be combined with adoptive cellular therapy incorporating 
memory T cells to render the tumour immunologically ‘hot’ and promote potent 
T cell recruitment.  
Needless to say, the vast range of cancers represent a continuum of multiple 
immune evasive strategies and the success of therapies may depend 
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stochastically on the balance of immune suppressive and inflammatory 
phenotypes in the individual patient. The cancer-immune set point is therefore 
a useful theoretical concept to define the threshold to be reached for 
successful anti-cancer treatment in groups of patients with specific molecular 
profiles, to guide the design of rational combination therapies (345).  
 
1.12.3 Challenges to the delivery of successful immunotherapies  
 
The complexity of genetic analysis and manufacturing cellular therapies to 
GMP standards represents a major challenge to existing clinical infrastructure 
that has traditionally deterred pharmaceutical investment. The step-change in 
the clinical environment following on from the dramatic success of CD19 
CAR-T cell and CPI therapies has completely altered this dynamic. Novel 
mechanisms for exploiting the potential of the immune system are rapidly 
being investigated. There are however a number of different technical, 
financial and regulatory hurdles before this success can be replicated in a 
wider range of cancers.  
The first issue is the lack of truly tumour-specific antigens suitable for 
targeting by the single-chain variable fragment (scFv) of CAR-T therapies. 
The majority of antigens currently under investigation such as mesothelin are 
also expressed to varying levels by normal tissues and there is potential for 
considerable on-target off-tumour toxicity (426-428). The solutions to this 
could involve use of safety switches to delete or regulate CAR-T activation. 
Suicide genes such as herpes simplex virus–thymidine kinase (HSV-TK) or 
inducible caspase-9 (iCasp9) have been shown to be effective, but can also 
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compromise the anti-tumour response (429, 430). A more subtle approach 
under investigation is to engineer CAR-T cells to require two separate tumour 
associated antigens for full activation (logic-gated CARs), inhibitory CARs 
(iCARs) or CARs in two parts requiring infusion of a small-molecule dimerising 
agent for precision assembly (ON-switch CARs) (431-433). 
A second solution is to find antigens uniquely expressed by the tumour in 
question, such as virally encoded genes (human papillomavirus) and driver 
gene mutations (KRAS, NRAS, etc) (434, 435). Heterogeneous tumour 
expression and selection for antigen-negative cells could compromise 
responses however, as would the requirement for compatible HLA haplotypes 
(436, 437). In this respect, an important development would be a clinical 
pipeline for targeting patient-specific neoantigens using autologous T cell 
therapy (401, 438). This pathway has been highly refined and offers the 
advantage of direct testing of CD8+ and CD4+ T cell reactivity to multiple 
neoantigens. Firstly, next-generation sequencing of tumour versus germline 
tissue identifies all non-synonymous mutations and constructs are 
synthesized encoding the mutant gene plus flanking codons. Autologous 
dendritic cells can then be transfected with construct RNA, or pulsed with 
mutant peptide, allowing for processing and presentation. We can then 
measure T cell reactivity to these cells in tandem using cytokine or activation 
molecule-based readouts (439).  
This workflow has been demonstrated with some success in treating patients 
with metastatic cancer, even in cases lacking high mutation burden or 
evidence of DNA mismatch repair (406, 409). It offers the advantage of 
targeting a number of mutations simultaneously, combating Darwinian 
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selection from heterogeneous clones (440). This approach benefits from 
avoiding limitations associated with current algorithms, such that of hundreds 
of predicted neoantigens, only a handful generate proven T cell responses 
(358, 370, 406, 441). Improvements in understanding of proteasomal 
processing and MHC-binding stability will also improve the accuracy of 
predictive mathematical modeling (442). 
Any strategy involving targeting of neo-epitopes must contend with the Red 
Queen effect: a successful strategy will become a victim of its own success 
due to selection for resistance (443). This risk is neatly highlighted by a recent 
case study using combined immunogenomic approaches to characterise 
immune infiltration into spatially distinct ovarian cancer metastases in one 
patient whilst off treatment (444). In a fascinating example of immune evasion 
at work, regressing metastases were infiltrated by oligoclonal expansions of T 
cells whilst progressing lesions displayed minimal infiltrates. Interestingly, site 
of later metastases had the highest neoantigen loads but no predicted 
neoantigens were shared between differentially responsive sites. Importantly, 
when the evolutionary relationship between tumour samples was 
reconstructed, truncal somatic mutations displayed lower immunogenicity 
scores than branched subclonal mutations. This, coupled with the lack of 
immune infiltrate in the primary tumour, suggests that mutations shared by 
every tumour cell are most likely to be eliminated, highlighting 
immunogenomic heterogeneity as a barrier to successful immunotherapy.  
Destruction of the tumour cell is known to release further tumour-specific 
antigens to increase the depth of any adaptive immune response via cytokine 
and chemokine amplification. A generalizable approach will likely require 
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synchronous targeting of multiple neoantigens associated with different HLA 
molecules to overcome heterogeneity. Single melanoma antigen (MAGE) 
vaccination or Epstein-Barr virus (EBV)-targeted T cells can mediate T-cell 
destruction of MAGE/EBV antigen-negative tumour cells and contribute to 
remissions (445, 446). This epitope spreading concept views immunotherapy 
as kick-starting a cancer-immunity cycle and providing momentum to 
overcome micro-environmental restraint (447). In contrast traditional 
chemotherapy has often served as an accelerant, selecting for more 
aggressive disease variants, without the ability to adapt (448, 449). The 
adaptive and long-term antitumour immunity generated by immunotherapy 
make this approach more attractive as a strategy. 
Serial monitoring of peripheral blood, tumour and immune response over time 
would potentially allow for detection of immune escape, such as alternative 
splicing of CAR-T targets in B-ALL (450). This would then allow for use of 
combination therapies to mitigate antigen–loss variants, or approaches aimed 
at altering tumour evolution through synthetic lethality, metronomic therapy 
and downstream targeting. Ultimately, the stochastic nature of tumour 
evolution can potentially be viewed as an Achilles heel, in that peripheral 
blood monitoring of tumour evolution and immune counter-response can be 
used to design effective extinction therapies (451), using two complementary 
therapies such that resistance to one entails susceptibility to the other in an 
evolutionary ‘double-bind’ (452).  
Response rates to TIL and TCR-modified therapies are currently limited by a 
number of factors including lack of potency and persistence, possibly because 
the expansion process enriches for terminally differentiated cells. The ability 
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to transfer cells of high functional potency able to expand rapidly and persist 
long-term is potentially important to ensure durable responses (192, 212). 
Other alternatives such as reprogramming induced pluripotent stem cells into 
T cells are still in the early stages of development, limited by ongoing 
investigation into immune rejection, reprogramming efficiency and risks of 
malignant transformation (453-455). 
The complex regulatory process involved in manufacture of GMP-grade viral 
vector has also introduced delays into the transfer of autologous neoantigens-
targeted therapies to the clinic. A streamlined approach to the high financial 
and temporal costs of replication-competent retrovirus testing has been 
proposed (456). Non-viral alternatives such as the Sleeping Beauty 
transposon/transposase method (457) and genome editing strategies promise 
to make this process cheaper, faster and safer (458).  
 
1.12.4 Safety concerns and toxicities 
Based upon the data presented above, modifying therapeutic CD8+ T cells to 
enhance homing to niches mediating improved persistence and function 
would seem an important and plausible strategy to improve upon current 
outcomes. Use of pre-conditioning regimes to increase accessibility of 
homeostatic cytokines, deplete suppressor populations and enhance antigen 
expression are important components of successful adoptive therapy (459). 
One strategy to mediate successful therapy has been suggested by analysis 
of CAR-T cells trials targeting multiply relapsed/refractory patients with bulky 
advanced-stage lymphoma. In this setting, the proportions of infused 
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autologous central memory CAR-T cells were directly associated with peak 
blood CAR-T levels, which in turn were associated with high serum IL-15 
levels and clinical remissions. This confirms that T cells from older patients 
previously exposed to multiple courses of chemotherapy can be successfully 
re-directed to target tumours by access to the correct molecular signals 
however neurologic toxicity in CAR-T trials is also associated with high peak 
CAR-T cells and IL-15 levels, suggesting the need for further investigation into 
dissociation of efficacy from toxicity (460).  
Using expression of chemokines in the tumour microenvironment to guide 
homing of CD8+ T cells has been explored previously. The Reed-Sternberg 
cells characteristic of Hodgkin’s lymphoma secrete CCL17 and CCL22. 
Infiltrating CD8+ T cells are infrequently detected in this disease, presumably 
due to preferential recruitment of TH2 CD4+ cells and Treg cells expressing 
CCR4 to create an immuno-suppressive milieu. Genetic modification of CD8+ 
T cells to over-express CCR4 was able to enhance tumour-specific migration, 
and combined with tumour antigen-targeted CAR expression mediated 
enhanced tumour control in mice, but did not alter memory phenotype or 
enhance effector/target killing beyond that seen using a monocistronic CAR-
CD30 vector (461).  
Strategies aimed at enhancing T cell homing to particular niches must test the 
unanticipated effects of altered trafficking. Chemokines such as CXCL12 are 
also produced in GVHD target organs such as lung, liver and small intestine; 
while another concern is that various stimuli such as O2 levels, chemokine 
signaling or ligand consumption could downregulate the effect of chemokine 
signaling in specific niches, impairing homing to the desired site, or affecting 
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BM homeostasis for other immune cells (462). Melanomas, squamous cell 
and colorectal carcinomas, to choose just three examples, express lower 
levels of selectins, integrin ligands, and exhibit impaired vascular integrity, 
reducing T cell homing to the tumour site (463). The chemokine and receptor 
partner for enhanced T cell homing must therefore be carefully assessed to 
ensure levels are appropriately high at tumour niches within the target organ, 
and the site is readily accessible.  
 
1.12.5 Over-expression of CXCR4 in CD8+ T cells 
We drew together three important strands of evidence: BM as a unique niche 
for T cell memory (3, 255, 257, 464), the pivotal role of CXCR4 in BM immune 
cell homing (53, 281, 282, 284, 465-467) and the finding that CXCR4-deficient 
CD8+ T cells display impaired homeostatic self-renewal (305).  Previous work 
in my supervisor’s lab had generated a retroviral vector enabling constitutive 
over-expression of CXCR4 through transduction of murine T cells (TCXCR4). Dr. 
Ben Carpenter demonstrated increased chemotaxis to CXCL12 in vitro and 
preferential BM accumulation of transferred TCXCR4 in irradiated hosts. In a 
murine model of B-cell lymphoma, allogeneic TCXCR4 mediated substantially 
greater anti-tumour control than allogeneic control T cells (TControl) without any 
worsening of graft versus host disease. Because the tumour stroma in this 
model expresses CXCL12 (292), one possible mechanism of enhanced 
control is enhanced T cell homing to the tumour bed. However in vivo imaging 
demonstrated that luciferase+ TCXCR4 did not accumulate at the tumour site 
earlier or in greater numbers than TControl. In addition, TCXCR4 did not 
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outcompete Treg cells to the tumour site, excluding impaired immuno-
suppression as an alternative mechanism. 
 
 
Hypotheses: 
Based upon these preliminary findings, I hypothesised that: 
a) CXCR4 over-expression increases therapeutic CD8+ T cell homing to 
BM niches 
b) CXCR4 over-expression in therapeutic CD8+ T cells increases the 
number and functional potential of memory T cells 
c) Enhanced memory potential is due to preferential access to cell-
extrinsic signaling factors within the BM niche 
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Aims: 
My overall aim for the project was to determine the mechanism underpinning 
the greater anti-tumour efficacy of TCXCR4 through the following strategies: 
 
1. Perform in vivo and ex vivo imaging experiments to identify if TCXCR4 
home to a specific cellular niche within the BM. 
 
2. Perform a detailed assessment of TCXCR4 phenotype and function in 
vitro and in vivo to identify the mechanism underlying enhanced anti-
tumour efficacy using appropriate murine models. 
 
3. Examine the phenotypic effect of altering the duration and level of 
CXCR4 expression by means of an inducible CXCR4 expression 
vector. 
 
4. Examine the effect of pharmacological blockade and enhancement of 
BM homing, and other strategies including physical BM emplacement, 
upon T cell phenotype. 
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2 Materials and methods 
 
Mice 
C57BL/6 and BALB/c mice were purchased from Charles River Laboratories 
(Margate, UK). B6.PL-Thy1a/CyJ (B6 Thy1.1), B6.SJL-Ptprca Pepcb/BoyJ 
(B6 CD45.1), Flk1-GFP and Rag1-/- OT-I mice were purchased from the 
Jackson Laboratory and bred in house. Rag1ko, Rag1ko.IL7ko and 
Rag1ko.IL15rako mice were a kind gift from Dr Benedict Seddon (UCL, UK). 
UCL Biological Services bred the above mice in house; irradiated or immune-
deficient recipients were maintained in individual ventilated cages. Animals 
used as recipients for BMT were 10-20 weeks old, and donors were 8-16 
weeks old. All procedures were conducted in accordance with the United 
Kingdom Home Office Animals (Scientific Procedure) Act of 1986, and were 
approved by the local ethics committees in UCL and Imperial College London 
(the latter for multi-photon imaging). 
 
Cell lines 
Ecotropic Phoenix packaging cells, used for retroviral particle production, 
were a gift from Dr. G. P. Nolan (Stanford University, USA). The murine A20 
B-lymphoblastic cell line has previously been described; in some experiments, 
the cell line was modified by pMP71 HuCD34 retroviral transduction to 
express human CD34 (huCD34-A20) followed by isolation and sequential 
immunomagnetic enrichment using a human CD34 microbead kit (Miltenyi, 
Germany). 
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Retroviral vectors, transfection and transduction 
The murine Cxcr4 gene was cloned into a pMP71 retroviral vector by Dr Ben 
Carpenter to generate pMP71-Cxcr4-IRES-GFP. pMP71-IRES-GFP was used 
as a control vector (468, 469). Dr Pedro Velica created inducible vectors 
encoding CXCR4 marked with GFP (pSERS-CXCR4-2A-GFP-M2-Q8), or 
GFP alone (pSERS-GFP-M2-Q8). Working quantities of plasmid were 
generated using transformation-competent DH5α bacteria (Invitrogen, Thermo 
Fisher Scientific, USA). Retroviral transduction was performed as described 
previously (469). Briefly, Ph-Eco were transfected with relevant plasmid in 
addition to Fugene-HD transfection reagent (Roche, Switzerland), Opti-MEM 
serum-free medium and Pcl-Eco DNA. Supernatant medium was used to 
resuspend CD8+ T-cells in Retronectin-coated (Takara, Japan) non-tissue 
culture-treated plates. CD8+ T cells were harvested 24 hours prior to 
transduction and activated with 2 µg/ml concanavalin-A (Sigma-Aldrich, USA) 
and 1 ng/ml human IL-7 (R&D Systems, USA). Transduction plates were spun 
at 1000g for 90 minutes and cells were then cultured with T-cell medium and 
10 u/ml IL-2 (Roche) on the day of transduction. Medium was refreshed, 
further IL-2 added on the following day and cells were checked for 
transduction efficiency at 72 hours post transduction.  
 
Primary and boost vaccination strategy 
Isolation of CD8+ T cells or CD11c+ DCs was performed by immunomagnetic 
selection from splenocytes using Manual MACS® Cell Separation Technology 
(QuadroMACS Separator, LS columns, CD8a (Ly-2) and CD11c Micro Beads; 
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Miltenyi, Germany), according to the manufacturer’s instructions. For in vitro 
experiments, SIINFEKL peptide (Invitrogen) was added at a concentration of 
5 µM. In competitive in vivo experiments, TCXCR4 and TControl were mixed into a 
1:1 ratio prior to injection and vaccination was performed 24 hours and on day 
29 by subcutaneous injection of 200 µM SIINFEKL or an irrelevant peptide in 
a 1:1 ratio with Incomplete Freund’s Adjuvant (Sigma-Aldrich, USA). 
Alternatively, mice received 1x106 CD11c+ peptide-loaded DCs intravenously. 
 
Isolation of murine immune cells 
Lymph nodes and spleens: To prepare cell suspensions from spleens and 
lymph nodes, the freshly removed organs were mashed and passed through a 
40 µm cell strainer; red blood cells were removed by isotonic lysis with 
ammonium chloride (ACK Lysing Buffer; Lonza, Switzerland). Cells were re-
suspended in FACS buffer (PBS, 2% FCS, 2 mM EDTA; Lonza) for counting 
and immunolabelling. Bone marrow: To isolate bone marrow cells, both 
epiphyses of the long bones of the hind limbs were cut and the bone marrow 
was flushed out with FACS buffer. The cell suspension was filtered through a 
40 µm cell strainer and red blood cells were removed by isotonic lysis with 
ammonium chloride. Cells were re-suspended in FACS buffer for counting 
and immunolabelling. Cells were counted using a Neubauer haemocytometer 
and light microscope. Cell viability was assessed using 0.1% trypan blue 
(Sigma-Aldrich, USA). CD8+ T cells were isolated by incubation with anti-
CD8α MACS beads (Miltenyi, Germany) using LS magnetic columns. 
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Media and cell culture 
 T cell medium was derived from RPMI-1640 (Roswell Park Memorial Institute, 
Lonza, Switzerland) with 10% heat-inactivated foetal bovine serum (FBS, 
Sigma-Aldrich, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Pen-
Strep), 2 mM L-glutamine and 0.05 mM 2-mercaptoethanol. Packaging 
Phoenix-Eco (Ph-Eco) cell medium was derived from IMDM (Iscove’s 
Modified Dulbecco’s Medium, Sigma) with added Pen-Strep and L-glutamine. 
MACS buffer was derived from phosphate-buffered saline (PBS) with 1% FBS 
and 0.1% EDTA. Recombinant murine CXCL12, 10 ng/ml IL-15 and 
SIINFEKL or UTY peptide (5 µM), (all from Peprotech, USA) were added as 
required.  
 
Flow cytometry 
The following monoclonal antibodies were used for flow cytometry: anti-
murine CXCR4 (2B11), CD8a (53-6.7), CD62L (MEL-14), CD127 (A7R34), 
CD122 (TM-β1), CD132 (TUGm2), CD45.2 (104), TNF-α (MP6-XT22), IL-2 
(JES6-5H4), BCL2 (3F11) and active caspase-3 (C92-605) (BD Biosciences, 
USA); anti-murine Thy-1.1 (H1S51), CD44 (IM7), CD25 (PC61), CD45.1 (A20), 
IFN-γ (XMG1.2), Eomes (Dan11mag), PD-1 (RMP1-30), KLRG1 (2F1) 
(eBioscience). For intracellular staining, cells were fixed and permeabilized 
with BD Cytofix/Cytoperm (BD Biosciences, USA). For measurement of 
proliferation, animals were injected with 100 µg 5-ethynyl-2-deoxyuridine i.p. 
(EdU) and cells were subsequently stained using the Click-iT Assay Kit 
(Thermo Fisher Scientific, USA). Multicolour flow cytometry data acquisition 
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was done with BD LSRFortessa and BD LSR II cell analysers equipped with 
BD FACSDiva v6.2 software (BD Biosciences, USA). Fluorescence activated 
cell sorting was performed on a BD FACSAria equipped with BD FACSDiva 
v5.0.3 software (BD Biosciences, USA). All samples were maintained at 4°C 
for the duration of the sort. A minimum of 5000 cells was collected and only 
those with purity ≥ 95% were used for RNA extraction. Cells were sorted 
directly into Buffer RLT (QIAGEN, USA) with 1% 2-β-mercaptoethanol 
(Sigma-Aldrich, USA), disrupted through vortexing at 3200rpm for 1min, and 
immediately stored at -80°C until further processing. Flow cytometry data 
were analysed with FlowJo X v10 (LLC, USA). 
 
Evaluation of T cell function 
In vitro and ex vivo analysis of cytokine generation following peptide 
stimulation was performed as described previously (470). In vivo analysis of 
specific cytotoxicity was performed as described previously (471). 
 
Imaging 
Intravital microscopy was performed using a combined Zeiss LSM 780 upright 
confocal/two-photon microscope as described previously (301). Blood vessels 
were highlighted by intravenous injection of 8 mg/ml 500 kDa Cy5-Dextran 
(Nanocs, USA). The following antibodies were used: anti-CXCL12 PE (R&D 
Systems, USA) and anti-IL15ra (Abcam, UK). For immunofluorescent imaging, 
femurs and tibias were harvested and processed as described previously 
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(301). Cryo-preserved sections were re-hydrated in PBS, permeabilized in 
0.1% Triton X-100, blocked in 5% goat serum and incubated with primary 
antibody (goat anti-rabbit IgG Alexa Fluor 633 (Life Tech, Thermo Fisher 
Scientific, USA) overnight, at 4 °C. After washing in PBS, slides were 
incubated with secondary antibodies, counter-stained with DAPI (Invitrogen), 
washed in 0.1% Triton X-100 and mounted using Prolong Diamond Antifade 
(Invitrogen). 
 
Image quantification 
Microscopy data were processed with multiple platforms. Tile scans were 
stitched using ZEN Black (Zeiss) software. Raw data were visualized and 
processed using Fiji (472). Automated cell segmentation, distance and 
volume measurements were performed in Definiens Developer 64 (Delfiniens, 
Munich, Germany) using local heterogeneity segmentation to isolate CXCL12+ 
cells. Definiens rule sets for these functions are available upon request. 
Distance measurements from this segmentation were performed as described 
previously (473). Cell tracking over time was analysed using Imaris (Bitplane, 
UK). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.00 for 
Mac OsX (GraphPad Software, USA). Significance was assessed using a 
two-tailed Mann–Whitney U test or two-tailed Wilcoxon signed-rank sum test 
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for paired comparisons of non-parametric data and a two-tailed student’s t-
test for parametric data. For multiple comparisons, a one-way ANOVA with 
Holm-Sidak’s post hoc test was used. Survival curve comparison was 
performed using the log-rank Mantel-Cox test. A p-value of ≤0.05 was taken 
to indicate a significant difference between groups. 
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3 Defining the BM location of TCXCR4 
3.1 Introduction 
 
Polyclonal model 
Previous work has established that polyclonal CD8+ TCXCR4 show enhanced 
homing to the bone marrow of irradiated mice in comparison to TControl. 
However CXCL12 expression is upregulated in the context of irradiation (57) 
and high CXCL12 concentrations have been shown to cause paradoxical 
repulsion of the receptor-expressing T-cell, known as fugetaxis (474, 475). 
Accordingly, Dr Pedro Santos e Sousa in our lab conducted short-term 
competition experiments to exclude the possibility that the homing and 
persistence characteristics of TCXCR4 were being substantially altered by host 
irradiation.  
Equal amounts of polyclonal TCXCR4 and TControl were transferred into Rag1ko 
mice. Mice homozygous for the Rag1tm1Mom mutation (Rag1ko) produce no 
mature T or B cells and are less likely to reject adoptively transferred T cells 
expressing a foreign GFP protein.  At day 7 post transfer, greater numbers of 
TCXCR4 accumulated in Rag1ko mice BM compared to TControl cells (mean 
TCXCR4: TControl ratio 2.2 (p=0.026, two-tailed Mann-Whitney test, n=10), as 
compared to 3.4 for irradiated mice (p=0.003) and 10.6 for non-irradiated B6 
mice (p=0.003) (Figure 3-1A). 
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Figure 3-1 Superior TCXCR4 BM recruitment is IL-15-dependent.  
(A) Box and whisker plots of TCXCR4: TControl ratio in BM, Spleen (Sp) 
and LN at day 7 following transfer into non-irradiated B6 mice (n=11) 
and Rag1ko mice (n=10). (B) Box and whisker graphs of TCXCR4: TControl 
ratio in BM, spleen and LN at day 7 following transfer into Rag1ko 
(n=10), Rag1ko.IL-15rako (n=10) and Rag1ko.IL-7ko (n=4). Data 
pooled from two independent experiments, *P≤0.05, **P≤0.01. 
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These experiments showed that TCXCR4 retain an advantage in BM homing 
compared to TControl in a non-inflammatory setting. They also suggest that 
TCXCR4 demonstrate a greater BM homing and retention capacity under non-
lymphopenic conditions in non-irradiated B6 mice, ie. when homeostatic 
cytokines are non-limiting, and hence suggests a competitive advantage in 
accessing survival factors. 
To investigate the importance of access to homeostatic cytokines, similar 
experiments were performed transferring equal amounts of polyclonal TCXCR4 
and TControl cells into Rag1ko mice genetically deficient in IL-7 (Rag1ko.IL7ko, 
henceforth IL-7ko mice) or IL-15Rα (Rag1ko.IL15rako, henceforth IL-15Rako 
mice). Strikingly, the advantage in day 7 BM accumulation for TCXCR4 was not 
altered by loss of IL-7 (BM TCXCR4: TControl ratio 2.2 for Rag1ko mice vs 2.0 for 
Rag1ko.IL7ko mice, p=ns) but was completely abrogated in the absence of IL-
15 signalling (BM TCXCR4: TControl ratio 0.4 for Rag1ko.IL15rako mice, p= 0.017 
vs Rag1ko mice, two-tailed Mann-Whitney test (Figure 3-1B). 
 
Summary 
These experiments demonstrated superior BM accumulation of TCXCR4 over 
TControl in a variety of models, particularly in competitive situations where 
access to homeostatic cytokines is limited. This advantage does not rely upon 
irradiation but appears to be specifically dependent upon the presence of IL-
15Rα. In the light of known expression of CXCL12 and IL-15Rα by stromal 
cells within the BM (281, 311), I first asked if in vivo imaging could shed light 
upon these findings by directly identifying T cell interactions within the BM. 
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3.2 Imaging the BM location of TCXCR4  
 
I first confirmed that expression of CXCR4 was uniformly low in murine B6 
bead-sorted CD8+ T cells transduced with pMP71-IRES-GFP (henceforth 
TControl), and that T cells transduced with pMP71-Cxcr4-IRES-GFP (henceforth 
TCXCR4) expressed CXCR4 in proportion to the level of GFP reporter 
expression (Figure 3-2). 
I considered the possibility that TCXCR4 homing to a specific microenvironment 
in the BM in some way enabled their enhanced antitumour potency and 
therefore sought to identify the nature of this putative niche.  In particular, I 
aimed to collect detailed information upon TCXCR4 interactions with structures 
within the BM over time, and how this differed from TControl.  I therefore 
performed imaging experiments involving intravenous transfer of polyclonal 
B6 CD8+ TCXCR4 and TControl into separate Rag1ko mice, in conjunction with Dr 
Cristina Lo Celso’s group at Imperial College London.  
In order to identify the CXCL12-expressing cells, we employed 2 
complementary approaches (calvarial intravital multiphoton imaging and 
immunofluorescence of the long bones). To capture dynamic whole tissue 
interactions we performed intra-vital calvarial imaging of anaesthetised mice 
using a custom-built combined fluorescence confocal/ multiphoton microscope 
at 8 weeks post injection. The extremely thin nature of calvarial bone allows 
single-cell resolution while the anaesthetic protocol permits detailed tile-based 
imaging of the entire tissue, and detailed time-lapse microscopy of cell-cell 
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Figure 3-2 Expression of CXCR4 in TControl and TCXCR4.  
(A) Schematic depicting CXCR4-GFP retroviral vector map: Long 
Terminal Repeat (LTR); Internal Ribosome Entry Site (IRES);  (B) 
Representative flow cytometric plots for expression of CXCR4 and 
GFP in murine B6 CD8+ T cells transduced with the CTRL-GFP vector 
(TControl in cyan) and CXCR4-GFP (TCXCR4 in red), pre-gated upon live 
lymphocyte gate. Numbers denote % of total CD8+ T cells. 
 
 
interactions. A surgically implanted imaging window using a lock and key 
mechanism was used to ensure accurate positioning of the mice on the 
microscope without motion artefact (476) (Figure 3-3). 
The calvarium has been shown to be equivalent to the long bones with 
regards to haematopoietic cell frequency, function and localisation, and allows 
longitudinal imaging with minimal intervention (477, 478). We performed 
immuno-imaging to define CXCL12 localisation by intravenous injection of 
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fluorescent antibodies to label cell-surface bound chemokine, between 5 and 
60 minutes before imaging (479). Mature T cells are known to localize to 
specialized vascular subregions within the BM (479) and we therefore 
identified vascular structures by means of iv injection of 500 kDa Cy5-Dextran 
(301). Raw microscopy data were then processed using local heterogeneity 
segmentation (LH-SEG) on the Definiens platform to isolate CXCL12+ cells 
and perform unbiased 3D distance measurements between cellular BM 
elements (473). Cell tracking over time was performed using Imaris (Bitplane, 
UK) to identify speed and motion characteristics of T cells. 
 
 
 
 
 
 106 
 
 
Figure 3-3 Experimental approach to in vivo BM imaging.  
Rag1ko mice were anaesthetised 8 weeks post injection of TCXCR4 or 
TControl. Tile scan imaging of multiple z-stacks was performed, enabling 
single-cell time-lapse imaging of T cells within the whole calvarial 
space, following iv injection of CXCL12 PE and Cy5-dextran antibody. 
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Visual evaluation of TCXCR4 location within the BM 
Consistent with flow cytometric findings, TCXCR4 were more numerous than 
TControl in the bone marrow for all mice imaged (Figure 3-4). TCXCR4 associated 
in dense clusters of cells close to vascular structures, whereas TControl 
appeared as single cells with less obvious proximity to vascular cells, as seen 
in the zoom insets. The distribution of CXCL12 staining was predominantly in 
close association with vascular structures. 
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Figure 3-4 TCXCR4 accumulate in greater numbers in perivascular 
BM locations. 
Representative maximum projection tile scans and corresponding high 
magnification zoom insets for intra-vital calvarial imaging of transduced 
TControl (top) and TCXCR4 (bottom), both in green, in proximity to 
CXCL12+ cells (purple) and vasculature (blue). Scale bars: 500 µm in 
tile scan image, 50 µm in zoom images. 
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Association with calvarial CXCL12+ cells  
We next sought to quantitate the distance of each T cells from the CXCL12-
producing cells. We performed image analysis on cells, using GFP fluorescent 
intensity to evaluate the level of CXCR4 expression in TCXCR4. We compared 
TCXCR4 cells with a GFP intensity >25 (TCXCR4 HIGH) with TCXCR4 LOW (GFP 
intensity 10-15) to test competition between cells expressing different levels of 
CXCR4 in the same environment, the latter acting as an internal control. 
Significantly more TCXCR4 HIGH cells were located within 0-5 µm of the CXCL12+ 
cells than TCXCR4 LOW (48% vs 22%, Mann-Whitney test p<0.0001) and 12% of 
TCXCR4 HIGH were in direct contact with CXCL12-expressing cells compared to 
2% of TCXCR4 LOW (p=0.015) (Figure 3-5A and B). The median distance of all 
TCXCR4 HIGH from CXCL12-expressing cells was 5.3 µm vs 9.8 µm for TCXCR4 
LOW (p<0.0001).  
Next, we asked whether CXCR4 over-expression enabled TCXCR4 to home 
more effectively to CXCL12+ cells than TControl. We found that significantly 
more TCXCR4 HIGH cells were located within 0-5 µm of the CXCL12+ cells than 
TControl (48% vs 32%, Mann-Whitney test p<0.0001) and a trend for greater 
numbers of TCXCR4 were in direct contact with CXCL12+ cells compared to 
TControl (12% vs 2%, p=0.070) (Figure 3-5C and D). TCXCR4 HIGH were located 
closer to the CXCL12+ cells compared to TControl (median distance 5.3 vs 8.5 
µm, p=0.026). The level of CXCR4 expression on TCXCR4 inversely correlated 
with distance to the nearest CXCL12+ cell for TCXCR4 but not TControl (distance 
from CXCL12+ cells considered as a continuous function, Figure 3-5E). 
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Figure 3-5 High CXCR4 expression dictates location in relation to 
calvarial CXCL12-expressing cells 
(A) Frequency distribution histogram representing proximity of TCXCR4 
HIGH (red) and TCXCR4 LOW (purple) to calvarial CXCL12+ cells. (B) 
Proportion of total TCXCR4 HIGH and TCXCR4 LOW in contact with the 
CXCL12+ cells. (C) and (D) As above for TCXCR4 HIGH and TControl (cyan), 
*P≤0.05, ****P≤0.0001. (E) X-y graphs comparing GFP intensity vs. 
distance of individual TCXCR4 and TControl from CXCL12+ cells measured 
on static images derived from the same experiments. Inset denotes 
Pearson’s correlation coefficient r and significance. n=2 TControl and 3 
TCXCR4, 1 independent experiment. 
 
Long-bone TCXCR4 location 
We then tested if the TCXCR4 relationship with CXCL12-expressing cells was 
replicated using a different experimental strategy. Following intravenous 
transfer of polyclonal B6 CD8+ TCXCR4 and TControl into separate Rag1ko mice, 
we performed immunofluorescence of femur and tibia sections using anti-
CXCL12 antibody. 
Similar to the calvarial model, we found that a significantly higher proportion of 
TCXCR4 HIGH were located within 0-5 µm of CXCL12+ cells than TCXCR4 LOW (62% 
vs 32%, p=0.008) and greater numbers of TCXCR4 HIGH were in direct contact 
with CXCL12+ cells compared to TCXCR4 LOW (25% vs 6.4%, p<0.0001) (Figure 
3-6A and B). Furthermore, we found that a significantly higher proportion of 
TCXCR4 HIGH were located within 0-5 µm of CXCL12+ cells than TControl (62% vs 
41%, p=0.003) and greater numbers of TCXCR4 HIGH were in direct contact with 
CXCL12+ cells compared to TControl (25% vs 6.6%, p<0.0001) (Figure 3-6C 
and D).  
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Figure 3-6 Over-expression of CXCR4 enables closer localisation 
to CXCL12+ cells in long bones. 
(A) Frequency distribution histogram representing proximity of TCXCR4 
HIGH (red) and TCXCR4 LOW (purple) to long bone CXCL12+ cells. (B) 
Proportion of total TCXCR4 HIGH and TCXCR4 LOW in contact with CXCL12+ 
cells. (C) and (D) As above for TCXCR4 HIGH and TControl (cyan). n=2 
TControl and 2 TCXCR4, 1 independent experiment, **P≤0.01, 
****P≤0.0001. 
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TCXCR4 dynamic motion 
T cell motility and antigen scanning behaviour is modulated by chemokine 
cues within lymphoid environments, including CXCL12 (27, 480). I therefore 
assessed whether TCXCR4 moved differently compared to TControl within the 
calvarial BM, using Imaris software to track multiple individual cells in 3 
dimensions over 30 minute time periods. Both TCXCR4 and TControl cells 
displayed substantial variation in dynamic behaviour. Some cells appeared to 
be arrested and largely retained a similar shape and position throughout the 
imaging period, often in close association with CXCL12+ cells, whilst other 
cells moved dynamically through the bone marrow environment, elongating 
into a polarized shape and altering speed as they mobilised around the 
physical parenchyma, often appearing to physically scan the surface of other 
cells (481). Videos available from: https://www.jci.org/articles/view/97454/sd/4 
https://www.jci.org/articles/view/97454/sd/5 
https://www.jci.org/articles/view/97454/sd/6 
https://www.jci.org/articles/view/97454/sd/7. 
Perivascular CXCL12 expression is known to affect lymphocyte rolling and 
movement within secondary lymphoid organs (23, 26), and this effect is likely 
to be heightened in cells expressing high levels of CXCR4. As GFP 
brightness indicates the level of CXCR4 expression in TCXCR4 but not in TControl, 
I was able to directly examine the effect of CXCR4 expression on T cell speed. 
T cells moving very quickly through the circulation without adhering to BM 
parenchyma or vascular structures were not included in the analysis. GFP 
intensity correlated positively with maximum T cell speed for TCXCR4 cells but 
not for TControl (Spearman’s rho = 0.46 vs 0.29, p=0.011 for TCXCR4, ns for 
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TControl) and to a lesser extent for mean speed (Spearman’s rho = 0.34 vs 0.13, 
p=0.067 for TCXCR4, ns for TControl).  
I measured another aspect of dynamic motion over time by calculating the 
arrest coefficient (AC) for each cell, using the standard definition of the 
proportion of time with a speed <2 µm/minute. We found that TCXCR4 cells 
could be divided into 2 distinct populations (Figure 3-7A): those with a high 
(Arrested, AC>0.75) and those with a low arrest coefficient (Migratory, 
AC<0.75). This clear difference was not evident in the TControl population. 
Furthermore, I found that migratory TCXCR4 moved twice as fast as migratory 
TControl cells (mean speed 0.14 µm/s vs 0.07 µm/s, Mann-Whitney p=0.003). 
Accordingly, mean velocity of all TCXCR4 was greater than TControl (3.9 ±	3.3 
µm/min vs 2.2 ±	1.6 µm/min, p=0.004 (Figure 3-7B). We did not see a 
difference in arrest coefficients between TCXCR4 HIGH and TCXCR4 LOW cells and 
speed of migratory cells was similar (median 0.14 vs 0.12 µm/s, p=ns).  
 When analysing the pattern of movement, I found that the speed of TCXCR4 
varied significantly less than TControl, ie. TCXCR4 tended to remain either 
migratory or arrested (median speed variation 0.6 vs 0.95, p<0.001, speed 
variation defined as standard deviation of speed) and their tracks were 
significantly less straight (median track straightness 0.17 vs 0.38, p=0.004, 
straightness defined as displacement/length). TCXCR4 HIGH cells also moved in 
less straight tracks than TCXCR4 LOW (0.17 vs 0.27, p=0.038). This deviation 
from straight tracks is presumably due to molecular cues, for which CXCL12 
is a prime candidate. 
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Figure 3-7 CXCR4 over-expression alters migratory behavior. 
Summary data showing (A) arrest coefficient (AC) and (B) mean 
velocity data for time lapse imaging of TCXCR4 and TControl). Median 
tracking period was 8.5 min/cell, range 8.5-30 min/cell (total number of 
cells tracked: n=72 TCXCR4, n=16 TControl). Data pooled from 14 different 
regions of interest in 5 mice, n=2 TControl and 3 TCXCR4, 1 independent 
experiment, data, **P≤0.01.  
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Defining the perivascular CXCL12+ population 
I then investigated whether the vascular CXCL12+ cell populations seen in the 
calvarial model were of endothelial origin or other CXCL12 sources, such as 
perivascular mesenchymal stromal cells.  I therefore injected iv CXCL12-PE 
antibody and Cy5-dextran into Flk1-GFP mice where GFP expression is 
confined to endothelial cells and performed intra vital calvarial imaging. As 
seen in the magnified composite images in Figure 3-8, the vascular CXCL12+ 
cells associated with TCXCR4 in the calvarial model were primarily of 
endothelial origin (yellow) but some sources of CXCL12 were of non-
endothelial origin (purple). This conclusion is dependent upon the imaging 
model used and delivery of CXCL12 staining antibody via the intravenous 
route, which may alter staining characteristics.  
I therefore attempted to further define the CXCL12+ cells with which the 
TCXCR4 were interacting. CD8+ T cells in the BM are maintained by IL-15, 
trans-presented on stromal cells also expressing IL-15Rα (482). The primary 
source of IL-15 in the BM matches the phenotype of CXCL12-abundant 
reticular cells (311) and we therefore used complementary imaging models to 
ask if TCXCR4 localise preferentially to IL-15Rα+ cells. 
I also used the calvarial imaging model to ask if IL-15Rα+ cells were 
associated with vascular structures by injecting IL-15Rα antibody iv followed 
by secondary Alexa Fluor 633 label; however the resultant images did not 
identify any positive staining, which may relate to technical issues with the 
antibody, impaired extravascular delivery due to the intravenous route or low 
IL15Rα+ expression levels in the non-inflammatory setting (311, 483).  
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Figure 3-8 Vascular CXCL12+ cells in the BM are of both 
endothelial and non-endothelial origin.  
Intra-vital confocal imaging was performed on Flk1-GFP mice. Calvarial 
images and high magnification insets are shown following intravenous 
injection of anti-CXCL12-PE (red) and Cy5-dextran to identify 
vasculature (blue). Yellow identifies endothelial sources of CXCL12 
and purple non-endothelial sources. 
 
 
We therefore moved to the immunofluorescent long bone model and stained 
sections with an IL-15Rα antibody and secondary Alexa Fluor 633 label. We 
otherwise used the same experimental model as before, injecting TCXCR4 and 
TControl into separate Rag1ko mice and quantitating distances to IL-15Rα+ cells.  
In a competitive setting we found that significantly more TCXCR4 HIGH cells were 
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located within 0-5 µm of IL-15Rα+ cells than TCXCR4 LOW (57% vs 26%, Mann-
Whitney test p<0.0001) and 24% of TCXCR4 HIGH were in direct contact with IL-
15Rα+ cells compared to only 6% TCXCR4 LOW (p<0.0001) (Figure 3-9A and B).  
Next, we compared distances with mice receiving TControl cells, ie. not in direct 
competition with TCXCR4 cells. In contrast to the CXCL12 setting, we found that 
only slightly more TCXCR4 HIGH cells were located within 0-5 µm of the IL-15Rα + 
expressing cells compared to TControl (57% vs 54%, p=0.017); or were in direct 
contact with IL-15Rα+ cells compared to TControl (24% vs 19%, p=0.016) 
(Figure 3-9C and D).  
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Figure 3-9 CXCR4 expression level dictates access to IL-15.  
(A) Frequency distribution histogram representing proximity of TCXCR4 
HIGH (red) and TCXCR4 LOW (purple) to long bone IL-15Rα+ cells. (B) 
Proportion of total TCXCR4 HIGH and TCXCR4 LOW in contact with IL-15Rα+ 
expressing cells (C) and (D) As above for TCXCR4 HIGH and TControl (cyan), 
n=2 TControl and 2 TCXCR4, 1 independent experiment. 
 
 
3.3 Discussion 
 
These experiments directly visualised the clustering association of TCXCR4 
within the bone marrow microenvironment, in close proximity to vascular 
structures. Increased CXCR4 expression enhanced proximity to and direct 
contact with CXCL12-expressing cells in two different experimental models 
and anatomical locations. TCXCR4 also moved faster than TControl and contained 
a subset of highly motile cells with low arrest coefficients, suggesting that 
higher CXCR4 expression is responsible for this behaviour and close 
association with vascular-associated CXCL12+ cells. We did not see a 
different in migratory speed between TCXCR4 HIGH and TCXCR4 LOW cells, This 
may be due to the fact that over a certain threshold of CXCR4 expression, 
speed may not increase, or that higher CXCR4 expression may have counter-
acting effects on speed by enhanced attraction to stationary CXCL12 sources. 
This theory is supported by the reduction in track straightness seen in cells 
expressing progressively higher levels of CXCR4.  
The nature of the CXCL12+ cells interacting with TCXCR4 is still up for debate 
as the Flk1+ model showed that intravenously injected CXCL12 antibody 
stains a substantial proportion of endothelial cells. In conjunction with 
observation of the dynamic behaviour of extravascular TCXCR4 within the BM 
parenchyma and studies showing that perivascular stromal cells express 125-
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fold higher levels of CXCL12 than endothelial cells (281) this may indicate a 
limitation of the intravenous antibody model. Antibody diffusion kinetics or 
staining characteristics may cause preferential uptake of antibody by CXCL12 
on the lumenal surface of vasculature, preventing an accurate tissue-wide 
view of CXCL12 distribution. 
In support of this concept, long bone immunofluorescence showed that in a 
competitive situation, cells expressing high levels of CXCR4 outcompete 
those expressing lower levels (TCXCR4 LOW) to be in contact with IL-15Rα+ cells. 
This difference was not noted between TCXCR4 and TControl cells in separate 
mice. We therefore draw the conclusion that if higher CXCR4 expression 
allows cells to compete better in accessing an IL-15Rα+ microenvironment, 
the sources of CXCL12 and IL-15/IL-15Rα may overlap. This may be a 
valuable advantage in situations where access to trans-presented IL-15 is 
limiting, or multiple other cells are competing for these niches. Given the 
limited current range of IL-15Rα antibodies, however, coupled with lower 
expression in the non-inflamed situation, other models are required to test 
these conclusions. 
Further imaging experiments were not performed due to lack of appropriate 
experimental tools and time, but would ideally employ IL-7 & IL-15 reporter 
mice in conjunction with stromal reporter strains to dissect the nature and 
behaviour of this microenvironment in detail (282, 311). Specifically, it would 
be important to evaluate how TCXCR4 behaviour might change in response to 
an inflamed or tumour microenvironment. Enhanced motility would enhance 
the chances of encounter with dendritic cells and immuno-stimulatory 
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cytokines, but might also reduce the duration of antigen priming with 
implications for memory formation (484).  
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4 The effect of CXCR4 overexpression on memory 
differentiation 
 
4.1 Introduction 
 
Based upon this evidence that TCXCR4 preferentially home to a CXCL12+ 
microenvironment in the BM, I considered whether this finding might be 
responsible for preferential anti-tumour efficacy and a previously observed 
tendency to retain CD62L expression. In order to investigate the mechanism 
underlying the memory phenotype associated with TCXCR4, and whether it 
might be responsible for enhanced functionality, I then developed an in vivo 
vaccination model to study antigen response and the influence of homeostatic 
cytokines in the BM in more detail. 
I first magnetic bead-sorted splenic OT-I CD8+ T cells, which express a TCR 
specific for the SIINFEKL peptide (485), and transduced them with either 
CXCR4-GFP or CTRL-GFP according to congenic marker. The use of 
vaccination allows controlled induction of a memory phenotype with 
observation of the kinetics of expansion and reduction in the population over 
time, in addition to markers of memory and cytokine receptors.  
In the first competition experiment, transduced T-cells were mixed in a 1:1 
ratio of TCXCR4: TControl and transferred iv into non-irradiated wild type B6 mice 
to assess a steady state response in the absence of the complicating factor of 
irradiation. Mice were vaccinated with bone marrow-derived dendritic cells 
pulsed with relevant (SIINFEKL) or irrelevant (UTY) peptide on day 1, and 
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harvest of bone marrow, spleen, peripheral blood and lymph nodes was 
performed on days 8 and 29 post injection. Mice receiving UTY peptide are 
henceforth referred to as unvaccinated. 
I observed enhanced bone marrow accumulation of TCXCR4 compared to 
TControl (median ratio 6.8:1, n=2) at day 8 in vaccinated mice. Insufficient GFP 
positive cells were seen in unvaccinated mice; however, at day 29 no GFP 
expression was seen for any animals in any organs. One explanation for this 
finding is that GFP-expressing cells, identified as bearing an immunogenic 
foreign protein, had been deleted by an intact host immune system response 
(486). Another possibility is that competition with endogenous lymphocytes 
had prevented adoptively transferred cells from engrafting in sufficient 
numbers in occupied niches, preventing their access to scarce survival factors 
such as homeostatic cytokines. This latter possibility is less likely because 
reasonable numbers of T cells were observed to be persisting in bone marrow 
and splenic environments at the early time point post SIINFEKL vaccination; 
however, the low numbers of cells observed in mice vaccinated with irrelevant 
peptide suggest that antigen-inexperienced cells may not persist long term in 
this model without access to adequate cytokine support. 
I therefore explored a model where the absence of lymphocytes acting as 
cytokine sinks reduces competition between adoptively transferred cells for 
survival and proliferation factors. I modified the vaccination model to use 
Rag1ko mice as recipients. Their deficiency in the recombination-activating 
gene prevents formation of mature T or B cells; however, innate immune cells 
including NK cells persist. This lymphopenic environment mimics the clinical 
 124 
environment post bone marrow transplantation, and chemotherapy as used in 
current immunotherapy trials, with relevance to translation.  
I modified the vaccination protocol to incorporate primary and boost 
vaccinations with subcutaneous peptide pre-mixed with Incomplete Freund’s 
Adjuvant (IFA) at days 1 and 29.  This strategy is associated with a robust 
antigen-specific response and the use of IFA plus antigen provides an antigen 
depot permitting prolonged antigen uptake and presentation in vivo by 
dendritic cells. 
In order to monitor the kinetics of the peak primary and boost vaccination 
responses, and compare them with a ‘steady state’ phenotype, I harvested 
secondary lymphoid organs from recipients at peak of primary vaccination 
(day 8), at day 29 post-primary response and following boost (day 36). These 
time points were chosen based upon well-established vaccination models of T 
cell memory utilising OT-I T cells, where assessment 7 days post primary and 
secondary infection defined distinct differences in T cell phenotype and clonal 
expansion that persisted over time (487). Splenocytes were re-stimulated with 
cognate peptide ex vivo to measure functional cytokine production (see Figure 
4-1 for model). T cells were left without exposure to antigen for 4 weeks 
between primary and secondary vaccination, and analysed prior to secondary 
vaccination (steady state) to identify changes in the initial phenotype 
corresponding to homeostatic cytokine exposure. 
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Figure 4-1 Constitutive vaccination model. 
Equal numbers of OT-I TCXCR4 and TControl were co-injected into Rag1ko 
mice, prior to vaccination with relevant SIINFEKL or irrelevant UTY 
peptide at days 1 and 29. Tissues were harvested at days 8, 29 and 36 
to examine accumulation and phenotype.  
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4.2 Primary constitutive vaccination response 
 
On the day of injection (day 0), TCXCR4 and TControl were comparable in terms 
of median TCM % (64 vs 53, 2 tailed t-test; p=ns), CD62L, CD44 and cytokine 
receptor expression. 
 
Number and ratio 
At day 8 in vaccinated mice receiving SIINFEKL antigen, TCXCR4 demonstrated 
an advantage in terms of absolute number and ratio in BM and spleen, as 
shown in Figure 4-2 and Figure 4-3 below. Median BM TCXCR4 cell number 
was 26462 vs 1269 TControl, spleen TCXCR4 20740 vs 10355 TControl (2 tailed 
paired t test; p=0.050 and ns respectively). Lymph node numbers were similar 
(5,198 vs 5,812). TCXCR4: TControl ratio was dramatically higher in bone marrow 
(median 14.4:1, 2 tailed paired t-test; p=0.03), higher in spleen (median 2.2:1, 
p=ns) and similar in lymph node (0.85:1, p=ns). The numerical advantage was 
notably higher for mice not exposed to relevant antigen (BM median ratio 
52.7:1, spleen 6.8:1, lymph node 1.6:1, p=0.07, ns, ns respectively). Similarly, 
median BM TCXCR4 cell number was 19,651 vs 462, spleen 15,475 vs 1355, 
lymph node 2576 vs 1559. These data show greater accumulation of TCXCR4 
cells in key secondary lymphoid organs, particularly in the absence of relevant 
antigen. In fact, TCXCR4 maintain higher numbers in unvaccinated spleen and 
BM than TControl undergoing antigen-dependent proliferation in vaccinated 
mice. 
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Figure 4-2 Constitutive TCXCR4 summary ratio kinetics. 
Summary data for (A) TCXCR4: TControl ratio in vaccinated mice (relevant 
antigen), n=16, data representative of 4 independent experiments, and (B) 
TCXCR4: TControl ratio in unvaccinated mice (irrelevant antigen), n=8, data 
representative of 3 independent experiments. Error bars denote SD, 
*P≤0.05, **P≤0.01 denote significant numerical differences between TCXCR4 
and TControl, purple arrows denote time of peptide injection. 
0 10 20 30 40
0.1
1
10
100
Days post transfer
TC
XC
R
4 :
 T
C
on
tro
l r
at
io
0 10 20 30 40
0.1
1
10
100
1000
Days post transfer
TC
XC
R
4 :
 T
C
on
tro
l r
at
io
A
B
**
*
BM Spleen LN
Vaccinated
Unvaccinated
 128 
 
Figure 4-3 Constitutive TCXCR4 bone marrow accumulation. 
Absolute number data for (A) BM TCXCR4 and TControl in vaccinated mice 
(relevant antigen), n=16, data representative of 4 independent experiments 
and (B) unvaccinated mice (irrelevant antigen), n=8, data representative of 
3 independent experiments. Error bars denote SD, purple arrows denote 
time of peptide injection.  
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Memory phenotype 
A greater proportion of vaccinated TCXCR4 exhibited a central memory (TCM) 
phenotype in all organs compared to TControl at day 8. The median BM %TCM was 
38% vs 9% (2 tailed paired t-test; p=0.003), spleen TCM 37% vs 13% (p=0.014) 
and LN 61% vs 38%, p=0.07) (Figure 4-4). In contrast, TCM proportions were 
similar in unvaccinated mice for all organs (BM 83% vs 89%, spleen 79% vs 77%, 
LN 87% vs 89%). 
 
Cytokine receptors 
To investigate the impact of cytokine signalling in the lymphopenic environment, I 
stained for the key components of homeostatic cytokine receptors. IL-2/15Rβ 
(CD122) expression was similar (TCXCR4 BM MFI 2429 vs TControl 2281, spleen 
1816 vs 1729). IL7Rα (CD127) expression was decreased on TCXCR4 compared to 
TControl in unvaccinated mice BM and spleen (BM MFI 136 vs 520, spleen 151 vs 
742, LN 671 vs 608) but no differences were seen in vaccinated mice as TControl 
downregulate CD127 to a similar extent as TCXCR4 in response to antigen (BM 150 
vs 133, spleen 118 vs 181, LN 477 vs 453).  
IL2Rα (CD25) expression was slightly lower in TCXCR4 vs TControl regardless of 
antigen exposure (vaccinated BM 206 vs 318, spleen 125 vs 278, LN 45 vs 352, 
unvaccinated BM 258 vs 362, spleen 152 vs 215, LN 15 vs 216), whilst expression 
of the common γ-chain receptor (CD132, receptor signalling component for IL-2, -
4, -7, 15 and 21) was similar in all conditions (vaccinated BM MFI 465 vs 485, 
spleen 912 vs 663, LN 1579 vs 1205, unvaccinated BM MFI 592 vs 577, spleen 
1381 vs 1312, LN 1939 vs 1686). 
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Figure 4-4 TCXCR4 retain central memory phenotype post initial 
vaccination. 
(A) Representative day 8 flow cytometry plots depicting CD44/CD62L 
expression of splenic CD8+GFP+ TCXCR4 and TControl from the unvaccinated 
and vaccinated mice. Summary paired day 8 TCM% data for (B) 
unvaccinated and (C) vaccinated TCXCR4 and TControl in lymphoid organs, 
n=8, data from 3 independent experiments, *P≤0.05, **P≤0.01. 
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Survival 
Next I investigated the expression of survival-related proteins. Expression of 
pro-survival protein BCL2 was increased in vaccinated mice TCXCR4 vs TControl 
(median % positive in BM 52.3 vs 31.9, spleen 73.2 vs 37.8). BCL2 MFI 
showed the same pattern (BM 347 vs 163, spleen 583 vs 256). 
 This difference was not seen in unvaccinated mice (median BM % positive 
85.3 vs 82.4, spleen 92.9 vs 90.1). Expression of pro-apoptotic effector 
caspase 3 was reciprocally decreased in BM and spleen of vaccinated mice 
for TCXCR4 vs TControl (median % positive 0.6 vs 2.7 and 0.5 vs 2.6, MFI 285 vs 
328 and 379 vs 446). A similar expression pattern was true for caspase 3 in 
unvaccinated mice (BM % positive 0.8 vs 4.2 and spleen 2.1 vs 7.3, BM MFI 
294 vs 370 and spleen 545 vs 681).  
 
Proliferation 
To determine the reason for differences seen in accumulation, I also 
examined the proliferation rate using 5-ethynyl-2-deoxyuridine (EdU) staining. 
TCXCR4 underwent similar or slightly lower levels of proliferation in both the 
vaccinated (BM EdU % positive 2.1 vs 11.5 and spleen 5.4 vs 9.6, 2 tailed 
paired t test; p=0.081 and 0.096 respectively) and unvaccinated setting (BM 
1.7 vs 1.0 and spleen 5.0 vs 11.5, p=0.074 and ns). EdU MFI was similar for 
all groups (BM vaccinated TCXCR4 median MFI 3033 vs TControl 3453 and 
spleen 1651 vs 1920, unvaccinated BM 3522 vs 3563 and spleen 2016 vs 
2117, p=ns for all).  
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Function 
Finally, I examined the functional ability of the T cells to produce effector 
cytokines after ex vivo re-stimulation of splenocytes with relevant peptide. 
TCXCR4 exhibited slightly reduced IFN-γ production for vaccinated mice 
(median % positive 39.8 vs 53.4) and similar levels in unvaccinated mice 
(49.3 vs 50.0).  
Primary vaccination summary 
TCXCR4 accumulate in greater numbers than TControl in spleen, dramatically so 
in bone marrow, and to a heightened extent in the absence of antigen. After 
antigen encounter, a significantly higher proportion of TCXCR4 maintain a 
central memory phenotype with higher expression of BCL2 but similar 
cytokine receptor expression, function and proliferation. These phenotypic 
differences are not seen in unvaccinated mice. These findings suggest that 
the early TCXCR4 numerical advantage relates primarily to improved survival 
rather than proliferation, and also indicate that the degree of numerical 
advantage is partially mitigated by heightened proliferation of TControl in the 
vaccinated setting (Table 2).  
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4.3 Steady state post-vaccination phenotype 
 
In order to examine how the change in the initial phenotypes over time in the 
absence of further exposure to antigen, I then studied these outputs in mice 
four weeks post initial vaccination, prior to boost vaccination.  
 
Number and ratio 
There were greater numbers of BM TCXCR4 at day 29 in vaccinated mice - 
median 60130 (median 27017 at day 8) vs BM TControl median 800 at day 29 
(median 2319 at day 8). Day 29 BM TCXCR4: TControl ratio was therefore 
dramatically enhanced at a median of 73:1.  The same was true to an even 
greater degree in unvaccinated mice – BM median absolute number TCXCR4 
345451 vs TControl 1103 and ratio 313:1 (Figure 4-2). The same pattern was 
true to a lesser extent for all other organs. Spleen absolute TCXCR4 number 
was 42,442 at day 29 (20740 at day 8) vs TControl 5,122 (day 8 10355). Spleen 
TCXCR4: TControl ratio was 8.3:1. There were greater numbers of TCXCR4 cells in 
unvaccinated spleen (361898 vs 4872, ratio 74.3:1). Lymph node TCXCR4 
showed a similar marked advantage (vaccinated ratio 5.9:1 and unvaccinated 
7.7: 1). In summary, these data demonstrate dramatically enhanced 
persistence of TCXCR4 and higher numbers at day 29 compared to day 8 in all 
organs in vaccinated mice, despite the absence of further antigen. The same 
was true to an even greater extent for TCXCR4 in unvaccinated mice. In 
contrast, numbers of TControl diminished over time in the vaccinated group, and 
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failed to increase significantly in the unvaccinated group. In particular very few 
TControl cells remained in unvaccinated lymph node and bone marrow. 
 
Memory phenotype 
A higher proportion of TCXCR4 maintained a central memory phenotype at Day 
29 in all organs in vaccinated mice (BM 81.1% vs 14.8%, spleen 79.2% vs 
22.9%, LN 96.3% vs 56.9%) (Figure 4-5). A similar effect of limited magnitude 
was seen in mice vaccinated with non-cognate peptide (BM 95.1% vs 79.4%, 
spleen 94.6% vs 81.6%, LN 96.2% vs 92.1%).  
 
 Cytokine receptors 
After prolonged exposure to the lymphopenic environment at day 29, 
vaccinated TCXCR4 expressed significantly higher levels of IL-15Rβ (CD122) 
compared to TControl in BM (MFI 1170 vs 437, 2 tailed paired t-test; p<0.001) 
and spleen (MFI 925 vs 438; p=0.005) and similar levels in lymph node (MFI 
1165 vs 974, p=ns). Common γ-chain receptor (CD132) expression was also 
significantly higher in vaccinated BM (599 vs 471, p=0.05), and similar in 
spleen (920 vs 559) and LN (1327 vs 1114). IL7Rα (CD127) was similar in all 
organs (BM MFI 494 vs 431, spleen 502 vs 445, LN 837 vs 1218, p=ns). 
CD25 was not significantly different between TCXCR4 and TControl in all organs 
(BM 0 vs 13, spleen 0 vs 103, LN 3 vs 113, p=ns).  
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Survival and Proliferation 
At day 29, TCXCR4 showed a similar pattern of significantly higher BCL2 
expression in TCXCR4 vs TControl (median BM % positive 46.8 vs 25.0, spleen 
43.6 vs 18.1, 2 tailed paired t-test; p=0.03 and 0.04 respectively). Caspase 
expression was not significantly different (BM MFI 325 vs 313, spleen 430 vs 
393, p=0.55 and 0.07). EdU proliferation was equivalent for TCXCR4 vs TControl 
(BM MFI 1172 vs 1117 and spleen 920 vs 800, p=ns for both). 
 
Function 
Upon ex-vivo restimulation of splenocytes with cognate peptide, previously 
vaccinated TCXCR4 displayed superior cytokine responses to TControl in terms of 
IFN-γ (median % positive 42.3 vs 33.3 and MFI 401 vs 205, 2 tailed paired t-
test; p=0.08 and 0.02), TNF-α (median % positive 37.5 vs 14.5 and MFI 1657 
vs 562, p=0.04 and 0.20) and IL-2 (median % positive 14.6 vs 2.5 and 410 vs 
109, p=0.25 and 0.03).  
  
Steady state phenotype summary 
The numerical advantage of TCXCR4 was maintained and increased over time 
in all organs regardless of prior vaccination. In vaccinated mice, the 
frequencies of TCXCR4 maintaining a central memory phenotype were 
dramatically higher than TControl, and also higher than TCXCR4 post primary 
vaccination. Vaccinated BM and splenic TCXCR4 expressed higher levels of 
stem memory phenotype markers IL-15Rβ and BCL2 and demonstrated 
 137 
greater functional responses upon ex vivo restimulation. The prolonged period 
prior to secondary vaccination was designed to identify phenotypic changes 
and ability to access homeostatic cytokine, and indicated that TCXCR4 possess 
the ability to maintain a less differentiated central memory phenotype 
regardless of initial antigen exposure. 
 
 
4.4 Recall response following boost vaccination 
 
I then re-vaccinated mice four weeks post primary vaccination at day 29 and 
determined phenotypes one week post boost at day 36 to establish the effects 
of repeated antigen exposure. 
 
Number and ratio 
 There were significantly increased absolute numbers of vaccinated TCXCR4 
compared to TControl in spleen and BM at day 36. Median BM numbers were 
12,477 vs 1087 (Wilcoxon signed rank; p=0.004) (Figure 4-3), spleen 19,170 
vs 7620 (p=0.027) and lymph node 482 vs 1323 (p=ns). Median TCXCR4: 
TControl ratios were also significantly higher in BM (14.1:1, Wilcoxon signed 
rank; p=0.004) (Figure and spleen (2.2:1, p=0.02) and similar in lymph node 
(0.7:1, p=ns), (Figure 4-2). These differences were magnified in unvaccinated 
mice for BM and spleen, but lacked significance due to a replicate value of 3. 
Absolute number was 264,450 for unvaccinated TCXCR4 BM vs TControl 1875, 
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and spleen TCXCR4 were 140,282 vs 3129, LN 1098 vs 874. Unvaccinated 
ratios were similarly increased (BM 136:1, spleen 45.8:1, lymph node 5.3:1). 
 
Memory phenotype 
The proportion of central memory cells was significantly greater post boost 
vaccination in all organs, BM median TCM% was 71.3 vs 23.7, spleen 50.5% 
vs 16%, lymph node 66.4% vs 37.7%, Wilcoxon’s signed rank; p=0.004 for all) 
(Figure 4-5). This difference was not present in unvaccinated TCXCR4 and 
TControl where TCM proportions were similar to each other. Thus, over time 
TCXCR4 retain higher levels of CD62L in all organs despite repeated antigenic 
challenge (Figure 4-5). 
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Figure 4-5 TCXCR4 retain a central memory phenotype after 
repeated antigen exposure 
%CD62Lhigh TCXCR4 (red) and TControl (cyan) over time after SIINFEKL 
peptide vaccination (purple arrows) at days 1 and 29 following transfer 
into Rag1ko mice and representative flow plots denoting relative 
proportions of CD8+GFP+ T cells and day 36 surface expression of 
CD44/CD62L. (A) BM, (B) Spleen and (C) LN were harvested at days 8, 
29 and 36 post transfer. Error bars denote SD, **P<0.01; ***P<0.001, 
n=16, data representative of 4 independent experiments. 
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Importantly, although the proportion of CD62Llow TEM/EFF cells was lower for 
OT-I TCXCR4 vs TControl, their absolute number was higher in BM and equivalent 
in other organs (Figure 4-6) suggesting that greater expansion of the entire 
TCXCR4 population enables superior production of both memory and effector 
CD8+ T cells. 
 
 
 
Figure 4-6 Absolute numbers of Ag-activated CD62Lhigh and 
CD62Llow transduced CD8+ T cells 
Box and whisker plots depicting day 36 numbers of TCXCR4 (red) and 
TControl (cyan) post vaccination, n=9, data representative of 4 
independent experiments, **P<0.01. 
 
Cytokine receptors 
Post boost vaccination, TCXCR4 expressed significantly higher levels of CD122 
(IL-15Rβ) compared to TControl in bone marrow (MFI 2408 vs 1939, Wilcoxon’s 
signed rank; p=0.008) (Figure 4-7) and spleen (2048 vs 1798, p=0.020) and 
similar levels in LN (MFI 2328 vs 2279, p=ns). In contrast, values were similar 
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for all organs in unvaccinated mice (BM 1624 vs 1728, spleen 1594 vs 1658, 
LN 1594 vs 1544). 
 
 
 
 
Figure 4-7 Post-boost vaccination memory phenotype. 
(A) Representative flow cytometric histograms and (B) summary data 
for day 36 IL-15Rβ (CD122), BCL2, EdU and activated caspase 3 
expression on BM CD8+GFP+ TCXCR4 and TControl post vaccination. Top 
right figures denote MFI, n=9, data representative of 4 independent 
experiments. *P<0.05, **P<0.01. 
 
CD127 (IL7Rα) levels were similar in vaccinated mice (BM MFI 326 vs 185, 
spleen 257 vs 190, LN 549 vs 606, p=ns for all) and CD132 (common gamma 
chain receptor) levels were significantly lower in BM (MFI 1093 vs 1315, 
Wilcoxon’s signed rank; p=0.012), trended lower for spleen (MFI 1121 vs 
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1495, p=0.055) and were similar in LN (MFI 1913 vs 1429, p=ns). Finally, 
CD25 expression was slightly lower in all organs for TCXCR4 (BM MFI 0 vs 140, 
Wilcoxon’s signed rank; p=0.039, spleen MFI 0 vs 130, LN MFI 0 vs 220, 
p=0.004 for both). All cytokine receptor levels remained similar in 
unvaccinated mice (CD122, CD132, CD127, CD25), demonstrating the 
requirement for antigen exposure to produce the TCXCR4 phenotype. 
 
Survival 
The proportion of TCXCR4 cells expressing BCL2 was again significantly higher 
than TControl in all vaccinated organs. Median BCL2 %positive for TCXCR4 vs 
TControl was 52.4% vs 17.0% in BM (Figure 4-7), 37.5% vs 19.4% in spleen 
and 62.9% vs 47.6% in LN (Wilcoxon’s signed rank; p=0.004, 0.004 and 0.008 
respectively). The same was true for BCL2 expression (BM MFI 1064 vs 689, 
spleen 978 vs 633, LN 1598 vs 1098, Wilcoxon’s signed rank; p=0.004, 0.004 
and 0.008 respectively). 
Similarly, caspase 3 positivity was significantly decreased in all vaccinated 
organs for TCXCR4 (BM 1.3% vs 7.5%, spleen 1.5% vs 13.1%, LN 4.1% vs 
14.5%, Wilcoxon’s signed rank; p=0.027, 0.008 and 0.008 respectively, BM 
MFI 504 vs 655, spleen 640 vs 805, LN 835 vs 887, Wilcoxon’s signed rank; 
p=0.004, 0.008 and ns respectively (Figure 4-7). No differences in BCL2 or 
caspase 3 were seen in unvaccinated mice. 
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Proliferation 
Vaccinated BM TCXCR4 proliferated to a slightly lower extent compared to 
TControl. BM EdU MFI was 2812 vs 3609 (Wilcoxon’s signed rank; p=0.02) 
(Figure 4-7), spleen 2311 vs 2609 (p=ns) and LN 1987 vs 2043 (p=ns). Levels 
of proliferation were similar in the unvaccinated setting (BM MFI 1609 vs 1588, 
spleen MFI 1152 vs 1125, p=ns for both). 
 
 
Function 
Upon ex vivo splenocyte restimulation, vaccinated TCXCR4 alone expressed 
significantly higher levels of all measured cytokines compared to TControl. 
Median IFN-γ-% positive was 50.8% vs 27.5%, TNF-α % positive 25.8% vs 
9.8% and IL-2 % positive 5.6% vs 1.3% (Wilcoxon’s signed rank; p=0.016, 
0.008 and 0.008 respectively) (Figure 4-8A and B).  The same was true for 
MFI: IFN-γ 545 vs 135, TNF-α 642 vs 521 and IL-2 MFI 253 vs 196 (p=0.016, 
0.008 and 0.027). I applied Boolean gating to measure the frequency of 
polyfunctional cells (cells expressing 2 or more cytokines). These were 
significantly increased for TCXCR4 (median 22.4% vs TControl 8.0%, p<0.001), as 
were all cytokine positive combinations (IFN-γ and TNF-α, IFN-γ and IL-2, 
TNF-α and IL-2) and trifunctional cells secreting all 3 cytokines (2.2% vs 0.7%, 
p=0.02) (Figure 4-8C). These differences were not seen in unvaccinated mice. 
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Figure 4-8 Cytokine production and polyfunctionality. 
 (A) Representative flow cytometric plots denoting intracellular IFN-γ 
and TNF-α co-staining by TCXCR4 and TControl at 4hrs post ex vivo 
SIINFEKL stimulation. Gating performed on vaccinated CD8+GFP+ 
splenocytes at day 36. (B) Summary data for %IFN-γ +, TNF-α+ and IL-
2+ production from vaccinated day 36 TCXCR4 and TControl splenocytes, 4 
hours post ex vivo SIINFEKL stimulation, n=7, data representative of 4 
independent experiments. (C) Pie charts depicting polyfunctional 
cytokine generation summary data according to Boolean combination 
gates identifying IFN-γ+, TNF-α+ and IL-2+ cells. *P<0.05; **P<0.01. 
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Senescence and exhaustion 
In order to investigate the effects of repeated antigen exposure upon 
vaccinated cells, I also investigated expression of the T-cell exhaustion and 
senescence markers KLRG1 and PD-1, and relevant transcription factors (T-
bet and Eomes). I used splenic samples because of insufficient BM TControl for 
comparison. Splenic TCXCR4 demonstrated significantly lower levels of PD-1 % 
positivity than TControl (median 18.8% vs 60.5%, Wilcoxon’s signed rank; 
p=0.031) and lower PD-1 MFI (183 vs 495, p=0.031). In addition, splenic 
TCXCR4 expressed lower levels of KLRG1 (MFI 44.8 vs 500, p=0.031). Splenic 
TCXCR4 were also characterised by significantly higher frequencies of a 
memory-associated EomesHigh T-betLow phenotype (median 52% vs 44%, 
Wilcoxon’s signed rank; p=0.031). Recent data has highlighted important 
differences between PD-1 expressing cells, differentiating between PD-1mid T-
bethigh cells which can be reinvigorated by antibody blockade, and terminally 
differentiated, ‘hyper-exhausted’ PD-1high Eomeshigh cells which cannot (359, 
488). The proportion of hyper-exhausted splenic TControl was markedly greater 
than TCXCR4 (median 65.8% vs 34.0%, p=0.015) (Figure 4-9). 
In an alternative conceptual model, antigen-specific T cells can be subdivided 
into memory precursor (MPECs) and short-lived effector cells (SLECs) 
according to KLRG1 and CD127 expression. When analysed according to this 
framework, TCXCR4 maintain significantly higher proportions of MPECs and 
lower numbers of SLECs in the spleen post boost vaccination (MPECs 35.8% 
vs 10.9% and SLECs 7.9% vs 40.2%, Wilcoxon’s signed rank; p=0.031 for 
both), (Figure 4-9). 
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Figure 4-9 Exhaustion and senescence phenotype. 
(A) Exemplar flow plots and (B) summary data showing frequency of 
day 36 splenic TCXCR4 and TControl SLECs (KLRG1high CD127low), 
MPECs (KLRG1low CD127high) and hyper-exhausted phenotypes (PD-
1high Eomeshigh), n=6, data representative of 1 independent experiment, 
*P<0.05. 
 
Boost vaccination summary 
TCXCR4 maintain a dramatically increased numerical advantage compared to 
TControl in bone marrow and spleen after boost vaccination. This numerical 
advantage is also enhanced in all organs in the absence of antigen, 
suggesting superior ability to access homeostatic cytokine. After antigen 
exposure, TCXCR4 maintain markedly higher proportions of TCM, IL-15Rβ and 
BCL2 expression in all organs. TCXCR4 also exhibit higher levels of effector 
cytokine expression upon restimulation, and higher frequencies of 
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polyfunctionality. Finally, consistent with an early memory phenotype, TCXCR4 
are characterised by higher frequencies of a memory-associated EomesHigh T-
betLow transcription factor profile and express very low levels of the inhibitory 
exhaustion marker PD-1 and terminal senescence marker KLRG1 despite 
repeated antigenic stimulation. These early memory phenotypes, summarised 
in Table 2 below, are not seen in the absence of antigen exposure. 
Phenotype Interpretation TCXCR4 TControl  Significance 
 
BM accumulation é 12477 
(1353-
195694) 
1087 
(189-
1803) 
 
 P=0.004 
BM %TCM é 71.3 (37.9-
82.8) 
23.7 
(10.1-
33.0) 
 P=0.004 
BM IL-15Rβ 
expression (MFI) 
é 2408 (978-
3145) 
1939 
(521-
2558) 
 P=0.008 
BM IL-7Rα 
expression (MFI) 
- 326 (138-
576) 
185 (121-
707) 
 P=ns 
BM BCL2%+ é 52.4 (22.4-
76.7) 
17.0 (5.1-
36.8) 
 P=0.004 
BM caspase 3%+ ê 1.3 (0.0-
2.5) 
7.5 (0.0-
21.2) 
 P=0.027 
EdU MFI ê 2812 (132-
4643) 
3609 (0-
6091) 
 P=0.020 
IFN-γ%+ 
 
TNF-α%+ 
é 
 
 
é 
50.8 (17.6-
78.6) 
 
25.8 (9.5-
46.4) 
27.5 (9.5-
49.5) 
 
9.8 (2.5-
22.6) 
 P=0.016 
 
P=0.008 
Polyfunctional % é 22.4 (13.6-
29.3) 
8.0 (3.3-
18.0) 
 P<0.001 
% MPEC é 35.8 (5.7-
85.0) 
10.9 (4.0-
25.7) 
 P=0.031 
% SLEC ê 7.9 (1.6-
25.9)  
40.2 
(36.5-
56.0) 
 P=0.031 
% Hyper-exhausted 
(PD-1high Eomeshigh) 
ê 34.0 (15.6-
51.8) 
65.8 
(34.6-
82.9) 
 P=0.015 
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Table 2 TCXCR4 recall phenotype post boost vaccination. 
Day 36 summary data from SIINFEKL-vaccinated mice. Numbers 
indicate median (95% confidence intervals). é denotes significantly 
increased values for TCXCR4 relative to TControl, ê denotes reduced for 
TCXCR4 relative to TControl and - denotes statistical equivalence. Cytokine 
production, polyfunctionality, %MPEC, SLEC and % hyper-exhausted 
data from splenic T cells. All p-values Wilcoxon’s signed rank test.  
 
 
4.4 Graded CXCR4 expression modulates the TCXCR4 phenotype 
 
I next examined the importance of the level of CXCR4 expression upon the 
phenotype generated. The transduced cells express a range of CXCR4 
correlating with GFP expression (Figure 3-2). Based upon the phenotype 
seen, I reasoned that CXCR4High TCXCR4 would be skewed towards the central 
memory phenotype. 
I therefore compared the change in phenotype for cells according to an 
increasing gradient of GFP expression. When GFP positive cells are 
subdivided according to degree of CXCR4 expression (GFP groups 1-4 where 
1 denotes GFP MFI 100-400 and 4 denotes the highest level of expression at 
GFP MFI >5000), an increased proportion of TCM was seen as CXCR4 
expression increased in all organs. No change was seen in TCM frequency as 
GFP MFI increased in TControl. 
Median BM TCM frequencies were 23.7% TControl vs 37.4% TCXCR4 group 1 (2 
tailed paired t-test p=0.012), 38.2% for group 2 (p=ns vs TCXCR4 group 1), 
54.5% for group 3 (p=0.002 vs group 2) and 72.7% for group 4 (p<0.001 vs 
group3) (Figure 4-10). Similarly splenic TCM frequencies were 16.0% TControl vs  
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Figure 4-10 TCXCR4 memory phenotype correlates with level of 
CXCR4 expression. 
(A) Representative flow plots showing GFP as a marker for CXCR4 
expression in vaccinated BM OT-I TCXCR4 at day 36, divided into 4 
gates (1-4) denoting increasing CXCR4 expression. Histograms show 
CD62L expression within each gate for BM OT-I TControl (cyan) and 
TCXCR4 (red) and bar graphs show summary data. Numbers top right 
denote CD62L MFI. (B) As above for BCL2 expression within each 
gate. Numbers top right denote % BCL2 positive.  Error bars denote 
SD, n=9, data representative of 4 independent experiments *P≤0.05; 
**P≤0.01; ***P≤0.001, ****P≤0.0001, ns=not significant. 
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23.2 TCXCR4 group 1 (p=0.013), 28.5% group 2 (p=0.002 vs group 1), 44.2% 
group 3 (p=0.016 vs group 2) and 64.4% group 4 (p=0.006 vs group 3). 
The same differences were shown when TCM frequencies were compared in 
matched GFP groups although there were few TControl cells expressing the 
highest levels of GFP (median BM TCM frequency in TControl was 20% for group 
1, 22.9% group 2, 20.7% for group 3 and 0% for group 4 (2 tailed paired t-test 
for comparison with matched TCXCR4; p=0.022, 0.001, 0.001 and <0.0001 
respectively). Similarly splenic TCM frequency in TControl was 15.8% for group 1, 
14.8% group 2, 15.6% group 3 and 7.9% for group 4 (p=0.013, 0.006, 
<0.0001 and <0.0001 respectively). 
The pattern was less pronounced in terms of BCL2 expression, suggesting 
that a threshold level of BCL2 may be required for this phenotype. BM TControl 
were 17.0% median BCL2 positive vs 40.8% TCXCR4 group 1 (p<0.001), 41.1% 
group 2 (p=ns vs group 1), 53.0% group 3 (p=0.001 vs group 2) and 62.7% 
group 4 (p=0.08 vs group 3). Similar findings were shown for the BM homing 
advantage, with no increase in the homing advantage above a set level of 
GFP expression (TCXCR4: TControl ratio 0.7:1 for group 1, 3.4:1 for group 2 
(Wilcoxon matched-pairs signed rank p=0.004 vs group 1), 6.7:1 for group 3 
(p=0.004 vs group 2) and 5.2:1 for group 4 (p=ns vs group 3), (Figure 4-10).  
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4.5 TCXCR4 central memory phenotype and BM accumulation are 
IL-15 dependent 
 
Data in Figure 3-1 demonstrated a requirement for IL-15 signalling to mediate 
superior BM accumulation of polyclonal TCXCR4. I hypothesised that the 
absence of IL-15 signalling would affect BM accumulation and central memory 
phenotype of TCXCR4 in the context of exposure to antigen. I therefore 
conducted vaccination experiments using OT-I CD8+ T cells transduced with 
CXCR4-GFP or CTRL-GFP in 1:1 competition experiments, injected into 
either Rag1ko or IL-15Rako mice.   
 
Number and ratio 
The BM homing advantage of TCXCR4 over TControl seen in Rag1ko mice after 
boost vaccination was not seen in IL-15Rako mice (Figure 4-11A) (TCXCR4: 
TControl ratio 2.3:1, Wilcoxon signed rank; p=ns). The ratio of TCXCR4: TControl 
was also further diminished in spleen and LN (ratio 0.5:1 & 0.2:1, p=ns for 
both). 
 
Memory phenotype 
The preferential maintenance of a central memory phenotype was also 
reduced in the IL-15Rako setting. In BM at day 36, TCM frequencies were only 
24.2% vs 8.8% in TCXCR4 vs TControl (Wilcoxon’s signed rank; p=0.031 (Figure 
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4-11B) compared with 71.3% for TCXCR4 in the Rag1ko setting. Spleen and 
LN-derived TCXCR4 no longer demonstrated a significant difference from 
control cells (Figure 4-11C and D). Splenic TCM% was reduced at 24.7% 
TCXCR4 vs 6.6% TControl (p=ns), down from 50.5% in the TCXCR4 Rag1ko setting. 
LN TCM% was 38.9% vs 24.6% (p=ns), down from 66.4% for TCXCR4 in Rag1ko 
hosts. 
 
Cytokine receptors 
The enhancement in IL-15Rβ expression seen for TCXCR4 in vaccinated 
Rag1ko mice was also diminished in IL-15Rako hosts. CD122 expression was 
now only slightly higher for TCXCR4 over TControl at day 36 in BM (MFI 2031 vs 
1775, Wilcoxon’s signed rank; p=0.03 (Figure 4-12A) compared to 2408 in 
Rag1ko mice, and equivalent in spleens and LNs  (MFI 1471 vs 1386 and 
1624 vs 1732 respectively, p=ns for both). 
BM CD132 expression remained slightly lower for TCXCR4 in IL-15Rako mice 
(MFI 1112 vs 1355, Wilcoxon’s signed rank; p=0.031) and similar for spleen 
and LN (1046 vs 1079 and 770 vs 1049, p=ns for both).  CD127 was similar 
between TCXCR4 and TControl for all IL-15Rako groups (BM MFI 723 vs 510, 
spleen 638 vs 730, LN 1115 vs 924, p=ns for all). CD25 remained slightly 
lower for TCXCR4 vs TControl (BM MFI 0 vs 50, spleen 0 vs 100, LN 0 vs 131, 
p=0.031, ns and 0.031 respectively).  
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Figure 4-11 TCXCR4 BM homing and CD62Lhigh phenotype are 
dependent upon IL15Ra in a vaccination model. 
(A) Box and whisker plots denoting TCXCR4: TControl ratio at day 36 in 
vaccinated IL-15Ra wt and IL-15Rako mice in BM, spleen and LN. 
Summary data showing the proportion of CD62Lhigh TCXCR4 (red) and 
TControl (cyan) at day 36 in vaccinated IL-15Ra wt and IL-15Rako mice 
in (B) BM, (C) spleen and (D) LN. Mice were vaccinated as above with 
SIINFEKL-IFA at days 1 and 29 and organs harvested on days 8, 29 
and 36. *P<0.05, **P<0.01, n = 15, 3 independent experiments. 
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Survival and Proliferation 
Expression of the pro-survival protein BCL2 also became equivalent between 
TCXCR4 and TControl in vaccinated IL-15Rako mice. BM BCL2 positivity was 
markedly reduced at 8.1 for TCXCR4 vs 5.0% for TControl (Wilcoxon’s signed 
rank; p=ns (Figure 4-12B) down from 52.4% in Rag1ko mice. Similarly, 
Spleen BCL2 positivity was 9.4% vs 6.3% (p=ns), down from 37.5% in 
Rag1ko mice. LN BCL2 %positive was 57.1% vs 54.5% (p=ns), down from 
62.9%. BCL MFI showed a similar equivalence in IL-15Rako mice (BM MFI 
396 vs 336, spleen 361 vs 342, LN 1297 vs 1324, p=ns for all). Reciprocally, 
expression of pro-apoptotic caspase 3 also became equivalent in all organs 
(BM caspase 3 MFI 504 vs 563, Figure 4-12C, spleen 642 vs 684, LN 836 vs 
782, p=ns for all). TCXCR4 and TControl proliferated to a similar extent in 
vaccinated IL-15Rako mice (BM EdU MFI 3244 vs 4000, spleen 2333 vs 2754, 
LN 2025 vs 1848, Wilcoxon’s signed rank; p=ns for all). 
 
 
 
Senescence and exhaustion 
The absence of IL-15Ra also rendered PD-1 and KLRG1 expression 
equivalent between splenic TCXCR4 and TControl (PD-1 %positive 29.8% vs 
30.2%, PD-1 MFI 267 vs 242, KLRG1 MFI 45.4 vs 43.9, Wilcoxon’s signed 
rank, p=ns for all) and there were no differences in the proportion of splenic 
MPECs and SLECs (MPECs 68.4% vs 32.9% and SLECs 2.6% vs 12.2%, 
p=ns (Figure 4-12D). The increased proportion of hyper-exhausted TControl 
cells (PD-1highEomeshigh) seen in the IL-15Ra wt setting was also not seen in 
IL-15Rako mice (median 23.5% TControl vs 30.4% TCXCR4, p=ns (Figure 4-12E).  
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Figure 4-12 Absence of IL-15 signalling nullifies the TCXCR4 
memory phenotype. 
Summary TCXCR4 (red) and TControl data (cyan) at day 36 in vaccinated 
IL-15Ra wt and IL-15Rako mice for (A) BM CD122 MFI, (B) %Bcl2+, 
(C) activated caspase 3 MFI, (D) splenic %SLEC and (E) %PD-
1highEomeshigh hyper-exhausted phenotype. (F-H) Summary data for 
cytokine production post ex vivo SIINFEKL stimulation of splenic 
TCXCR4 (red) and TControl. *P<0.05, **P<0.01, ***P<0.001, n = 15, data 
pooled from 3 independent experiments. 
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Function 
Post ex vivo splenocyte restimulation, there were no significant differences in 
the levels of cytokine expression between TCXCR4 and TControl in the absence of 
IL-15 signalling. IFN-γ% positive was 56.8% vs 40.7%, TNF-α 30.2% vs 
25.8%, IL-2 6.1% vs 5.5%, (p=ns for all) (Figure 4-12F-H). The same was true 
for measurements by MFI (IFN-γ 692 vs 391, TNF-α 775 vs 673, IL-2 172 vs 
147, p=ns for all). 
 
IL-15Rako summary 
In the absence of IL-15Ra, the defining TCXCR4 phenotypes of preferential 
bone marrow accumulation, TCM formation, higher CD122 and BCL2 
expression, and superior cytokine production are no longer seen. In addition, 
there are no longer any differences in markers of proliferation, senescence or 
exhaustion, suggesting that key differences in differentiation status between 
TCXCR4 and TControl are no longer present. 
Two distinct phenotypic alterations were seen when comparing cells from IL-
15Ra wt and IL-15Rako mice. For CD62L, BCL2 and CD122 expression, 
TCXCR4 lose their ‘enhanced’ phenotype to fall to similar levels as TControl 
(Figure 4-11B-D and Figure 4-12A-B). In contrast, for caspase 3 expression, 
formation of SLECs and hyper-exhausted phenotypes, the remaining TControl 
cells adopt the less terminally differentiated phenotype of TCXCR4 cells (Figure 
4-12C-E). These conclusions are limited by numbers, but may be due to the 
fact that the tiny numbers of surviving TControl cells have managed to locate 
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alternative survival pathways, or represent a small proportion of memory cells 
with a long-lived phenotype. 
 
4.6 In vitro TCXCR4 phenotype 
 
An important question not yet addressed is the contribution of intrinsic 
CXCR4-CXCL12 signalling to the TCXCR4 phenotype. I investigated the in vitro 
TCXCR4 phenotype comparison to the TControl phenotype by culturing cells with 
recombinant CXCL12 under a number of different cytokine conditions.  
Because CXCL12 is present in serum at low concentrations, I also examined 
the effect of CXCR4 blockade with Plerixafor in vitro. The aim was to compare 
the in vitro phenotype with in vivo findings to determine to what degree the 
TCXCR4 phenotype resulted from intrinsic CXCR4-CXCL12 signalling, as 
opposed to extrinsic regulation by other factors. Thus, if a particular 
phenotype was seen to the same extent both in vitro and in vivo, and reversed 
by Plerixafor in vitro, this would suggest a dependence upon cell intrinsic 
signalling, as cell-extrinsic factors were lacking in my vitro model. In contrast, 
a phenotype seen solely in vivo would suggest a requirement for cell extrinsic 
signalling, possibly relating to the bone marrow microenvironment.  
 
Previous experiments conducted by Dr. Ben Carpenter using transduced OT-I 
T cells showed that expression of CD44 and CD6L was equivalent between 
TCXCR4 and TControl after stimulation with relevant or irrelevant peptide, and the 
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presence or absence of 500 ng/ml murine CXCL12 did not alter phenotype, or 
IFN-γ generation following in vitro TCR activation. I therefore conducted a 
series of competition experiments exposing transduced polyclonal TControl and 
TCXCR4 to homeostatic cytokines during in vitro culture in the presence of 
varying levels of CXCL12. I examined the effect of prolonged culture over 
periods of 3-5 days post transduction upon memory phenotype, cytokine 
receptor expression and markers of survival and proliferation. Briefly, CD8+ T 
cells were removed from transduction medium at day +3 post transduction, as 
per standard protocol, mixed in a 1:1 ratio, washed, and incubated with either 
IL-2 or a combination of IL-7 and IL-15 in T cell culture medium, in the 
presence or absence of CXCL12 or the CXCR4 antagonist Plerixafor. 
 
Number, ratio, proliferation and survival 
No differences were noted in phenotype at day 3 prior to 1:1 mixing. At day 5 
post-transduction, numbers of TCXCR4 and TControl were comparable in wells 
where no additional CXCL12 was added (Baseline), regardless of the 
presence of IL-2 or IL-7 and IL-15 (median TCXCR4 number 38,877 vs TControl 
51,752 in IL-2, 57,791 vs 51,699 in IL-7 and 15). Plerixafor did not alter 
absolute number or TCXCR4: TControl ratio significantly (median TCXCR4 number 
36,416 and TControl 45,414 in IL-2, 34,414 and 66,840 in IL-7 and IL-15). At low 
levels of CXCL12 (0.1 to 5 ng/ml), TCXCR4 and TControl numbers were similar to 
baseline. At higher concentrations of CXCL12 (100-1000 ng/ml) there was a 
progressive increase in absolute TCXCR4 number, whilst TControl number 
remained similar, resulting in an increased TCXCR4: TControl ratio at high 
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CXCL12 levels (ratio 0.8 at baseline vs 2.2 at 1000 ng/ml CXCL12 with IL-2 
and 0.9 at baseline vs 2.8 at 1000 ng/ml CXCL12 with IL-7 and IL-15 (Figure 
4-13 and Table 3).  Absolute TCXCR4 number trended towards correlation with 
increasing CXCL12 levels in the presence of homeostatic cytokines 
(Spearman’s rho 0.59 for IL-2 and 0.80 for IL-7 and IL-15, 2 tailed t-test; 
p=0.09 and 0.014 respectively). 
At higher CXCL12 levels there was a small increase in cellular proliferation for 
TCXCR4 in conjunction with IL-7 and 15, as measured by Ki67 staining (median 
Ki67 58.8% positive TCXCR4 at baseline vs 65.1% at 1000 ng/ml CXCL12 and 
TControl 47.2% positive at baseline vs 41.2% at 1000 ng/ml in IL-7 and IL-15, 
Figure 4-13). Ki67 proliferation showed a strong trend towards significant 
correlation with increasing CXCL12 levels for TCXCR4 regardless of cytokine 
conditions, but not TControl (Spearman’s rho =0.66 and 0.65, p=0.05 and 0.06 
for IL-2 and IL-7 and IL-15 respectively). No effect was seen for Plerixafor.  
BCL2 expression was similar between TCXCR4 and TControl and did not change 
significantly upon exposure to CXCL12 in either cytokine condition (median 
MFI 1774 for TCXCR4 vs 2037 TControl at baseline and 2076 vs 1440 at 1000 
ng/ml CXCL12 in IL-7 and 15). 
 
Memory phenotype, CXCR4 and cytokine receptor expression 
The majority of transduced cells maintained a CD62L+CD44+ central memory 
phenotype (TCM) in culture and no differences were noted between TCXCR4 and 
TControl at baseline (median %TCM 84.5 vs 84.7 respectively in IL-7 and IL-5 
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Figure 4-13 In vitro effects of CXCL12 upon cell number, 
proliferation and memory phenotype. 
 (A) Summary data for TCXCR4: TControl ratio at day 5 post transduction. 
Summary (B) absolute cell number (C) Ki67% positivity and (D) TCM% 
for TCXCR4 and TControl at day 5 in wells containing IL-7 and IL-15 with 
Plerixafor or varying levels of CXCL12. Points and bars indicate 
median and inter-quartile range, data pooled from 4 independent 
experiments. 
 
and 86.2 vs 81.9 in IL-2, p=ns for both) or at other CXCL12 concentrations 
(median %TCM 92.2 vs 88.5 respectively in IL-7 and IL-5 and 91.4 vs 84.1 in 
IL-2 with 1000ng/ml CXCL12, p=ns for both) (Figure 4-13). CXCL12 
concentration correlated with TCXCR4 %TCM in IL-2, with a similar trend for IL-7 
and IL-15 (Spearman’s rho = 0.97 and 0.6, p<0.0001 and 0.08 respectively); 
however, the numerical difference was minimal. This effect was not seen in 
TControl cells and Plerixafor did not alter this phenotype.  
CXCR4 expression on TCXCR4 correlated strongly with CXCL12 level in both 
IL-2 and IL-7 and IL-15 (Spearman’s rho = -0.74 and -0.71, p=0.022 and 
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0.033 respectively (Figure 4-14) but not for TControl cells. Although median 
CXCR4 MFI on TCXCR4 reduced as CXCL12 level increased (2766 at baseline 
to 583 at 1000 ng/ml CXCL12 in IL-2), levels remained above those of TControl 
(baseline MFI 155 to 171 at 1000 ng/ml CXCL12 in IL-2). Plerixafor did not 
alter levels of CXCR4 expression under any conditions. No significant 
differences in cytokine receptor expression were seen between TCXCR4 and 
TControl at baseline (Figure 4-14 and Table 3) or at differing levels of CXCL12 
and no correlations were seen between CXCL12 concentration and cytokine 
receptor expression.  
 
Figure 4-14 In vitro effects of CXCL12 upon CXCR4 and cytokine 
receptor expression. 
Summary data at day 5 for (A) CXCR4 expression, (B) CD122, (C) 
CD127 and (D) CD25 expression for TCXCR4 and TControl in wells 
containing IL-7 and IL-15 with Plerixafor or varying levels of CXCL12. 
Points and bars indicate median and inter-quartile range, data pooled 
from 4 independent experiments. 
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 IL-2 IL-7 and IL-15 Correlation with 
CXCL12 
concentration 
 TCXCR4 TControl TCXCR4 TControl  
Number 38877 
(19366-
195000) 
51752 
(35310-
1060000) 
57,791 
(9484-
672000) 
51,699 
(29600-
114052) 
TCXCR4 alone  
IL-2: rho= 0.59, p=0.09 
IL-7 and IL-15: rho= 0.80, 
p=0.014 
% Ki67+ 61.1 
(40.0-
72.1) 
58.4 
(30.6-
67.1) 
58.8 
(36.8-
60.8) 
47.2 
(42.2-
54.0) 
TCXCR4 alone 
IL-2: rho= 0.66, p=0.05 
IL-7 and IL-15: rho= 0.65, 
p=0.06 
% TCM 86.2 
(71.6-
90.2) 
81.9 
(79.8-
85.0) 
84.5 
(80.0-
87.6) 
84.7 
(77.3-
85.3) 
TCXCR4 alone 
IL-2: rho= 0.97, p<0.0001 
IL-7 & IL-15: rho= 0.60, 
p=0.08 
CXCR4 MFI 2766 
(515-
3575), 
p<0.001 
155 (35-
161) 
2140 
(567-
2734), 
p=0.045 
113 (31-
194) 
TCXCR4 alone 
 IL-2: rho= -0.74, p=0.022 
IL-7 & IL-15: rho= -0.71, 
p=0.033 
BCL2 MFI 1983 
(1405-
2387) 
1842 
(1532-
2992) 
1774 
(1421-
1777) 
2037 
(2025-
2871) 
No 
IL-2/15Rβ 
MFI (CD122) 
570 (370-
728) 
423 343-
576) 
601 (461-
1784) 
517 (317-
596) 
No 
IL-7Rα MFI 
(CD127) 
486 (149-
712) 
765 (153-
1130) 
310 (113-
712) 
250 (108-
436) 
No 
IL-2Rα MFI 
(CD25) 
1380 
(828-
1702) 
1295 
433-
2144) 
1202 
(923-
1340) 
1660 
(541-
2123) 
No 
 
Table 3 Summary of in vitro data for TCXCR4 and TControl at baseline. 
Median (ranges) values shown for all, data pooled from 4 independent 
experiments, p=ns except when shown. 
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In vitro summary 
No difference was seen between TCXCR4 and TControl in wells where no 
exogenous CXCL12 was added, or Plerixafor was used, suggesting that the 
effect of CXCL12 signalling at baseline is minimal due to insufficient quantities 
of CXCL12 in T cell culture medium. Low exogenous CXCL12 levels also had 
minimal effects upon cellular proliferation or cell number. At high CXCL12 
concentrations (>100 ng/ml), cell number and proliferation were specifically 
enhanced in TCXCR4, enabling a tiny advantage over TControl cells at the highest 
level. This difference did not relate to cell survival, as shown by unaltered 
BCL2 expression, and was unaffected by the choice of cytokine.  
Increasing CXCL12 had a similarly tiny effect in increasing the proportion of 
TCXCR4 with a central memory phenotype. As expected, high CXCL12 levels 
had the effect of reducing CXCR4 expression in TCXCR4 4-fold from baseline 
due to receptor internalisation, but TCXCR4 at 1000 ng/ml retained 5-fold higher 
expression than TControl, suggesting that prolonged high level CXCR4 
signalling can persist despite receptor downregulation. None of these findings 
were affected by homeostatic cytokine addition, which may relate to localised 
concentration gradients and IL-15 trans-presentation causing differing effects 
within the complex in vivo BM microenvironment.  
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4.7 Discussion 
 
The data presented above demonstrate that TCXCR4 maintain a dramatically 
increased numerical advantage compared to TControl in bone marrow and 
spleen after boost vaccination, with greater proportions of TCM, IL-15Rβ and 
BCL2 expression in all organs, enhanced levels of effector cytokine 
expression upon restimulation, and higher frequencies of polyfunctionality. 
One of the interesting differences between TCXCR4 and TControl was the ability of 
a proportion of TCXCR4 to produce IL-2. This feature has an autocrine role in 
enhancing IFN-γ production independent of proliferation in protective immune 
responses (489) and T cells with high IL-2: IFN-γ ratios demonstrate superior 
long-term persistence and self-renewal in patients with metastatic melanoma 
(490). 
One potential concern with efforts to alter the phenotypic balance to generate 
memory T cells, for example by inhibition of the mTOR signalling pathway, is 
the production of cells with limited expansion and effector capability (491). In 
our model CXCR4 over-expression led to enhanced bone marrow and splenic 
accumulation at early time points post vaccination and subsequently superior 
numbers of TCXCR4 in all organs at later time points, suggesting that 
substantial trafficking of T cells from the bone marrow niche and enhanced 
bone marrow persistence allows seeding of other tissues. Consistent with the 
multipotent profile of TCM, TCXCR4 also produced higher number of TEM/EFF cells 
at day 36, indicating proficiency in recapitulating the entire immune repertoire.  
Consistent with an early memory phenotype, TCXCR4 are characterised by 
higher frequencies of a memory-associated EomesHigh T-betLow transcription 
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factor profile and express very low levels of the inhibitory exhaustion marker 
PD-1 and terminal senescence marker KLRG1 despite repeated antigenic 
stimulation. In contrast, the in vitro model failed to demonstrate major 
differences between TCXCR4 and TControl in terms of memory phenotype, 
expression of cytokine receptor expression, apoptosis-associated proteins, or 
production of effector cytokines. Any differences seen in number seemed to 
relate to higher levels of proliferation seen at high CXCL12 concentrations, 
conflicting with the in vivo phenotype. 
Coupled with the findings of the IL-15Rako experiments, these differences 
suggest that the TCXCR4 phenotype is predominantly maintained by extended 
in vivo exposure to extrinsic factors, in particular IL-15 signalling. As the BM is 
a site of superior IL-15 bioavailability, this would explain the greater tendency 
towards this phenotype seen in the IL-15Ra.wt BM niche compared to other 
organs.  The incomplete abolition of this phenotype in the BM of IL-15Rako 
mice suggests that other factors such as IL-7 may play a minor role, or the 
persistence of residual IL-15 signalling.  
The polyfunctional TCM profile suggests that TCXCR4 possess superior tumour 
control abilities on a per-cell basis, as implied by data from the tumour model. 
We did not see evidence of the rare TSCM subset in our experimental model 
after antigen-exposure, highlighting experimental difficulties in isolating this 
subset without pharmacological manipulation. Although TCXCR4 were 
CD122high and BCL-2high, they were also uniformly CD44high and Sca-1 
expression levels were no greater than TControl. This finding may relate to the 
extensive antigen exposure in our OT-I model, TCR avidity or the degree of 
activation and exposure to IL-2 involved in the retroviral transduction protocol.   
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5 The effect of transient CXCR4 overexpression upon T 
cell phenotype and function 
 
5.1 Introduction 
 
I have shown that constitutive high level CXCR4 expression produces a 
pronounced TCM phenotype in vivo. Continuous expression may have 
undesirable effects such as excessive retention in particular niches and is less 
tractable to the demands of clinical translation and the requirements of 
different immunotherapeutic strategies. An approach employing transient 
overexpression might achieve similar phenotype imprinting without potential 
negative effects. This is based upon the concept that transient exposure to 
factors such as IL-15 responsible for the early memory phenotype would be 
sufficient to determine long-term cell fate and implies that long-term exposure 
is not required.  
This idea is in keeping with models suggesting that conditions during initial 
antigen priming and memory generation are more important in determining 
cell fate than the later stages of memory homeostasis (492). This may also be 
complementary with the concept that continuous intrinsic CXCL12 signalling is 
not required for the maintenance of this phenotype. This approach is 
potentially more easily employable as concerns over continuous CXCL12 
signalling in a long-lived stem-like cell might hinder clinical translation. In the 
next set of experiments, I therefore tested the hypothesis that transient 
overexpression of CXCR4 would be sufficient to convey an early memory 
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phenotype upon transduced T cells. I used a model where CXCR4 expression 
can be switched on and off through exposure to the commonly available 
antibiotic doxycycline. In the ‘Tet-ON’ retroviral system the gene of interest 
(CXCR4 marked with GFP or GFP alone for control cells) is under control of a 
Tet-Operon rendering the promoter transcriptionally inactive.  
The vector, which was created and validated by Dr Pedro Velica in our lab, 
also encodes the reverse-tetracycline-controlled transactivator (rtTA2-M2), 
marked by the Q8 surface tag (Figure 5-1A). In the absence of doxycycline, 
the promoter is inactive and the transduced cells express Q8 alone. In the 
presence of doxcycline, rtTA2-M2 binds to the Tet Operon and promotes 
CXCR4 and GFP transcription (493). Removal of doxycycline from the system 
reinstates repression, switching off CXCR4 and GFP expression. The vector 
was validated in vitro. 24 hours post transduction, CD8+ T cells were divided 
into 2 flasks and doxycycline was added to 1 flask at 0.5 µg/ml. Cells were 
analysed 72 hours post transduction, and CXCR4 expression for iCXCR4 No 
Doxycycline and iCXCR4 Doxycycline were compared to mock transduced 
and constitutive CXCR4-transduced cells. As shown in Figure 5-1B below, 
iCXCR4 No Doxycyline express similar low levels of CXCR4 to mock 
transduced cells. Induced CXCR4 expression as measured by flow cytometry 
increased MFI level to approximately 40% of the constitutive vector.  
My hypothesis consisted of two parts. Firstly, transient CXCR4 expression in 
a polyclonal setting would recapitulate the constitutive polyclonal phenotype in 
the short term in the absence of antigen priming. Secondly, that this 
phenotypic advantage over iGFP could also be established and maintained in 
the primary-boost model after CXCR4 expression had been switched off. 
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Figure 5-1 iCXCR4 vector map and flow cytometry validation. 
(A) iGFP and iCXCR4 doxycycline-inducible vector maps: Long 
Terminal Repeat (LTR); Tetracycline operator (TetO7); Foot-and-mouth 
disease 2A sequence (FMD-2A); Human phosphoglycerate kinase 
(hPGK); optimized reverse tetracycline-controlled transactivator (rtTA2-
M2); Woodchuck hepatitis Post-transcriptional Regulatory Element (W-
PRE); Picornavirus 2A sequence (P2A). (B) At 24 hours post iCXCR4-
transduction CD8+ T cells were cultured in the absence (No DOX) or 
presence of doxycycline (DOX). Cells were analysed by flow cytometry 
48 hours later for expression of Q8 surface marker of transduction and 
GFP. (C) CXCR4 expression 72 hours post-transduction for 
constitutive CXCR4-transduced cells, Q8-positive doxycycline and no 
doxycycline iCXCR4 and mock-transduced cells. Figures indicate MFI.  
 
 
 
DOX 
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5.2 Testing the effect of transient CXCR4 over-expression upon 
memory generation in a polyclonal model 
 
In the first set of experiments I used a polyclonal model for comparison with 
the polyclonal constitutive CXCR4 phenotype, as this setting is more 
analogous to the clinical setting, and reflects the polyclonal repertoire of gene-
engineered cells used in most clinical trials. Bead-sorted activated polyclonal 
CD8+ T cells from B6 splenocytes were transduced with the inducible CXCR4 
construct (iCXCR4) or the inducible GFP construct (iGFP). iCXCR4 and iGFP 
cells were mixed in a 1:1 ratio of Q8-positive cells and injected into irradiated 
B6 recipients. Mice were divided into 3 groups; those exposed to doxycycline 
continuously for the length of the experiment (Continuous), those exposed 
transiently from Day -1 to Day 8 (Transient), and those never exposed (Non-
exposed) (Figure 5-2). I used a Continuous group to establish if the lower 
level of CXCR4 expression seen with the inducible vector resulted in 
differences in phenotype compared to the constitutive vector. As before I 
investigated accumulation and memory phenotypes in lymphoid organs. On 
the day of injection (day 0) iCXCR4 and iGFP were no different in terms of 
TCM frequency (median 75.9 vs 80.6%) or cytokine receptor expression. 
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Figure 5-2 Transient CXCR4 polyclonal model. 
Congenically distinct transduced iGFP and iCXCR4 polyclonal B6 
CD8+ T cells were mixed in a 1:1 ratio and transferred into irradiated 
recipients. Mice were exposed to doxycycline continuously, transiently 
or not at all and organs were harvested for assessment at days 8 and 
22 post injection. Data representative of 2 independent experiments, 
n=10. 
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Number and ratio 
On day 8 post injection, in the Continuous group, there were increased 
numbers of iCXCR4 compared to iGFP in the bone marrow (median ratio 
2.4:1 and reduced levels in spleen and LN (median ratios 0.8:1 and 0.3:1 
respectively). On day 22 post injection in the Continuous group, there was 
again slightly increased BM accumulation for iCXCR4: iGFP (median ratio 
1.4:1) and reduced accumulation in spleen and LN (ratio 0.65:1 for both). A 
similar pattern was seen in the Transient group, with a tendency to increased 
BM accumulation (median ratio 3.4:1) and reduced ratios in the spleen and 
LN (0.3:1 and 0.4:1 respectively). 
 
Memory and survival phenotype 
On day 8, there were no consistent differences in central memory phenotype 
between iCXCR4 and iGFP (median TCM% 44.0 vs 45.1, 41.4 vs 33.9 and 
42.3 vs 37.9 in BM, spleen and LN respectively).  
However, by day 22, iCXCR4 in the Continuous group showed a similar 
central memory skewing to the constitutive vector phenotype in all organs (BM 
iCXCR4 vs iGFP TCM 66.4% vs 19.0%, spleen 74.8% vs 29.3%, LN 78.5% vs 
68.0%). In contrast, iCXCR4 in the Transient group showed no differences 
from iGFP controls (BM TCM 9.3% vs 7.3%, spleen 36.0% vs 26.0%, LN 
54.9% vs 57.2%).  
IL-15Rβ expression remained similar at day 8 and 22 in all groups (day 8 BM 
MFI 395 vs 379, day 22 Continuous BM 421 vs 295, day 22 Transient BM 356 
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vs 354). Finally, there was a tendency towards enhanced expression of BCL2 
for iCXCR4 vs iGFP in the Continuous group at day 22 only (BM MFI 380 vs 
340, spleen 801 vs 571).  
 
Summary 
Continuous CXCR4 expression using the inducible vector did not initially 
enable a memory phenotypic advantage in iCXCR4 compared to iGFP, but 
did enable a later advantage at day 22, and as expected showed a BM 
accumulation advantage at both time points.  All the features of the 
constitutive phenotype were not recapitulated in terms of IL-15Rβ expression 
and BCL2 expression however the limited number of replicates did not allow 
for statistical comparison. Similarly, although there was enhanced BM 
accumulation for the Transient group, this did not confer any enhancement of 
memory phenotype. In response to the first part of my hypothesis, transient 
CXCR4 expression in a polyclonal setting did not recapitulate in full the 
constitutive polyclonal phenotype in the short term in the absence of antigen 
priming. I therefore sought to shed light upon these inconclusive preliminary 
findings by evaluating the inducible vector further in the vaccination setting. 
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5.3 Testing the effect of transient CXCR4 over-expression upon 
memory generation in the vaccination model 
 
Having established some similarities between the phenotype of polyclonal T 
cells transduced with inducible and constitutive vectors, I then extended 
investigation of the inducible phenotype into the primary-boost vaccination 
model. For comparison purposes with the constitutive vaccination 
experiments I used Rag1ko mice. Owing to difficulty identifying the Q8 surface 
tag by flow cytometry in some organs, I labeled and flow-sorted Q8 positive-
transduced OT-I CD8+ T cells on the day of injection to aid identification of 
iCXCR4 and iGFP. iCXCR4 and iGFP Q8-positive cells were mixed in a 1:1 
ratio before injection (see Figure 5-3). TCM frequency of sorted iCXCR4 and 
iGFP cells were similar on day 0 (median 53.1% vs 58.3% respectively). 
Mice were vaccinated with SIINFEKL-IFA on days 1 and 29 and divided into 
three groups (Continuous, Transient and Non-exposed). As before, CXCR4 
and GFP expression were induced in vivo by oral administration of 
doxycycline to mice for day -1 to day 8 (Transient) or day -1 to day 36 
(Continuous).  
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Figure 5-3 Q8 Sort strategy. 
iGFP (cyan) and iCXCR4 (red)-transduced CD8+ T cells were stained 
and flow-sorted for Q8 positivity at 72 hours post-transduction, mixed in 
1:1 ratio and injected into recipients. Flow plots gated on live CD8+ T 
cells show pre and post-sort Q8-GFP plots, central memory 
frequencies for iCXCR4 and iGFP, 1:1 mix by congenic marker and 
mock-transduced cells. 
 
Number and ratio 
 At day 8, the median ratio of Q8+GFP+ iCXCR4: iGFP was increased in BM 
at 2.1:1 and reduced in spleen and LN (ratios 0.6:1 and 0.4:1, p=0.074, 0.002 
and 0.049 respectively). Median numbers were 6027:2752 in BM, 6810:12678 
in spleen and 1066 vs 2581 in LN, p=ns for all (Figure 5-4A). At day 29, 
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Q8 
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absolute numbers were markedly increased in BM in the Continuous group 
(286,356: 2464, ratio 116:1), and also in spleen (170556:11051, ratio 15.4:1) 
 
Figure 5-4 iCXCR4 kinetics and phenotype post vaccination. 
Summary data for iCXCR4: iGFP ratio in (A) the continuous 
doxycycline group, (B) the transient and (C) non-exposed doxycycline 
groups. Data representative of one experiment, n=14. (D) Day 8 central 
memory frequency, CD122 and BCL2 MFI for iCXCR4 and iGFP 
exposed or not to continuous doxycycline. Data representative of two 
independent experiments, n=11, statistical significance tested using the 
2-tailed paired t-test. (E) Day 36 central memory frequency, CD122 
and BCL2 MFI for iCXCR4 and iGFP exposed to continuous or 
transient doxycycline. Data representative of two independent 
experiments, n=14, statistical significance tested using the Wilcoxon 
ranked sum test, *P<0.05. 
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and LN (6460:2213, ratio 2.9:1). In contrast numbers were similar in the 
Transient group at day 29 in BM (8323:6958, ratio 1.2:1) and LN (2528:1771, 
ratio 1.4:1), and reduced in the spleen (28087:51242, ratio 0.5:1) (Figure 5-4A 
& B). 
At day 36, following boost vaccination in the Continuous group, absolute 
numbers were increased in BM (7845:2613, ratio 4.2:1), similar in spleen 
(45785:46327, ratio 1.0:1.0) and reduced in LN (1344:2650, ratio 0.5:1) 
(Figure 5-4A). In the Transient group, numbers were slightly enhanced in BM 
(20757:6786, ratio 2.3:1) and similar in spleen and LN (108742:63414 and 
14239:6925, ratios 0.8:1 and 1.6:1 respectively) (Figure 5-4B). Ratios in the 
Non-exposed group were similar to the Transient group at 2.6, 1.0 and 1.2 in 
BM, spleen and LN respectively, n=1 (Figure 5-4C). 
 
Memory phenotype 
At day 8, there were small increases in TCM frequency for iCXCR4 over iGFP 
in all organs (BM median 36.5% vs 28.6%, spleen 37.8% vs 24.9%, LN 62.2% 
vs 51.2%; p=0.036, 0.006 and 0.016 respectively). TCM frequencies in the 
Non-exposed group at day 8 were 18.5 vs 14.5, 16.6 vs 14.8 and 36.1 vs 36.7 
for BM, spleen and LN respectively, n=2 (Figure 5-4D). 
 At day 36 in the Continuous group however, there were no significant 
differences in the frequencies of TCM for iCXCR4 vs iGFP in any organs (BM 
median 31.1 vs 20.8, spleen 14.0 vs 10.1, LN 43.9 vs 36.5; p=ns for all). In 
contrast, there was a modest increase in the Transient group iCXCR4 TCM 
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frequency over iGFP for all organs (BM% 29.1 vs 16.8, spleen 19.7 vs 11.3 
and 44.5 vs 29.0; p=0.016, 0.031 and 0.016 respectively) (Figure 5-4E). In the 
same pattern as for cell number however, iCXCR4 TCM frequencies were 
similarly increased in the Non-exposed group at 36.2 vs 22.1, 27.6 vs 11.6 
and 33.0 vs 18.4 for BM, spleen and LN respectively. 
 
Cytokine receptors 
At day 8 there were no significant differences between IL-15Rβ expression for 
iCXCR4 vs iGFP in any organs (BM MFI 1888 vs 1725, spleen 1548 vs 1431, 
LN 1546 vs 1439) (Figure 5-4D). The same was true of CD127/132/25.  
At day 36, IL-15Rβ expression was again similar in the Continuous group for 
iCXCR4 vs iGFP (BM MFI 1487 vs 1642, spleen 1190 vs 1332, p=ns for all) 
(Figure 5-4E). Transient group iCXCR4 IL-15Rβ expression was slightly 
higher in both BM and spleen (BM MFI 1567 vs 1322, spleen 1154 vs 1078, 
p=0.031 for both, insufficient cells for LN analysis) (Figure 5-4E). Expression 
in the Non-exposed group was 1503 vs 1271 for BM and 715 vs 982 for 
spleen. 
 
 
Survival and proliferation 
At day 8, there was a small increase in BCL2 expression for iCXCR4 over 
iGFP (BM, spleen and LN median BCL2 MFI 655 vs 518, 779 vs 550 and 768 
vs 668; p=0.020, 0.009 and 0.028) (Figure 5-4D). Caspase 3 expression was 
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not different in any organ. A similar pattern was also noted in the Non-
exposed group: BM BCL2 MFI was 936 vs 377, spleen 2422 vs 2040, LN 
1053 vs 637 in LN.  
At day 36 in the Continuous group, iCXCR4 expressed slightly increased 
BCL2 levels in BM and spleen (BM MFI 1379 vs 1265 and spleen 769 vs 603, 
p=0.031 for both) and similar in LN (MFI 1517 vs 1153, p=ns). In the Transient 
group, BCL2 expression was higher for iCXCR4 vs iGFP in all organs (BM 
MFI 1065 vs 518, spleen 1173 vs 1001, LN 1548 vs 990, p=0.031 for all) 
(Figure 5-4E). In the Non-exposed group, BCL2 MFI was 8936 vs 8512 in BM, 
2789 vs 2875 in spleen and 7668 vs 7557 in LN. 
Caspase 3 expression was similar between groups in all organs at day 36, 
other than a slight increase in spleen in the Transient group ((MFI 454 vs 260, 
p=0.031). Proliferation was similar for iCXCR4 vs iGFP in BM and spleen post 
primary and boost vaccinations (day 8 EdU MFI in BM 6933 vs 7215, spleen 
5889 vs 6315, p=ns for both). 
 
Function 
At day 8, IFN-γ release from stimulated splenocytes was significantly lower in 
iCXCR4 vs iGFP (IFN-γ MFI 1674 vs 3369; p=0.008) and TNF-α release was 
equivalent (TNF-α MFI 613 vs 454, p=ns). At day 36, IFN-γ MFI again trended 
lower for iCXCR4 vs iGFP in the Continuous group and was equivalent for the 
Transient group (MFI 0 vs 40.4 and 0 vs 10, p=0.063 and ns respectively). No 
differences were seen for TNF-α production. 
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5.4 Discussion 
 
In answer to the second part of my hypothesis, a relevant memory phenotypic 
advantage for iCXCR4 over iGFP was not seen in the primary-boost 
vaccination model after CXCR4 expression was switched off. Firstly, although 
small differences were seen in TCM accumulation, CD122 and BCL2 
expression at day 8 and day 36 in the Transient group, these differences were 
not of the same magnitude as seen in the constitutive vaccination setting. 
Indeed, the degree of TCM frequency and increased BM accumulation was 
similar to that seen in the Non-exposed group. This suggests that the negative 
control in this experiment (the Non-exposed group) did not function as 
required and that absence of doxycycline incompletely repressed CXCR4 
expression. The reverse tetracycline transactivator system (rtTA) is known to 
display problems with ‘leaky’ target gene transcription and expression in the 
absence of tetracycline, despite use of a vector designed to reduce this issue 
(494). The rtTA system undergoes a conformational change in the presence 
of tetracycline, increasing affinity of the activation domain for a DNA binding 
site and enabling dramatic enhancement of transcription. Leakiness is 
dictated by basal affinity retained by the rtTA for the DNA binding site even in 
the absence of doxycycline. It may have been that a small increase in the 
number of CXCR4 molecules expressed on the T cell surface was enough to 
offer a competitive BM accumulation advantage over iGFP cells. Recent 
studies have suggested techniques for mitigating against this unwanted 
transcription by use of single amino acid substitutions and sensitivity-
enhancing mutations, reducing leakiness to undetectable levels (494). 
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Continuous CXCR4 expression induced by doxycycline was able to enhance 
BM accumulation of iCXCR4 over iGFP in competition assays using both 
polyclonal and antigen-specific T cells in a vaccination model. However 
iCXCR4 did not show the preferential splenic accumulation seen with the 
constitutive vector. Importantly, continuously induced CXCR4 expression over 
the duration of the experiment failed to recapitulate the constitutive vector 
early memory phenotype in terms of markedly increased TCM frequency, IL-15 
receptor and BCL2 expression or cytokine production. As shown in Section 
4.4 and Figure 4-10, level of CXCR4 expression correlates with memory 
phenotype, hence these findings probably relate to the lower level of CXCR4 
expression of CXCR4 produced by the inducible vector. 
The Continuous group is the positive control in the experiment, but this finding 
renders interpretation difficult. The fact that enhanced BM accumulation is 
maintained suggests that sufficient CXCR4 is expressed to enhance homing 
in a similar way to the constitutive vector, but that lower level expression 
relative to the constitutive vector may prevent formation of advantageous 
memory features. The concept of this ‘threshold’ effect is supported by the 
findings of reduced BCL2 expression in TCXCR4 expressing lower levels of 
CXCR4 in the constitutive primary-boost model, and indirectly by imaging 
findings showing that higher CXCR4 expression alters dynamic T cell 
behaviour by reducing track straightness (Section 3.2). 
To summarise, in their current state these retroviral tools do not allow us to 
answer the question of whether transient CXCR4 expression is sufficient to 
recapitulate the CXCR4 memory phenotype seen with the constitutive vector. 
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They also reiterate the requirement for high-level CXCR4 expression to 
produce marked changes in T cell memory phenotype.  
Further experiments are required to answer the hypotheses using vectors that 
inducibly enable higher levels of CXCR4 expression, and it would be 
interesting to assess if we could ‘tune’ expression level to achieve the desired 
phenotype. We used a transient expression period of 8 days in these 
experiments, to assess whether expression at the time of priming could 
enhance memory formation. The second question therefore is whether this 
expression period is too short, and a period of 4-5 weeks is required, as seen 
in the constitutive primary-boost model. Continuous expression using the 
inducible vector for 5 weeks was able to enhance BM accumulation 
progressively over time in the vaccination setting, in a very similar pattern to 
the constitutive model, so further experiments could be employed to vary the 
period of transient expression. It is particularly important to examine if re-
expression at time of boost vaccination is important.  This question feeds into 
the issue of how much exposure to putative niche-mediated factors such as 
IL-15 is required to mediate memory phenotype. Continuous or repeated 
exposure may hinder the translational applicability of the CXCR4 concept.  
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6 Pharmacological blockade and induction of bone 
marrow homing 
6.1 Introduction 
 
Thus far, I have demonstrated that constitutive over-expression of CXCR4 in 
CD8+ T cells enhances accumulation in the bone marrow and functional 
memory characteristics. In order to examine if this memory phenotype was 
purely dependent upon BM homing per se, I hypothesised that alternative 
methods of BM homing, namely (a) physical emplacement of T cells within the 
BM and (b) pharmacological enhancement, would replicate this phenotype.  
If these hypotheses were proven correct, this would potentially offer a more 
straightforward and cost-effective means of producing a similar phenotype for 
quicker clinical translation, without the regulatory hurdles of genetically 
modified immune cells. If not, this would suggest that the requirement for 
high-level CXCR4 expression might enable preferential homing to a particular 
niche, which is not replicated by alternative methods. This finding would be 
potentially important for future exploration of the underlying mechanism and 
clinical development of this approach. I firstly investigated if the effect of 
CXCR4-mediated bone marrow homing could be replicated by physically 
injecting CD8+ T cells into the bone marrow cavity. 
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6.2  Testing the effects of physical CD8+ T cell emplacement 
within the BM upon accumulation and memory phenotype 
 
Experiments with haematopoietic stem cells have demonstrated the utility of 
intra-bone marrow injection (IB) in enhancing levels of engraftment in non-
obese diabetic/ severe combined immunodeficient (NOD/ SCID) mice 
compared with iv injection (495). This is a straightforward technique with 
considerable advantages for development. However, as we have seen in the 
previous chapter, transient enhancement of BM homing does not substantially 
alter memory phenotype. As we directly observed, dynamic T cell motion is 
involves rapid movement to and from the BM, so initial physical emplacement 
may not replicate longer-term interactions with cellular and soluble niche-
related factors. 
I attempted to replicate the effect of enhanced bone marrow homing by 
injecting CD8+ T cells into the murine tibial cavity in a competition assay. 5 x 
106 MACS-sorted CD8+ T cells from B6 splenocytes were injected 
intravenously (IV) and IB into anaesthetised B6 mice. Numerical and 
phenotypic outputs were analysed 1 and 2 weeks post injection. Congenic 
markers were used to distinguish IV and IB cells. 
Numerical accumulation 
At day 7, the median ratio of IV:IB cells was 3.5:1 in BM, 4.7:1 in spleen and 
4.1:1 in LN. At day 14 this pattern was unchanged, such that median BM ratio 
was 6.2:1, spleen 7.5:1, LN 5.5:1, n=4, data from 2 independent experiments. 
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Memory phenotype and proliferation 
The proportion of TCM phenotype cells was similar for both groups in all 
organs at both time points (day 7 BM median IB vs IV TCM frequency was 
33.0% vs 34.0%, spleen 54.3% vs 55.1%, LN 52.3% vs 55.4%). At day 14, 
BM TCM frequency was 50.0 vs 30.3, spleen 36.9% vs 44.5%, LN 43.5% vs 
52.3%. 
Similarly, there was no evidence of changes in cytokine receptor expression 
for IB vs IV at either time point (day 14 BM CD122 MFI 0 vs 130, spleen 0 vs 
76, LN 0 vs 29, day 14 BM CD127 MFI 1585 vs 4633, spleen 1001 vs 1256, 
LN  1022 vs 1037), day 14 BM CD25 MFI 249 vs 102, spleen 0 vs 194, LN 0 
vs 115). Finally, proliferation was similar for IB vs IV (day 14 BM EdU MFI 
2909 vs 3172, spleen 2508 vs 2710, LN 2408 vs 2765). 
 
Summary 
These findings suggest that physical placement of un-manipulated CD8+ T 
cells within normal bone marrow does not replicate the TCXCR4 phenotype or 
numerical BM advantage.  
The numerical advantage seen for IV cells suggests that the physical 
constraints of the tibia meant a lower number of cells were successfully 
injected into the bone marrow cavity rather than surrounding tissue, resulting 
in excessive loss of the IB cells before they could gain access to survival 
factors. Given the lack of any advantage seen and technical difficulties with 
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successful injection into the cavity I then pursued a different approach to 
enhance BM homing. 
 
6.3 Testing the effects of pharmacological modification of DPPIV 
expression on BM homing of CD8+ T cells 
 
A number of groups have investigated regulation of haematopoietic stem cell 
trafficking to the bone marrow niche. One suggested approach to enhance 
cord blood CD34+ migration in response to CXCL12 is to inhibit 
CD26/dipeptidylpeptidase IV (DPPIV) (91). CD26 is a membrane-bound 
extracellular peptidase expressed on the surface of CD34+ haematopoietic 
cells and activated T lymphocytes. CD26 has been shown to cleave the first 
two amino acids from certain chemokines, in particular CXCL12, owing to its 
N-terminal structure (496). Truncated CXCL12, known as CXCL12 (3-68), is 
unable to induce chemotaxis of haematopoietic stem cells but retains the 
ability to bind the CXCR4 receptor, acting as an antagonist to normal CXCL12 
(91). Treatment of haematopoietic stem cells with DPPIV inhibitors such as 
Diprotin A (DipA) enhances migration in response to CXCL12.  
 
DPPIV inhibitors have been extensively studied in large clinical trials without 
safety concerns and are approved for type II diabetes treatment. DPPIV 
inhibition is an attractive pharmacological option to preserve CXCL12 in its 
active form and potentially enhance lymphocyte homing to the CXCL12 bone 
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marrow niche. CD26 peptidase activity is depleted within 15 minutes of DipA 
treatment and although recovery begins by 4 hours, we postulated that initial 
preferential access to the BM niche might enhance accumulation and memory 
formation (92).  
In addition to avoiding regulatory issues involved in genetic modification of 
therapeutic T cells, we could potentially avoid the activation steps required in 
current retroviral transduction protocols. Transduction unavoidably prolongs 
time spent in culture, involves use of expensive reagents (to good 
manufacturing practice (GMP)- grade standards in the clinical setting), and 
cause some cell loss, differentiation and phenotypic change such as reduction 
in CD27 expression (497). In a setting where the aim is to preserve a less 
differentiated subset, this may be deleterious to long-term persistence and 
stem-like qualities (6, 498). Although many safety issues have been 
addressed and mature T cells appear to be resistant to tumourigenicity, given 
the early issues with gene therapy trials, there are still safety concerns 
surrounding preferential insertion of retroviral sequences into tumour-
promoting regions of the genome and a limited truly long-term experience with 
engineered T cells undergoing extensive clonal proliferation (499, 500).  
I therefore hypothesised that exposure of non-activated T cells to DPPIV 
inhibitors would preserve higher proportions of less differentiated/stem-like T 
cell memory phenotypes. In addition, the somewhat rudimentary approach of 
intrabone injection detailed above only deposits T cells within the BM cavity 
and not a specialized niche, without altering trafficking behaviour. DPPIV 
inhibition aims to enhance homing specifically to a CXCL12+ niche, and is 
hence more likely to replicate the TCXCR4 memory phenotype. 
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 I examined the potential of this approach utilizing polyclonal CD8+ T cells, 
MACS-sorted from B6 splenocytes and treated with 5 mM DipA for 15 minutes 
at 37 ºC as per published protocols. These cells were mixed in a 1:1 ratio with 
congenically distinct PBS-treated CD8+ T cells and injected intravenously into 
Rag1ko mice. The numerical accumulation and phenotype were assessed at 
days 1 and 7. At day 0, DipA and PBS-treated cells were similar in terms of TN 
proportions (79.0% vs 79.1%) and cytokine receptor expression (CD122 MFI 
348 vs 365, CD127 MFI 1442 vs 1384). 
 
Numerical accumulation 
At day 1, the median ratio of DipA: PBS-treated cells in BM, spleen and LN 
was 1.1:1, 1:1 and 1.1:1 respectively. Median absolute numbers of cells were 
2834 and 2538 in BM, 16,321 vs 14,663 in spleen and 1619 vs 1769 in LN. At 
day 7 median ratios were similar (BM and spleen 0.9:1, LN 1.2:1). Cell 
numbers remained similar at day 7 in all organs for DipA and PBS 
respectively (BM 1038 vs 1143, spleen 14,666 vs 13,153 and LN 10,660 vs 
11,202) (Figure 6-1A). Between days 1 and 7, the numbers of BM cells 
declined for both DipA and PBS (2834 to 1038 and 2538 to 1143, 2 tailed 
paired t-test, p=0.07 & 0.19), remained similar in the spleen (16,321 to 14,666 
and 14,663 to 13,153) and increased in LN (1619 to 10,660 and 1769 to 
11,202, 2 tailed paired t-test, p=0.07 & 0.09). 
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Figure 6-1 Diprotin A treatment does not alter T cell accumulation 
or memory phenotype. 
(A) Ratio of Diprotin A: PBS-treated CD8+ T cells in BM, spleen and LN 
over time post injection. (B) BM phenotype of Diprotin A-treated (red) 
and PBS-treated (blue) cells. Data derived from one experiment, n=5. 
 
Memory phenotype and cytokine receptor expression 
At day 1, the majority of cells expressed TN markers in all organs for DipA vs 
PBS-treated cells (BM %TCM 16.8% vs 12.4%, spleen 19.5% vs 14.4%, LN 
9.4% vs 8.1%). At day 7 both groups possessed a similar proportion of 
CD62L+CD44+ TCM-phenotype cells (BM 44.0% vs 45.7%, spleen 66.8% vs 
57.9%, LN 53.8% vs 48.1%), (Figure 6-1B).  
Receptors for cytokines IL-2, IL-7 and IL-15 were expressed to a similar level 
on DipA and PBS-treated cells at day 1 (day 1 median BM CD122 MFI 325 vs 
318, spleen 353 vs 212 and LN day 1 226 vs 109, median CD127 MFI BM 
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1304 vs 1177, spleen 923 vs 703, LN 740 vs 545, median CD25 MFI BM -166 
vs -129, spleen -121 vs -97, LN -224 vs -166). Median CD132 MFI BM 1366 
vs 1016, spleen 3308 vs 2749, LN 10724 vs 11186, 2 tailed paired t-test, 
p=0.01, 0.02 and ns respectively). 
At day 7 CD122 BM and spleen expression were similar (median BM MFI 
1225 vs 1154, spleen 743 vs 866) and slightly higher expression was seen in 
DipA cells for LN (755 vs 590, p=0.01). CD127 expression was also similar in 
BM and slightly increased in spleen and LN (median BM MFI 1738 vs 1535, 
spleen 1474 vs 1274, LN 1209 vs 992, p=ns, <0.01 and <0.01 respectively), 
(Figure 6-1B). 
Day 7 DipA CD132 expression was higher in all organs (BM 984 vs 534, 
spleen 1515 vs 1141, LN 2076 vs 1188, p=0.04, 0.04 and <0.01) and 
reciprocally CD25 expression was slightly lower for DipA cells at day 7 in 
spleen and LN (BM 67.9 vs 98.7, spleen 81.9 vs 116, LN 88.4 vs 145, p=ns, 
0.03 and 0.005 respectively).  
Survival and Proliferation  
At day 1 BCL2 %positivity was higher in DipA cells vs PBS (median BM 85.4 
vs 51.1, spleen 95.4 vs 75.0, LN 98.3 vs 70.2, p=0.05, 0.03 and 0.07), 
similarly for BCL2 MFI (median BM MFI DipA 2071 vs PBS 752, spleen 1883 
vs 1682, LN 3086 vs 1664, p=0.08, 0.04 and 0.03) however this advantage 
persisted only in LN at day 7 (BM %positive 27.4 vs 25.0, spleen 44.2 vs 56.4, 
LN 49.6 vs 23.2, p=ns, 0.02 and <0.01), (Figure 6-1B).  
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Proliferation as measured by Ki67 staining was higher in all organs for DipA at 
the early time point (median BM Ki67 MFI 334 vs -89, spleen 265 vs 33, LN 
536 vs 95, p<0.01, 0.02 and 0.02) however at day 7 the pattern had changed 
such that proliferation was higher for PBS-treated cells in spleen and 
equivalent in other organs (BM Ki67 MFI 234 vs 269, spleen 457 vs 945, LN 
1188 vs 1246, p=ns, 0.01 and ns). 
 
CXCR4 expression level 
CXCR4 expression was similar between DipA and PBS groups in all organs at 
all time points (median day 1 BM MFI 99 vs 64, spleen 97 vs -14, LN 82 vs 68 
and day 7 255 vs 209, 205 vs 267, 267 vs 207, p=ns for all). 
 
Summary 
DipA-treated cells showed no enhancement in homing towards the BM niche 
or differential tendency to form a central memory phenotype in comparison to 
PBS-treated cells. Small increases were seen in CD127 and CD132 at the 
later time point in spleen and LN, coupled with a reduction in CD25 
expression in DipA cells. BCL2 and Ki67 expression was higher for DipA-
exposed cells in all organs at the early time point but by day 7 the only 
advantage was for BCL2 in the LN.  
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6.4 Testing the effects of in vivo CXCR4 blockade on primary 
vaccination response 
 
Thus far physical or pharmaceutical methods have not enhanced either BM 
homing or memory T cell phenotype. I hypothesised that if CXCR4 over-
expression enabled preferential homing to a BM niche enabling memory 
precursor formation in the context of antigen, blockade of physiological 
CXCR4 expression on naïve CD8+ T cells during antigen priming would result 
in reduced BM homing and polarization towards a more differentiated effector 
phenotype. If this hypothesis was proven, this would suggest physiological 
levels of CXCR4 on naïve-phenotype T cells are important for BM homing and 
memory phenotype generation. This in turn would support further exploration 
of methods designed to improve homing to a CXCL12+ BM microenvironment.  
If no evidence could be found to support this hypothesis, this might suggest 
that physiological CXCR4 levels on naïve non-activated T cells are not 
sufficient to confer BM homing and are not relevant for memory precursor 
differentiation in an antigen-dependent setting. This in turn suggests that 
pharmacological approaches to leverage physiological T cell expression of 
CXCR4 by preserving intact CXCL12 are less likely to succeed given the 
likelihood of out-competition by other cells expressing higher levels of CXCR4, 
and that approaches aimed at increasing basal T cell CXCR4 expression are 
more likely to be successful. 
In the following experiments I used a similar vaccination model as described 
above to examine the effects of CXCR4 blockade upon memory phenotype 
and bone marrow accumulation, which differed only in that naïve OT-I CD8+ T 
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cells were injected into Rag1ko mice at day 0 without prior activation or 
transduction. Mice received either the CXCR4 antagonist Plerixafor or PBS 
daily from Day -1 to Day 8. The time period for blockade was chosen based 
upon the antigen-dependent nature of the TCXCR4 memory phenotype. I 
hypothesised that CXCR4 over-expression is particularly important at the time 
of initial antigen exposure, and hence that blockade during this period would 
be most relevant to alter phenotype. This supposition is based upon evidence 
that primary antigen exposure results in distinct T cell fates (189, 191). If we 
saw differences in effector phenotype polarization post initial vaccination that 
were then lost upon boost vaccination in the absence of any further CXCR4 
blockade, this would suggest the need for continued CXCR4 blockade to 
prevent BM homing, and therefore perhaps an ongoing influence of 
homeostatic cytokine exposure. 
In addition Plerixafor has low oral bioavailability (501) and daily injections for 
the duration of the experiment would require justification based upon initial 
results. Other approaches to inhibit G-protein mediated signalling, for example 
using Pertussis toxin, would have multiple off-target effects. All mice received 
primary and boost vaccinations with SIINFEKL peptide on days 1 and 29, and 
phenotype was assessed as before (Figure 6-2).  
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Figure 6-2 CXCR4 blockade vaccination model 
Naïve OT-I CD8+ T cells were injected into Rag1ko mice receiving daily 
ip PBS or Plerixafor injections from days -1 to day 8. Organ 
accumulation and memory response were assessed at days 8, 29 and 
36 post SIINFEKL-IFA vaccination on days 1 and 29. 
 
 
 
Numerical accumulation 
At day 8, 1 week post primary vaccination, the median absolute numbers of 
cells in Plerixafor-treated animals were numerically lower in BM and spleen 
compared to PBS-treated animals (BM 19,957 vs 40,817 and spleen 164,365 
vs 250,613, p=ns for both, Mann-Whitney test) and higher in LN (56,091 vs 
37,431), (Figure 6-3). The BM/LN ratio was similar between Plerixafor and 
PBS-treated animals (0.5 vs 0.4). 
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Figure 6-3 CXCR4 blockade organ accumulation data. 
(A-C) Absolute cell number kinetics for Plerixafor (red) and PBS-
treated mice (blue) over time in bone marrow, spleen and lymph node, 
n=24, data pooled from 3 independent experiments. Purple arrows 
indicate time of vaccination, error bars denote SD. 
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 Memory phenotype 
At day 0, a median of 86% OT-I CD8+ T cells were classed as Tnaive (CD44-
CD62L+). At day 8 in vaccinated BM, 23% of Plerixafor-treated and 27% of 
PBS-treated expressed TCM markers (Mann-Whitney test, p=ns). TCM 
proportion was similarly unchanged in spleen (28% vs 25%, p=ns) and LN 
(75% vs 73%, p=ns), (Figure 6-4).  
 
Cytokine receptors, survival and proliferation 
There were no significant differences in cytokine receptor expression between 
vaccinated Plerixafor and PBS-treated animals (BM CD122 MFI 1014 vs 1102, 
spleen 1085 vs 1076, LN 1223 vs 1294, CD127 MFI 581 vs 562, 585 vs 692, 
1271 vs 1220, CD25 MFI 138 vs 256, 163 vs 214, 103 vs 176, CD132 751 vs 
697, 945 vs 851, 1302 vs 1071, Mann-Whitney test p=ns for all), (Figure 6-4). 
Similarly, there were no differences in survival or proliferation between the 2 
groups (BM BCL2 MFI 409 vs 318, spleen 498 vs 454, LN 673 vs 727, BM 
EdU MFI 1191 vs 1377, spleen 1087 vs 1974, LN 810 vs 983, Mann-Whitney 
test p=ns for all), (Figure 6-4). 
 
 Function 
Finally, at the early time point Plerixafor did not alter cytokine secretion upon 
splenocyte restimulation (IFN-γ MFI Plerixafor 417 vs PBS 479%, TNF-α MFI 
410 vs 395 and IL-2 MFI 29.6 vs 17.4, p=ns for all), (Figure 6-4). 
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Figure 6-4 In vivo Plerixafor treatment does not alter CD8+ T cell 
memory phenotype post vaccination. 
(A) Summary T cell CD62Lhigh frequency over time in BM, spleen and 
LN for PBS (blue) and Plerixafor-treated (red) mice. Purple arrows 
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indicate time of vaccination. Error bars denote SD, n=24, data pooled 
from 3 independent experiments. (B) Summary data for BM CD62Lhigh 
frequency, CD122 MFI, % BCL2+, %EdU+, caspase 3 MFI, and 
cytokine release post splenocyte restimulation in PBS and Plerixafor-
treated mice post initial vaccination at day 8, n=12, data pooled from 3 
independent experiments. 
 
 
 
6.5 Testing the effects of boost vaccination following initial 
CXCR4 blockade 
 
Numerical accumulation 
At day 36, the median absolute numbers of cells in Plerixafor-treated animals 
were similar in all organs compared to PBS-treated animals (BM 20,402 vs 
21,288, spleen 146,268 vs 330,752, LN 19,044 vs 18488, p=ns for all, Mann-
Whitney test), (Figure 6-3). BM/LN ratio remained similar between Plerixafor 
and PBS-treated animals (1.3 vs 1.4).  
 
Memory phenotype 
At day 36 in the BM, 27% of Plerixafor-treated and 26% of PBS-treated 
expressed TCM markers (Mann-Whitney test, p=ns). TCM proportion was also 
similar in spleen (20% vs 20%, p=ns) and LN (55% vs 62%, p=ns). 
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Cytokine receptors, survival and proliferation 
There were no significant differences in cytokine receptor expression between 
Plerixafor and PBS-treated animals (BM CD122 MFI 1130 vs 969, spleen 620 
vs 615, LN 966 vs 1071, CD127 MFI 442 vs 525, 411 vs 325, 1077 vs 1393, 
CD25 MFI 175 vs 121, 130 vs 105, 195 vs 125, CD132 800 vs 809, 649 vs 
639, 1108 vs 1089, Mann-Whitney test p=ns for all). Similarly, survival and 
proliferation were similar in all organs (BM BCL2 MFI 3234 vs 3193, spleen 
1705 vs 2182, LN 4905 vs 4515, BM EdU MFI 2673 vs 2688, spleen 1989 vs 
1948, LN 1946 vs 1959, p=ns for all).  
 
Function 
Upon restimulation post boost vaccination, there were no functional 
differences apparent between Plerixafor and PBS-treated mice (IFN-γ MFI 
417 vs 479, TNF-α MFI 410 vs 395, IL-2 MFI 30 vs 17, p=ns for all).  
 
Summary 
Short term Plerixafor treatment did not induce any changes in numerical 
accumulation or memory CD8+ T cell phenotype, either during the initial 
period of CXCR4 blockade post primary antigen exposure or following boost 
vaccination. 
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6.6 Discussion 
 
Intra-bone injection & DPPIV inhibition 
Neither physical intrabone injection, ex vivo inhibition of DPPIV or in vivo 
CXCR4 antagonism were able to substantially alter T cell BM accumulation or 
modify memory phenotype. The lack of effect of direct BM emplacement of 
CD8+ T cells is perhaps unsurprising given that T cell migration into the BM is 
a complex multi-step process requiring sequential activation and interaction of 
a series of molecules including selectins and integrins. In the absence of 
directed migration, the speed of blood flow is likely to rapidly re-distribute 
injected T cells before substantial migration into the BM parenchyma occurs. 
Furthermore, judging from the rapid transient homeostatic behaviour of 
imaged T cells within the parenchyma, injected BM T cells are unlikely to be 
preferentially retained in the absence of altered signalling at a molecular level. 
In vivo data demonstrating that memory T cells only transiently retain some 
traits of previous stimulation following exit from the BM support this conclusion 
(502). 
The lack of effect of DPPIV inhibition on cell number or phenotype is 
unexpected. The impressive effects of CD26 inhibition seen in mouse and 
human haematopoietic stem cells in terms of BM engraftment were not seen 
in CD8+ T lymphocytes following ex vivo inhibition. This issue might stem from 
differential CD26 expression on T cells. I used bead-sorted non-activated 
naïve CD8+ T cells, which express lower levels of CD26 than activated and 
memory T cells and might therefore exhibit less pronounced responses (503). 
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It is also possible that the short exposure to Diprotin A was insufficient to 
inhibit CD26. One way to test for effective inhibition would be a DPPIV 
Protease Assay, combining a luminogenic DPPIV substrate (Gly-Pro-
aminoluciferin) and a luciferase enzyme. This generates a luminescent signal 
to quantitate remaining DPPIV activity present with greater sensitivity and 
accuracy than fluorescence-based assays (96). We could further test the 
effect on CXCL12-induced T cell migration in vitro using Transwell migration 
assays following Diprotin A exposure. 
The more likely explanation, given the successful use of this protocol to 
modulate stem cell homing, is that DPPIV was successfully inhibited by 
treatment but as CD26 recovery begins within 4 hours of treatment (92), this 
is insufficient time to allow the treated T cells to gain access to BM-based 
factors mediating the memory phenotype. BM homing may have been only 
transiently enhanced and migration patterns then return to normal. This would 
be in keeping with results from the intrabone injections, and the lack of effect 
of transient expression with the inducible vector.  
It may also be relevant that Diprotin A treatment only enhances CXCL12-
induced migration two-fold in ex vivo C57BL/6 Sca-1+ Lin- BM cells, and in 
vivo homing of HSCs on a short-term basis (92). Work demonstrating 
enhanced lymphocyte trafficking in mice and enhanced cord blood transplant 
engraftment in patients has employed the DPPIV inhibitor sitagliptin (Januvia), 
which has been approved by the European Medicines Agency (EMA) (94, 96).  
Other BM transplantation models failed to confirm enhancement of 
engraftment by Diprotin A or sitagliptin despite proven DPPIV inhibition (504). 
Our data from Chapter 4 suggest that high-level CXCR4 expression creates a 
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very distinctive phenotype that is not replicated by lower level expression. A 
longer duration of signalling and/or more potent effects may be required to 
mediate durable change in phenotype and fate. Further experiments should 
therefore examine the effects of longer term and more potent in vivo inhibition 
on BM homing, memory responses and tumour infiltration.  
 
In vivo CXCR4 antagonism 
The effect of once daily Plerixafor in animals receiving predominantly naïve-
phenotype CD8+ T cells is negligible. This effect is perhaps slightly surprising 
given the dramatic effects of CXCR4 over-expression, and the effects of 
Plerixafor in altering haematopoietic stem cell homing. Two possible reasons 
present themselves. Firstly, relatively low CXCR4 expression on 
unmanipulated CD8+ T cells suggests lower likelihood of success in accessing 
CXCL12-abundant reticular cell niches, particularly in the context of 
competition from CXCR4high haematopoietic stem cells. Naïve T cells home 
preferentially to lymphoid organs expressing selectin ligands such as lymph 
nodes and hence Plerixafor-treated mice may simply undergo antigen-
dependent priming in lymph nodes to form memory precursors. This 
phenomenon may be more pronounced in the context of abundant 
homeostatic cytokines in immunodeficient mice. Secondly, Plerixafor has a 
short half-life of 4-5 hours (505), meaning that the impact of once daily 
administration may be insufficient to ensure T cells do not interact with BM 
microenvironments mediating a memory phenotype. Once drug levels have 
diminished, cells may home to the BM niche and gain sufficient access to 
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cytokines and other mediators to prevent alterations in phenotype. Evidence 
that Cre-mediated deletion of CXCR4 in CD8+ T cells results in impaired BM 
homing of both TN and TCM with impacts upon the size of the TCM pool in 
secondary lymphoid organs suggests that basal CXCR4 signalling is 
important for homeostatic self-renewal, and therefore that the second 
explanation is more likely (305).  
 
Interestingly CXCR4-deficient T cells can undergo normal rechallenge self-
renewal in the presence of antigen, producing equivalent proportions and 
numbers of TCM phenotype cells to CXCR4-sufficient CD8+ T cells (305). This 
suggests that differing mechanisms for homeostatic and antigen-dependent 
self-renewal may also explain our experimental findings. In the context of lack 
of CXCR4-mediated BM homing, CXCR4-independent TCM formation and 
maintenance induced by antigen may occur predominantly in spleen and LNs, 
resulting in sufficient production of the full range of memory phenotypes. Thus, 
differences in memory phenotype would then not be apparent unless 
extended duration constant inhibition of CXCR4 reveals impaired homeostatic 
maintenance of memory precursors, and terminal differentiation in response 
to repetitive antigenic stimulation.  
It would be interesting to perform further experiments with twice daily 
Plerixafor in both the antigen-dependent and independent setting, to confirm 
effects upon BM homing. Further experiments using longer term CXCR4 
inhibition or stronger antagonists, and comprehensively profiling markers of 
senescence and differentiation such as T-bet, Eomes and PD-1 after multiple 
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antigenic exposures would be important to test the effects of basal CXCR4 
expression in T cells. This is potentially important if one wished to pursue a 
strategy of pharmacological enhancement of BM homing in CD8+ T cells. 
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7 Discussion 
 
7.1 Putative mechanisms underlying the early memory TCXCR4 
phenotype 
 
The experimental results obtained in Chapter 4 suggest that constitutive 
CXCR4 over-expression enhances BM accumulation and polarises CD8+ T 
cells to a BCL2High IL-15RβHigh polyfunctional central memory phenotype that 
is dependent upon IL-15Rα signalling. These data are consistent with 
transcriptional analyses confirming expression of a memory precursor-like 
signature (222, 506). This finding could be due to several possible 
mechanisms. 
Firstly, preferential localisation to a CXCL12-secreting IL-15Rα+ stromal niche 
(IL-15Rα+ niche mechanism) could enhance preferential retention and 
survival of a CD62L+CD122High memory phenotype. CD122 expression is 
required for responsiveness to trans-presented IL-15 through formation of the 
heterotrimeric receptor (507). We were not able to obtain direct imaging 
evidence for privileged interaction with this cellular niche, perhaps due to 
limitations of the antibodies available. The finding of IL-15 dependence for the 
phenotype could be interpreted as further evidence in support of this 
hypothesis.  
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Secondly, central memory polarization could relate to alterations in the nature 
of T cell-APC interactions, mediated by enhanced CXCR4 expression 
(altered priming mechanism). CXCR4 is known to be recruited into the 
immunological synapse, hence altered signalling as well as migration patterns 
will influence the quality and duration of synapse formation. Strength of signal 
and competition for antigen are known to influence asymmetric T cell division 
and unequal partitioning of cell molecular regulators, and hence the extent of 
differentiation and memory fate (190, 191, 484). Recent findings have 
suggested that curtailing T cell activation can generate T stem memory cells 
with low effector-associated genes and considerable self-renewal potential in 
response to IL-15 (508). Once formed, central memory T cells also 
preferentially rely upon IL-15 for upregulation of BCL2 and TCM survival is 
markedly impaired in IL-15Rako mice. The few remaining TCXCR4 cells in our 
IL-15Rako experiments predominantly express an effector memory/effector 
phenotype. In the absence of IL-15 signalling, it is likely that rely upon the 
same survival pathways as TControl cells, predominantly IL-7. This would 
explain the TCXCR4 requirement for IL-15 signalling. Although the complexities 
of dynamic long-term interactions with multiple cellular components with a 
three-dimensional niche cannot be recapitulated in a short-term tissue culture 
environment, in vitro antigen activation demonstrated no differences between 
TCXCR4 and TControl, excluding a direct costimulatory effect of CXCR4 upon 
TCXCR4 phenotype.  
We saw distinct differences in movement when imaging steady state TCXCR4 
and TControl that offer clues as to how phenotype may be shaped. TCXCR4 could 
be divided into two distinct populations: arrested cells moved very slowly, if at 
 207 
all, whilst migratory cells displayed significantly greater speeds. No such 
distinction could be made between TControl cells. In addition, TCXCR4 tracks 
were significantly less straight, suggesting diversion in response to chemokine 
cues. One might hypothesize that TCXCR4 interactions with APCs in an 
inflammatory setting would also be more disrupted by chemokine cues than 
TCXCR4, supporting the altered priming mechanism. However, despite profound 
differences in memory phenotype between TCXCR4 HIGH and TCXCR4 LOW, we did 
not observe differences in speed or arrest coefficient. This suggests that 
dynamic behaviour does not reflect phenotype, but requires further study.  
A third possible mechanism is that the enhanced memory phenotype could 
relate to preferential access to IL-15 throughout the BM parenchyma, not just 
a specific microenvironment or niche.  Enhanced numbers of TCXCR4 in the BM 
might lead to more numerous stochastic interactions with either stromal or 
haematopoietic sources of IL-15. It is also possible that soluble IL-15/IL-15Rα 
complexes (sIL-15 complexes), as opposed to trans-presented IL-15, 
contribute towards enhanced T cell responses, as no models yet exist to 
distinguish these effects (509). This mechanism is less likely because TCXCR4 
demonstrate a preferential TCM phenotype in comparison to TControl within the 
BM itself. 
A final possibility is that TCXCR4 undergo lower levels of antigen exposure due 
to a quantitative lack of DC-mediated antigen presentation in the BM as 
opposed to the LN where TControl might undergo activation. This is also less 
likely because of the preferential TCXCR4 TCM phenotype in comparison to 
TControl within the BM itself. Indeed, our method has been used to visualise 
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dendritic cells triggering recall responses through interactions with central 
memory T cells within the BM itself (510).  
Prolonged duration imaging experiments in the context of antigen-exposure 
will be important to investigate changes in TCXCR4 cell behaviour in 
inflammatory and tumour-specific models, and the importance of antigen-
presenting cell interactions. Using homeostatic cytokine (311) and stromal 
reporter mice (281, 282) would enable precise identification of the mechanism 
underlying the TCXCR4 phenotype, and potentially provide important and 
generalizable new insights into enhancing formation of more potent memory T 
cell phenotypes.  
Both the IL-15Rα+ niche and the altered priming mechanisms are consistent 
with enhanced bone marrow persistence and absolute numbers of TCXCR4. 
The superior persistence in secondary lymphoid organs shown in both 
homeostatic and inflammatory settings can be explained by increased 
numbers of T cells homing to the bone marrow. This could lead to more 
numerous stochastic interactions with either stromal or haematopoietic 
sources of IL-15, mediating enhanced survival and greater cell number, 
consistent with the superior expansion potential of central memory T cells. A 
proportion of BM-derived T cells then recirculate to other organs, enhancing 
persistence in all organs sampled. Direct observation of close clustering 
between bone marrow TCXCR4, in contrast to isolated TControl, further suggests 
that these cells might provide survival factors for each other, for example by 
paracrine IL-2 secretion in an inflammatory situation, as seen in our ex vivo 
antigen restimulation data.  
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A second question following on from this raised by our observations is the 
specific cellular source of IL-15, which may be important for generation of the 
distinctive phenotype. Dendritic cell-derived IL-15Rα has been suggested to 
preferentially support central memory CD8+ T cells while macrophage-derived 
IL-15Rα supports both TCM and TEM. Although the mechanism remains 
unclear, it may relate to the strength of TCR and cytokine signalling (484, 511, 
512). This is relevant because of the potential for combination immunotherapy. 
Administration of an agonist anti-CD40 antibody increases expression of 
IL15Ra on CD11+ DCs and prolongs survival in tumour-bearing models in 
combination with IL-15 in additive benefit to either agent alone (513). If TCXCR4 
are accessing a dendritic cell-IL-15Rα niche this opens up the possibilities of 
engineering tumour-specific responses based upon tunable cytokine and 
small molecule delivery (514). IL-15 functions as a tissue distress signal and 
reduces the TCR activation threshold, hence intensification of IL-15 
generation and costimulatory signalling during trans-presentation might 
provide an amplification loop to mediate tissue and tumour destruction, 
particularly in situations of high IL-15 bioavailability, such as BM-derived 
malignancies (515). 
Transcriptional profiling of TCXCR4 has shown upregulation of several IL-15-
associated genes including Cpt1a (506). IL-15 promotes mitochondrial 
biogenesis and spare respiratory capacity in memory T cells by enhanced 
expression of carnitine palmitoyl transferase, the product of Cpt1a, required to 
initiate fatty acid oxidation in the mitochondria (516). Furthermore, gene set 
enrichment analysis (GSEA) of TCXCR4 confirms enrichment for a memory 
stem cell-like signature that is also induced in human T cells modified to 
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undergo constitutive IL-15-IL-15Ra signalling (506, 517). The suggestion that 
TCXCR4 display a different metabolic profile, preferentially employing oxidative 
phosphorylation over glycolysis, would also be consistent with a stem cell-like 
T memory profile, and open the door to combinatorial enhancement of T cell 
potency, perhaps by pharmaceutical modification of T cell metabolism (518). 
Studies investigating memory T cell generation have highlighted the 
importance of an appropriate balance between effector and memory cells for 
anti-tumour potency, and further data is needed on whether combinatorial 
strategies aimed at modifying phenotype are synergistic or counter-productive 
(491). Despite central memory polarization, both CD62LHigh and CD62LLow 
TCXCR4 accumulate to a greater extent than TControl in secondary lymphoid 
organs in our anti-tumour models, highlighting dual benefits of this strategy.  
Our data suggest increased accumulation of TCXCR4 relates primarily to 
enhanced cellular survival, as we saw no evidence of enhanced proliferation. 
Some data suggest that, unlike the situation in the spleen, BM memory T cells 
are less susceptible to chemotherapy agents such as cyclophosphamide as 
they do not rely upon proliferation to enhance cell numbers (519). The 
concept that at least two memory T cells niches exist within the BM has been 
proposed as a division of labour to explain seemingly contradictory findings of 
different groups suggesting both cell cycling and quiescence to be prominent 
features (262).  
Our data could be interpreted as supporting the latter concept although given 
the heterogeneity of the BM stroma these features may be dictated by specific 
localisation to certain factors, such as IL-15 in the case of TCXCR4. It may be 
that TCXCR4 are more appropriately described as accessing a cell-survival 
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niche, as proliferation in either the antigen-independent or dependent setting 
is generally similar to TControl whilst anti-apoptotic molecule expression and 
accumulation are enhanced. In addition, our imaging data highlight key 
differences in T cell behaviour, suggesting division into at least two subsets 
on the basis of dynamic motion.  
Imaging single cell interactions with IL-15Rα+ cells may shed light on the 
complex picture of T cell fate and offers the prospect of finally resolving this 
issue. It will be interesting to see if the anatomical localisation of survival and 
proliferative T cell niches parallels the association of HSCs with LepR+ 
CXCL12High perisinusoidal niches, or if function and form vary flexibly and are 
more appropriately defined by molecular signalling (520-522). In our model we 
did not observe the CD44low phenotype of putative TSCM but given that 
quiescent memory T cells can be mobilised from the BM by Plerixafor (264), 
the development of more potent CXCR4 inhibitors may also offer the 
opportunity to investigate the physiological presence and anatomical 
localisation of quiescent memory stem or resident memory T cells (523, 524).  
In terms of further exploration of this therapeutic strategy, it would be 
interesting to study the effect of CXCR4 over-expression on therapeutic CD4+ 
T cells. Niche-specific homing of CCR9+ CXCR3+ CD4+ T cells has been 
shown to be crucial for the success of PD-1 blockade in epithelial cancers 
(367), and the preferential in vivo expansion of important CD4+ subsets such 
as Treg cells is of enormous potential value in treatment of auto-immunity and 
transplantation-related toxicity. Cytokine-based therapies to expand pre-
existing in vivo populations have not yielded dramatic benefits (525, 526). 
Given that CD4+ T cells may inhabit slightly different BM niches owing to 
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differential homeostatic cytokine usage, the CD4+ TCXCR4 phenotype may be 
subtly different from their CD8+ counterparts. Memory CD4+ T cells are known 
to undergo enhanced proliferation in response to IL-15 (527) and imaging 
data from reporter mice shows considerable overlap between IL-15 and IL-7 
expressing PDGFRα+ BM stromal cells likely to represent CXCL12-abundant 
reticular cells (311, 528), suggesting that detailed analysis of CD4+ TCXCR4 
would be interesting to support translational work. 
 
Tumour-specific discussion 
I would like to conduct further experiments to test the ability of TCXCR4 to 
mediate polyfunctional responses to tumour antigen following repetitive 
exposure, to assess a full checkpoint profile for evidence of tumour-related 
exhaustion, and to examine the effects of TCXCR4 in known immune evasive 
settings. The A20 tumour stroma expresses CXCL12, and although TCXCR4 
homing to the tumour site was not enhanced, heightened CXCR4 expression 
might enhance the costimulatory effects of CXCL12 upon the TCR, for 
example upon cytokine secretion. It is therefore important to test these 
constructs in alternative tumour models, preferably patient-derived xenografts. 
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7.2 Alternative strategies to enhance BM homing and CXCR4 
expression 
 
A pharmacological approach to modify BM homing is more attractive in terms 
of ease of clinical translation and requires in-depth investigation, which 
unfortunately time did not allow. The effect of DPPIV inhibition might be more 
relevant in future experiments exploring the use of ex vivo activation prior to 
use of Diprotin A, or in vivo vaccination of mice on a sitagliptin-containing diet.  
The effect of DPPIV inhibition upon other immune cells needs to be carefully 
assessed. CD26High CD4+ T cells have been proposed as multi-functional cells 
capable of mediating antitumour regression, as well as activated B cells and 
DCs (529). Administration of DPPIV inhibitors in vivo may also enhance non-
CXCR4 mediated lymphocyte homing. For example, murine melanoma 
growth and lung metastases are reduced by DPPIV inhibition, due to 
suppressed truncation of CXCL10, leading to enhanced CXCR3+ T cell 
recruitment into the tumour parenchyma (96). This strategy is enhanced by 
use of an adjuvant CpG oligodeoxynucelotide to induce CXCL10 formation, 
which could also be explored in the context of CXCL12 (96).  
Unbiased large-scale flow or mass cytometric analysis of a wide range of 
chemokine receptors may be required to tease apart the precise effects of 
CD26 inhibition upon T cell trafficking, which may vary dependent upon 
tumour-specific expression of CD26 and chemokine ligands. Furthermore, 
mouse DPPIV has significant differences from the human protein, notably a 
lack of binding to adenosine deaminase, meaning that murine models may not 
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be predictive of clinical effects (530, 531). DPPIV costimulation has been 
reported to induce Treg cells with high expression of the LAG-3 coinhibitory 
protein. In summary, DPPIV inhibition might therefore have unpredictable 
effects upon immune responses, requiring further study, which might be 
enhanced by prospective cancer incidence registries for the large numbers of 
people receiving DPPIV inhibitors worldwide (532). 
Finally, a counter-intuitive method to enhance CXCR4 expression is 
suggested by data revealing that low-dose endogenous glucocorticoids 
induce IL-7Rα and CXCR4 expression in CD4+ and CD8+ T cells, resulting in 
diurnal homing to CXCL12 producing cells in spleen and immuno-enhancing 
memory responses (533). Glucocorticoids and histone deacetylase 5 
(HDAC5) inhibition promote CXCR4 expression and homing in HSCs via 
epigenetic regulation (534, 535). Further work along this line to examine the 
effects of this form of immune-enhancement could focus on depth and quality 
of immune responses mediated by T cells in the bone marrow by targeted 
glucocorticoid signalling or use of other epigenetic modulators. Modulating 
diurnal variation has the advantage of enhancing physiological mechanisms 
and therefore less likelihood of off-target side effects. Alteration of T cell 
migration by enforced homing towards CXCL12 would also be an attractive 
strategy in autoimmune conditions characterised by aberrant T cell migration 
(536). 
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7.3 Identifying the role of TCXCR4: deficiencies in current IL-15-
targeting strategies and cellular therapies  
 
Strategies aimed at exploiting the anti-tumour effects of IL-15 are well 
documented however they suffer from a lack of specific application to the 
tumour environment and have yet to translate into clinical therapies. 
Recombinant IL-15 (rIL-15) has a short half-life and requires very high doses 
for efficacy (537). In addition to its role in enhancing survival and function of 
immune cells, injection of IL-15 also expands CD215+ myeloid cells and 
promotes tumour progression (538). Exploiting transpresentation through IL-
15/IL-15Rα complexes is more attractive as cell-directed signalling allows for 
focused delivery to specific cell types, and lower potential for off-target side 
effects linked to IL-15 such as autoimmunity. The use of fusion protein super 
agonists such as ALT-803 has the potential to mitigate some of these issues 
but retains numerous issues including off-target impact and the need for 
frequent dosing due to a half-life of 8 hours (539). A recent clinical trial of 
ALT-803 for relapse post-allograft demonstrate the ability to stimulate 
proliferation of CD8+ T cells, but the low rates of response to single agent 
therapy highlight the benefits of a cell-specific approach (540). The one-off 
infusion approach of ACT offers numerous advantages, particularly tumour-
targeted efficacy and potentially cost-effectiveness. 
Two of the key hurdles in successful clinical translation of adoptive T cell 
therapy are lack of expansion of sufficient numbers of viable cells and poor in 
vivo survival. Current ACT protocols predominantly use undefined and 
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multiply stimulated T cells of effector memory/effector phenotype. These cells 
are likely to develop functional deficits and exhausted-anergic phenotypes in 
the usual CAR-T setting of high antigen levels and persistent high-level 
stimulation. Lack of long-term persistence is strongly associated with frequent 
relapses, as evinced by rapid recovery of peripheral blood B cells in most 
protocols (541). The only study to demonstrate persistent aplasia over 26 
months used a 4-1BB costimulatory domain (itself a bone marrow-associated 
‘late-acting’ costimulatory agent supplying survival signals) in paediatric 
patients (542). Given the poor thymic function and immunosenescent T cell 
phenotype present in the elderly patients likely to be the major recipients of 
these therapies, there is a pressing need for strategies to maintain potency 
and early phenotypes in the face of multiple exhaustion-promoting signals 
(543).  
 
The long-term persistence and expansion of T cells maintained by BM niches 
in our study suggests that superior long-term capacity for immune surveillance 
is provided by central memory T cells. This is notably different from the 
effector memory T cells obtained by many clinical protocols, including IL-12-
secreting 3rd generation ‘armoured’ CAR-T cells, and avoids multiple genetic 
modifications required to create TCR-deleted (TRAC) CAR-T cells (544-547). 
Demonstration of long-term persistence is one of the key indicators required 
for CAR-T cell and other adoptive cell therapies to be able to replace 
allogeneic HSCT as definitive therapy for poor prognosis haematological 
malignancies.  
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It is likely that tumours presenting with a high mutational load will have 
developed immunosuppressive micro-environments as a counter-measure, 
hence combination therapies potentially employing CPI in conjunction with 
adoptive cell therapy may be required to overwhelm tumour resistance. In 
contrast, those tumours with a low somatic mutation burden have less 
evolutionary pressure to develop immuno-evasion strategies, and would 
respond well to single-agent antigen-targeted therapies, as seen for CAR-T 
cells in B-ALL (<1 mutation/megabase) (542). 
The degree of heterogeneity within tumours has been shown to correlate with 
reduced immune infiltration and lack of response to CPI (411, 548). Further 
studies are required to establish whether enhancing cell number and 
modulation of the memory-exhaustion phenotype can overcome this barrier. 
Data from checkpoint inhibitor trials in melanoma patients suggest that 
response is a matter of the ratio of T cell invigoration to the magnitude of 
tumour burden, implying that success is a matter of engineering, but this may 
not be true for less immunogenic tumours (361). 
The impact of spatially distinct tumour microenvironments using a variety of 
immune evasion strategies therefore needs to be assessed when designing 
targeted therapies (549, 550). This distinction is particularly important in solid 
cancers but is also relevant in haematological cancers due to different stromal 
components of malignant niches in bone marrow, spleen and lymph nodes. 
The challenges of targeting therapeutic T cells to a variety of cellular niches 
therefore need to be addressed by longitudinal studies assessing dynamic 
heterogeneity in four key spheres: the tumour, the immune environment, the 
stromal environment and the microbiome, which will take some time. 
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Another concern in the treatment of multiple relapsed-refractory patients is the 
possiblity of GVHD in the post-allogeneic transplant setting. An increased risk 
might be expected with the use of ‘off the shelf’ allogeneic CAR-T cells such 
as UCART19, with the potential for expansion of T cells retaining their TCR 
despite genetic disruption (551). We did not see any evidence of increased 
GVHD in linked work, despite enhanced clinical efficacy (506). The high 
expansion capacity of TCXCR4 suggests that infusing low numbers of 
oligoclonal T cells might minimise the risk of GVHD associated with large 
doses of polyclonal T cells (552).  
Contrary to previous suggestions, human TCM provide primary tissue-based 
immunosurveillance, have considerable effector functions and express tissue-
homing receptors allowing entry to non-inflamed tissues, suggesting utility in 
combating immuno-evasion (553). These findings are in line with clinical data 
suggesting that use of TCM-enriched therapies is safe and effective, and 
positioning therapies aimed at enhancing bone marrow homing as a potential 
route to render allogeneic CAR-T protocols more clinically feasible (398). An 
alternative approach to mitigating the risk of GVHD is to use lymphoid 
progenitors tolerised by thymic maturation post-allograft, but this is 
challenging given the thymic atrophy seen in most elderly allograft recipients 
and the extended period of delayed T cell maturation permits disease relapse 
particularly in high-risk malignancies (554). 
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7.4 Limitations of CXCR4 over-expression 
 
The functional attributes of TCXCR4 may have unintended drawbacks. Firstly, 
altered homing to one particular organ may compromise homing to other 
crucial organs such as the tumour bed or lymph node. Although the BM can 
act as a location for antigen-dependent priming, evidence that the BM niche 
can be damaged or altered both by chemoradiotherapy and by malignant cells 
themselves might limit the ability of BM-homing T cells to traffic to protective 
niches and develop the memory phenotype. Although we saw enhanced anti-
tumour efficacy in our B cell lymphoma model, we were not able to test the 
efficacy of TCXCR4 in models where new data has shown the BM niche to be 
compromised. For example, acute myeloid leukaemia blasts can suppress BM 
adipocytes, impairing myeloid maturation, although the fact that lymphocyte 
levels are normal and lymphoid development is minimally affected suggests 
that a spatially distinct TCXCR4 niche might be unaffected (555).  
In contrast, data from my collaborator’s lab using a Notch-driven T-acute 
lymphoblastic leukaemia model suggests that malignant lymphoid clones 
destroy the osteoblastic BM niche, while retaining perivascular elements. 
These data highlight the importance of testing ACT in appropriate humanised 
tumour models in conjunction with clinical data. Interestingly, and in contrast 
to previous theories, tissue-wide in vivo confocal BM imaging of leukaemia 
cells at presentation and relapse revealed they did not associate with any 
particular cellular niche, but retained highly dynamic cellular interactions, with 
some similarity to the in vivo behavior of our gene-modified T cells (301). Any 
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therapeutic targeting of these interactions would hence need to target multiple 
elements of the bone marrow microenvironment, or would need to 
demonstrate similar abilities in terms of rapid mobility and cellular interactions, 
as demonstrated by the in vivo imaging behavior of our therapeutic T cells.  
One possibility to bear in mind is that these malignant lymphoid cells might 
compete for the same rate-limiting survival factors such as IL-15, and hence 
expansion of ACT might be affected, although malignant cells, particularly 
immature subtypes, use transcriptional deregulation, driven by oncogenes 
and super-enhancers, via distinct molecular pathways (556). Malignant T-ALL 
also uses higher expression of CXCR4 than normal T cells to gain access to 
the BM niche and CXCR4 signalling is known to be required for the survival of 
T-ALL through interactions with CXCL12+ endothelial cells rather than Leptin 
Receptor+ CXCL12-abundant reticular cells (128, 557).  
Interestingly, this finding dovetails with our observations regarding endothelial 
cell expression of CXCL12 and preferential association with TCXCR4 (Figure 
3-5 and Figure 3-8). VE-cadherin+ endothelial cells are known to be the 
second most abundant source of CXCL12 in BM, but at a magnitude 125-fold 
lesser than LepR+ perivascular cells. Given that LepR+ perivascular cells are 
the major source of CXCL12 in the BM, and that cells mobilise down the 
chemokine concentration gradient, CXCL12low/intermediate endothelial cells may 
have unexpected roles in maintenance of TCXCR4. It is possible that our use of 
a novel dynamic in vivo imaging model with intravenously injected CXCL12 
antibody caused preferential binding to endothelial cells ahead of 
extravascular stromal niches due to diffusion kinetics. An alternative 
explanation for the imaging evidence of TCXCR4 association with endothelial 
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CXCL12 is fugetaxis from excessively high CXCL12 concentrations 
surrounding perivascular cells towards CXCL12low/intermediate endothelial cells.  
This finding may have bearing when considering use of T cells over-
expressing CXCR4 in the context of T-cell malignancies, but may not 
otherwise be relevant given distinct niches identified for HSCs, myelo-
erythroid and lymphoid progenitors. This imaging result suggests that vascular 
access to the BM is important in addition to other putative perivascular or 
osteoblastic niches. Clarification is limited by the lack of adequate histological 
markers. However endothelial cells are not known to be a source of IL-15 nor 
have they the ability to trans-present via CD215, suggesting that TCXCR4 must 
be accessing an additional IL-15 rich niche. The prime candidate would be IL-
15Rα+ perivascular stromal cells (311). These data can be reconciled by 
observation of the dynamic in vivo behaviour of TCXCR4. These cells exhibit a 
wide range of motility patterns over extended imaging period. Some cells 
localise to a particular area whilst others range widely, without obvious 
association with level of CXCR4 expression. The consistency with the T-ALL 
imaging data suggests that multiple dynamic stochastic interactions are 
relevant for BM T cells rather than the old paradigm of a fixed niche for each 
cell-type. 
Further work using novel niche models such as the perivascular niche-on-a-
chip or three-dimensional biological scaffolds would be helpful to analyse the 
precise spatial location of BM-homing T cells in terms of the molecular 
interactions with different tumour models (558, 559). Novel bacterial sortase 
A-mediated cell labeling could be used across immune synapses to label and 
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record dynamic in vivo cellular interactions and identify important receptor-
ligand interactions mediating immune killing or evasion (560).  
A current limitation in gene modifying therapeutic CD8+ T cells is the need to 
activate and retrovirally transduce naïve cells. Although retroviral transduction 
with currently used vectors is far safer than historical tools associated with 
insertional mutagenesis, newer modalities employing clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-
9 (Cas9) and other techniques are potentially far more tractable and easily 
deployed, and may offer the additional benefit of reducing excessive 
activation and differentiation. Other recent developments in the field of 
lentiviral vectors offer the possibility of transducing non-activated cells at 
extremely high efficiencies (561).  
In relation to the risk of insertional mutagenesis, concerns have been 
expressed over the risks associated with generation of a long-lived stem-like 
cell with resistance to pro-apoptotic signalling. Adult T-cell 
leukaemia/lymphoma (ATLL) is a rare malignancy initiated and sustained by a 
small minority of T memory stem cells transformed by human T-cell 
lymphotrophic virus type 1 (HTLV-1) (562). However, the existence of long-
lived memory stem cells has been shown in a variety of human situations, 
including retrovirally modified clones tracked over a decade post bone marrow 
transplantation without evidence of malignant clonality (2, 563). 
Furthermore, a wide variety of experimental strategies have been mooted to 
enhance the generation of early memory anti-tumour T cells, from metabolic 
approaches (Akt inhibition) to modification of self-renewal pathways (glycogen 
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synthase kinase-3β (GSK-3β) inhibition) or epigenetic agents (DNA 
methyltransferase 3a (DNTM3a)) (187, 192, 518). As yet none of these 
approaches have yet been translated into clinical success. For example, 
GSK-3β inhibition also reduces T cell proliferation, preventing generation of 
sufficient cell numbers (211). Other groups have suggested priming cells ex 
vivo in the presence of low dose IL-7 and IL-15 can generate greater number 
of T memory stem cells but numbers remain limiting (564). Rapid good 
manufacturing practice (GMP)-compliant generation of cells capable of 
immediate tumour lysis is one of the major rate-limiting steps preventing 
effective translation of adoptive T cell therapy. Using a pre-existing 
homeostatic BM niche to dramatically amplify cell numbers in vivo could 
reduce the duration of ex vivo culture, provide rapid ongoing anti-tumour 
control and prevent induction of senescence.  
The financial implications of cellular therapy cannot be ignored, particularly in 
the light of astronomical price tags placed upon the first CAR-T cell products 
to market. Whilst these companies have undoubtedly accelerated 
commercialization with the use of closed automated systems and large-scale 
manufacturing, a lack of investment and input into initial development has 
been a major reason for the wasted decades before the potential of 
immunotherapy was realized. The majority of people in middle-income and 
developing countries will be unable to access these therapies using current 
pricing strategies. The growth of high-cost precision medicines tailored to very 
small populations has only exacerbated this issue. In the United States the 
launch price of oncology drugs per life-year gain has quadrupled within two 
decades, whilst the number of new drugs approved per billion dollars spent 
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has halved every nine years since 1950 (565). The current unsustainable 
trajectory presents us with the possibility that effective drugs, particularly cell 
therapies, will only be developed for an increasingly small market able to 
afford them. With this in mind, there is a new imperative for alternative models 
for bringing drugs to market, potentially through public ownership of not-for-
profit companies spun out of academia. The Organisation for Economic 
Cooperation and Development (OECD) and government ministers in the 
Netherlands have recently called for new solutions to this problem, such as 
agreements linking price to innovation, research funding input and long term 
outcomes (566, 567), and it is important that academics and clinicians engage 
with and drive these discussions based upon their understanding of patient 
need. 
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